Basic Pharmacological Properties

  • E. Müller-Schweinitzer
  • H. Weidmann
Part of the Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie book series (HEP, volume 49)


This chapter intends to portray the present knowledge on site and mechanism of action of the ergot alkaloids. The presentation is based chietly on selected work performed in defined isolated systems in which the interference with specific substrates usually called receptors has been sufficiently proven. We hope that this presentation will contribute to the understanding of the complexity of ergot pharmacology as presented in the following chapters.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aberg, G., Andersson, R., Welin-Fogelberg, I.: Inhibition of tone in the taenia of the guinea pig caecum. Europ. J. Pharmacol. 7, 296–299 (1969)CrossRefGoogle Scholar
  2. Abrahams, S.L.: Effect of serotonin, LSD, and other indoleamines on adenyl cyclase in the liver fluke. Fed. Proc. 33, 1249 (1974)Google Scholar
  3. Abrahams, S.L., Northup, J.K., Mansour, T.E.: Adenosine cyclic 3′, 5′-monophosphate in the liver fluke, Fasciola hepatica. I. Activation of adenylate cyclase by 5-hydroxyptamine. Molec. Pharmacol. 12, 49–58 (1976)Google Scholar
  4. Acheson, G.H.: The responses of the nictitating membrane of the cat to certain stimulants after ergotoxine. Amer. J. Physiol. 128, 695–702 (1940)Google Scholar
  5. Aellig, W.H.: Periphere Kreislaufwirkungen von Ergotamin, Dihydroergotamin und 1-Methylergotamin an der innervierten, perfundierten Hinterextremitat des Hundes. Helv. physiol. Pharmacol. Acta 25, 374–396 (1967)PubMedGoogle Scholar
  6. Aellig, W.H.: Venoconstrictor effect of dihydroergotamine in superficial hand veins. Europ. J. clin. Pharmacol. 7, 137–139 (1974)CrossRefGoogle Scholar
  7. Aellig, W.H., Berde, B.: Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Brit. J. Pharmacol. 36, 561–570 (1969)Google Scholar
  8. Aghajanian, G.K.: Influence of drugs on the firing of serotonin-containing neurons in brain. Fed. Proc. 31, 91–96 (1972a)PubMedGoogle Scholar
  9. Aghajanian, G.K.: Chemical feedback regulation of serotonin-containing neurons in brain. Ann. N.Y. Acad. Sci. 193, 86–94 (1972b)PubMedCrossRefGoogle Scholar
  10. Aghajanian, G.K., Haigler, H.J.: Mode of action of LSD on serotonergic neurons. Adv. Biochem. Psychopharmacol. 10, 167–177 (1974)PubMedGoogle Scholar
  11. Aghajanian, G.K., Weiss, B.L.: Block by LSD of the increase in brain serotonin turnover induced by elevated ambient temperature. Nature (Lond.) 220, 795–796 (1968)CrossRefGoogle Scholar
  12. Aghajanian, G.K., Rosecrans, J.A., Sheard, M.H.: Serotonin: release in the forebrain by stimulation of midbrain raphe. Science 156, 402–403 (1967)PubMedCrossRefGoogle Scholar
  13. Aghajanian, G.K., Foote, W.E., Sheard, M.H.: Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science 161, 706–708 (1968)PubMedCrossRefGoogle Scholar
  14. Aghajanian, G.K., Foote, W.E., Sheard, M.H.: Action of psychotogenic drugs on single midbrain raphe neurons. J. Pharmacol. exp. Ther. 171, 178–187 (1970a)PubMedGoogle Scholar
  15. Aghajanian, G.K., Graham, A.W., Sheard, M.H.: Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors. Science 169, 1100–1102 (1970b)PubMedCrossRefGoogle Scholar
  16. Aghajanian, G.K., Haigler, H.J., Bloom, F.E.: Lysergic acid diethylamide and serotonin: direct actions on serotonin-containing neurons in rat brain. Life Sci. 11(I), 615–622 (1972)CrossRefGoogle Scholar
  17. Aghajanian, G.K., Kuhar, M.J., Roth, R.H.: Serotonin-containing neuronal perikarya and terminals: differential effects of p-chlorophenylalanine. Brain Res. 54, 85–101 (1973)PubMedCrossRefGoogle Scholar
  18. Ahlquist, R.P.: A study of the adrenotropic receptors. Amer. J. Physiol. 153, 586–600 (1948)PubMedGoogle Scholar
  19. Ahlquist, R.P., Levy, B.: Adrenergic receptive mechanism of canine ileum. J. Pharmacol. exp. Ther. 127, 146–149 (1959)PubMedGoogle Scholar
  20. Aiello, E., Guideri, G.: Nervous control of ciliary activity. Science 146, 1692–1693 (1964)PubMedCrossRefGoogle Scholar
  21. Aiello, E., Guideri, G.: Relationship between 5-hydroxy tryptamine and nerve stimulation of ciliary activity. J. Pharmacol. exp. Ther. 154, 517–523 (1966)PubMedGoogle Scholar
  22. Aiello, E., Paparo, A.: A role for acetylcholine in the regulation of ciliary activity. Comp. gen. Pharmacol. 5, 285–297 (1974)CrossRefGoogle Scholar
  23. Alabaster, V.A., Bakhle, Y.S.: Release of smooth muscle-contracting substances from isolated perfused lungs. Europ. J. Pharmacol. 35, 349–360 (1976)CrossRefGoogle Scholar
  24. Allen, G.S., Henderson, L.M., Chou, S.N., French, L.A.: Cerebral arterial spasm. Part 2: In vitro contractile activity of serotonin in human serum and CSF on the canine basilar artery, and its blockage by methylsergide and phenoxybenzamine. J. Neurosurg. 40, 442–450 (1974)PubMedCrossRefGoogle Scholar
  25. Altura, B.M., Malaviya, D., Reich, C.F., Orkin, L.R.: Effects of vasoactive agents on isolated human umbilical arteries and veins. Amer. J. Physiol. 222, 345–355 (1972)PubMedGoogle Scholar
  26. Ambache, N., Zar, M.A.: Evidence against adrenergic motor transmission in the guinea-pig vas deferens. J. Physiol. (Lond.) 216, 359–389 (1971)Google Scholar
  27. Ambache, N., Dunk, L.P., Miall, P., Zar, M.A.: Unexplained inhibitory action of D-lysergic acid diethylamide (LSD) on postganglionic motor transmission in the guinea-pig vas deferens. Brit. J. Pharmacol. 42, 659P–660P (1971)Google Scholar
  28. Ambache, N., Dunk, L.P., Verney, J., Zar, M.A.: An inhibition of post-ganglionic motor transmission in the mammalian vas deferens by D-lysergic acid diethylamide. J. Physiol. (Lond.) 231, 251–270 (1973a)Google Scholar
  29. Ambache, N., Killick, S.W., Srinivasan, V., Zar, M.A.: Presynaptic inhibition of adrenergic motor transmission in rat anococcygeus muscle by D-lysergic acid diethylamide (LSD). J. Physiol. (Lond.) 233, 35P–37P (1973b)Google Scholar
  30. Ambache, N., Killick, S.W., Srinivasan, V., Zar, M.A.: Effects of lysergic acid diethylamide on autonomic postganglionic transmission. J. Physiol. (Lond.) 246, 571–593 (1975)Google Scholar
  31. Ames, A. III, Pollen, D.A.: Neurotransmission in central nervous tissue: A study of isolated rabbit retina. J. Neurophysiol. 32, 424–442 (1969)PubMedGoogle Scholar
  32. Ammon, R.: Die Cholinesterase. Ergebn. Enzymforsch. 4, 102–110 (1935)Google Scholar
  33. Andén, N.-E.: Changes in the impulse flow of central monoamine nerves by drugs affecting monoamine receptors. Acta pharmacol. (Kbh.) 25, 5–6 (1968)CrossRefGoogle Scholar
  34. Andén, N.-E., Dahlström, A., Fuxe, K., Larsson, K., Olson, L., Ungerstedt, U.: Ascending monoamine neurons to the telencephalon and diencephalon. Acta physiol. scand. 67, 313–326 (1966)CrossRefGoogle Scholar
  35. Andén, N.-E., Corrodi, H., Fuxe, K., Hökfelt, T.: Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Brit. J. Pharmacol. 34, 1–7 (1968)Google Scholar
  36. Andén, N.-E., Carlsson, A., Haggendal, J.: Adrenergic mechanisms. Annu. Rev. Pharmacol. 9, 119–134 (1969)PubMedCrossRefGoogle Scholar
  37. Anderson, E.G.: Bulbospinal serotonin-containing neurons and motor control. Fed. Proc. 31, 107–112 (1972)PubMedGoogle Scholar
  38. Anderson, E.G., Baker, R.G., Banna, N.R.: The effects of monoamine oxidase inhibitors on spinal synaptic activity. J. Pharmacol. exp. Ther. 158, 405–415 (1967)PubMedGoogle Scholar
  39. Ansell, G.B., Beeson, M.F., Bradley, P.B.: The effects of stressful stimuli and drugs on the concentrations and turnover rates of monoamines in rat brain. In: The Present Status of Psychotropic Drugs. Cerletti, A., Bové, F.J. (eds.), pp. 299–301. Amsterdam: Exerpta Medica Foundation 1969Google Scholar
  40. Apperley, E., Humphrey, P.P.A., Levy, G.P.: Receptors for 5-hydroxytryptamine and noradrenaline in rabbit aorta and central ear artery. Brit. J. Pharmacol. 52, 131P–132P (1974)Google Scholar
  41. Apperley, E., Humphrey, P.P.A., Levy, G.P.: Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Brit. J. Pharmacol. 58, 211–221 (1976)Google Scholar
  42. Arcari, G., Dorigotti, L., Fregnan, G.B., Glasser, A.H.: Vasodilating and alpha-receptor blocking activity of a new ergoline derivative. Brit. J. Pharmacol. 34, 700P (1968)Google Scholar
  43. Arcari, G., Bernardi, L., Bosisio, G., Coda, S., Fregnan, G.B., Glässer, A.H.: 10-Methoxyergoline derivatives as α-adrenergic blocking agents. Experientia (Basel) 28, 819–820 (1972)CrossRefGoogle Scholar
  44. Arefolov, V.A., Pidevich, I.N., Panasyuk, L.V., Firsov, V.K.: Pharmacological analysis of some adrenomimetic effects of serotonin. Byul. eksp. Biol. Med. 80, 45–48 (1975)Google Scholar
  45. Ariens, E.J.: Affinity and intrinsic activity in the theory of competitive inhibition. Part I: Problems and theory. Arch. int. Pharmacodyn. 99, 32–49 (1954)PubMedGoogle Scholar
  46. Ariens, E.J., Van Rossum, J.M., Simonis, A.M.: A theoretical basis of molecular pharmacology. Part II: Interactions of one or two compounds with two interdependent receptor systems. Arzneimittel-Forsch. 6, 611–621 (1956)Google Scholar
  47. Arunlakshana, O., Schild, H.O.: Some quantitative uses of drug antagonists. Brit. J. Pharmacol. 14, 48–58 (1959)PubMedGoogle Scholar
  48. Ascher, P.: Inhibitory and excitatory effects of dopamine on Aplysia neurones. J. Physiol. (Lond.) 225, 173–209 (1972)Google Scholar
  49. Åström, A., Samelius, U.: The action of 5-hydroxytryptamine and some of its antagonists on the umbilical vessels of the human placenta. Brit. J. Pharmacol. 12, 410–414 (1957)PubMedGoogle Scholar
  50. Bach, N.J., Hall, D.A., Kornfeld, E.C.: Descarboxylysergic acid (9,10-didehydro-6-methylergoline). J. med. Chem. 17, 312–314 (1974)PubMedCrossRefGoogle Scholar
  51. Bacq, Z.M.: The action of ergotamine on the chromatophores of the catfish (Ameiurus nebulosus). Biol. Bull. 65, 387–388 (1933)CrossRefGoogle Scholar
  52. Bacq, Z.M.: La pharmacologic du système nerveux autonome, et particulièrement du sympathique, d’après la théorie neurohumorale. Ann. Physiol. 10, 468–528 (1934a)Google Scholar
  53. Bacq, Z.M.: Action de l’ergotamine et de l’ergotaminine sur la membrane nictitante. C.R. Soc. Biol. (Paris) 116, 341–342 (1934b)Google Scholar
  54. Bacq, Z.M.: Recherches sur la physiologie du système nerveux autonome. IV. Réactions de la vésicule séminale et du canal déférent du cobaye à l’adrénaline, à l’acétylcholine et aux ions Ca et K. Arch. int. Pharmacodyn. 47, 123–129 (1934c)Google Scholar
  55. Bakhle, Y.S., Smith, T.W.: Release of spasmogenic substances induced by vasoactive amines from isolated lungs. Brit. J. Pharmacol. 46, 543P–544P (1972)Google Scholar
  56. Bakhle, Y.S., Smith, T.W.: The nature of the tryptamine receptor mediating spasmogen release from rat isolated lungs. Brit. J. Pharmacol. 50, 463P (1974a)Google Scholar
  57. Bakhle, Y.S., Smith, T.W.: Tryptamine receptors in rat pulmonary artery. Brit. J. Pharmacol. 51, 459–461 (1974b)Google Scholar
  58. Baldratti, G., Arcari, G., Suchowsky, G.K.: Studies on a compound antagonistic to 5-hydroxytryptamine. Experientia (Basel) 21, 396–397 (1965)CrossRefGoogle Scholar
  59. Banna, N.R., Anderson, E.G.: The effects of 5-hydroxytryptamine antagonists on spinal neuronal activity. J. Pharmacol. exp. Ther. 162, 319–325 (1968)PubMedGoogle Scholar
  60. Barabe, J., Park, W.K., Regoli, D.: Application of drug receptor theories to the analysis of the myotropic effects of bradykinin. Canad. J. Physiol. Pharmacol. 53, 345–353 (1975)CrossRefGoogle Scholar
  61. Barasi, S., Roberts, M.H.T.: The action of 5-hydroxytryptamine antagonists and precursors on bulbospinal facilitation of spinal reflexes. Brain Res. 52, 385–388 (1973)PubMedCrossRefGoogle Scholar
  62. Barasi, S., Roberts, M.H.T.: The modification of lumbar motoneurone excitability by stimulation of a putative 5-hydroxy-tryptamine pathway. Brit. J. Pharmacol. 52, 339–348 (1974)Google Scholar
  63. Barfknecht, C.F., Nichols, D.E., Rusterholz, D.B., Long, J.P., Engelbrecht, J.A., Beaton, J.M., Bradley, R.J., Dyer, D.C.: Potential psychotomimetics. 2-amino-1,2,3,4-tetrahydronaphthalene analogs. J. med. Chem. 16, 804–808 (1973)PubMedCrossRefGoogle Scholar
  64. Barlow, R.B.: Effects on amine oxydase of substances which antagonize 5-hydroxytryptamine more than tryptamine on the rat fundus strip preparation. Brit. J. Pharmacol. 16, 153–162 (1961)PubMedGoogle Scholar
  65. Barlow, R.B., Khan, I.: Actions of some analogues of tryptamine on the rat uterus and on the isolated rat fundus strip preparation. Brit. J. Pharmacol. 14, 99–107 (1959a)PubMedGoogle Scholar
  66. Barlow, R.B., Khan, I.: Actions of some analogues of 5-hydroxy-tryptamine on the isolated rat uterus and the rat fundus strip preparations. Brit. J. Pharmacol. 14, 265–272 (1959b)PubMedGoogle Scholar
  67. Barthel, W., Markwardt, F.: Aggregation of blood platelets by biogenic amines and its inhibition by antiadrenergic and antiserotoninergic agents. Biochem. Pharmacol. 23, 37–45 (1974)PubMedCrossRefGoogle Scholar
  68. Barthel, W., Markwardt, F.: Aggregation of blood platelets by adrenaline and its uptake. Biochem. Pharmacol. 24, 1903–1904 (1975)PubMedCrossRefGoogle Scholar
  69. Bartlet, A.L.: Actions of putative transmitters in the chicken vagus nerve/oesophagus and Remak nerve/rectum preparations. Brit. J. Pharmacol. 51, 549–558 (1974)Google Scholar
  70. Bartlet, A.L., Hassan, T.: Some actions of histamine and 5-hydroxytryptamine on isolated chicken oesophagus. Brit. J. Pharmacol. 32, 156–163 (1968)PubMedGoogle Scholar
  71. Barzaghi, F., Baumgartner, H.R., Carruba, M., Mantegazza, P., Pletscher, A.: The 5-hydroxytryptamine-like actions of 5,6-dihydroxytryptamine. Brit. J. Pharmacol. 48, 245–254 (1973)Google Scholar
  72. Beernink, K.D., Nelson, S.D., Mansour, T.E.: Effect of lysergic acid derivatives on the liver fluke Fasciola hepatica. Int. J. Neuropharmacol. 2, 105–112 (1963)CrossRefGoogle Scholar
  73. Belamarich, F.A., Simoneit, L.W.: Aggregation of duck thrombocytes by 5-hydroxytryptamine. Micro vasc. Res. 6, 229–234 (1973)CrossRefGoogle Scholar
  74. Beleslin, D., Varagić, V.: The effect of cooling and of 5-hydroxytryptamine on the peristaltic reflex of the isolated guinea-pig ileum. Brit. J. Pharmacol. 13, 266–270 (1958)PubMedGoogle Scholar
  75. Belisle, S., Gagnon, D.J.: Stimulating action of catecholamines on isolated preparations of the rat colon and human and rabbit taeniae coli. Brit. J. Pharmacol. 41, 361–366 (1971)Google Scholar
  76. Bell, J.A., Martin, W.R.: Studies of tryptamine and lysergic acid diethylamide (LSD) on cutaneous C-fiber and polysynaptic reflexes in the cat. J. Pharmacol. exp. Ther. 190, 492–500 (1974)PubMedGoogle Scholar
  77. Benfey, B.G., Cohen, J., Kunos, G, Vermes-Kunos, I.: Dissociation of 5-hydroxytryptamine effects on myocardial contractility and cyclic AMP accumulation. Brit. J. Pharmacol. 50, 581–585 (1974)Google Scholar
  78. Bennett, A., Stockley, H.L.: The intrinsic innervation of the human alimentary tract and its relation to function. Gut 16, 443–453 (1975)PubMedCrossRefGoogle Scholar
  79. Bennett, J.L., Aghajanian, G.K.: D-LSD binding to brain homogenates: Possible relationship to serotonin receptors. Life Sci. 15, 1935–1944 (1974)CrossRefGoogle Scholar
  80. Bennett, J.L., Aghajanian, G.K.: Response of single raphe neurons to (+)-LSD: Correlation with (+)-LSD binding in brain. J. Pharm. Pharmacol. 28, 516–518 (1976)PubMedCrossRefGoogle Scholar
  81. Bennett, J.L., Bueding, E.: Uptake of 5-hydroxytryptamine by Schistosoma mansoni. Molec. Pharmacol. 9, 311–319 (1973)Google Scholar
  82. Bennett, J.P., Snyder, S.H.: Stereospecific binding of D-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res. 94, 523–544 (1975)PubMedCrossRefGoogle Scholar
  83. Bennett, J.P., Snyder, S.H.: Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Molec. Pharmacol. 12, 373–389 (1976)Google Scholar
  84. Bennett, M.R., Middleton, J.: An electrophysiological analysis of the effects of amine-uptake blockers and α-adrenoceptor blockers on adrenergic neuromuscular transmission. Brit. J. Pharmacol. 55, 87–95 (1975)Google Scholar
  85. Berde, B.: New studies on the circulatory effects of ergot compounds with implications to migraine. In: Background to Migraine. Cumings, J.N. (ed.), pp. 66–75. London: William Heinemann Medical Books 1971Google Scholar
  86. Berde, B.: Some new vascular and biochemical aspects of the mechanism of action of ergot compounds. Headache 11, 139–147 (1972)PubMedCrossRefGoogle Scholar
  87. Berde, B., Cerletti, A.: Über den Melanophoreneffekt von D-Lysergsäure-diäthylamid und verwandten Verbindungen. Helv. physiol. pharmacol. Acta 14, 325–333 (1956)PubMedGoogle Scholar
  88. Berde, B., Cerletti, A.: Über den Angriffspunkt von D-Lysergsäure-diäthylamid und 5-Hydroxytryptamin im Melanophorentest. Z. ges. exp. Med. 129, 149–153 (1957)PubMedCrossRefGoogle Scholar
  89. Berde, B., Doepfner, W., Cerletti, A.: Über die Wirkungsdauer einiger Serotoninantagonisten. Helv. physiol. pharmacol. Acta 18, 537–544 (1960)Google Scholar
  90. Beretta, C., Locatelli, A.: Inhibitory activity of 8β-carbobenzyloxyaminomethyl-1,6-dimethyl-10α-ergoline towards stimulant effects by 5-hydroxytryptamine and amphetamine on liver fluke, Fasciola hepatica, in vitro. J. Pharm. Pharmacol. 20, 744–748 (1968)PubMedCrossRefGoogle Scholar
  91. Beretta, C., Ferrini, R., Glässer, A.H.: 1-Methyl-8β-carbobenzyloxy-aminomethyl-10α-ergoline, a potent and long-lasting 5-hydroxytryptamine antagonist. Nature (Lond.) 207, 421–422 (1965a)CrossRefGoogle Scholar
  92. Beretta, C., Glässer, A.H., Nobili, M.B., Silvestri, R.: Antagonism of 5-hydroxytryptamine-induced bronchospasm in guinea-pigs by 8β-carbobenzyloxyaminomethyl-1,6-dimethyl-10α-ergoline. J. Pharm. Pharmacol. 17, 423–428 (1965b)PubMedCrossRefGoogle Scholar
  93. Bernardi, L., Bosisio, G., Elli, C., Patelli, B., Temperilli, A., Arcari, G., Glässer, H.A.: Ergoline derivatives. Note XIII. α-adrenergic blocking drugs. Farmaco [Sci.] 30, 789–801 (1975)Google Scholar
  94. Berridge, M.J., Prince, W.T.: Mode of action of hallucinogenic molecules. Nature (Lond.) New Biol. 243, 283–284 (1973)CrossRefGoogle Scholar
  95. Berridge, M.J., Prince, W.T.: The nature of the binding between LSD and a 5-HT receptor: A possible explanation for hallucinogenic activity. Brit. J. Pharmacol. 51, 269–278 (1974)Google Scholar
  96. Berry, P.A., Collier, H.O.J.: Bronchoconstrictor action and antagonism of a slow-reacting substance from anaphylaxis of guinea-pig isolated lung. Brit. J. Pharmacol. 23, 201–216 (1964)PubMedGoogle Scholar
  97. Berry, M.S., Cottrell, G.A.: Excitatory, inhibitory and biphasic synaptic potentials mediated by an identified dopamine-containing neurone. J. Physiol. (Lond.) 244, 589–612 (1975)Google Scholar
  98. Bevan, P., Bradshaw, C.M., Roberts, M.H.T., Szabadi, E.: The effect of microelectrophoretically applied mescaline on cortical neurones. Neuropharmacology 13, 1033–1045 (1974a)PubMedCrossRefGoogle Scholar
  99. Bevan, P., Bradshaw, C.M., Szabadi, E.: Potentiation and antagonism of neuronal responses to monoamines by methysergide and sotalol. Brit. J. Pharmacol. 50, 445 P (1974b)Google Scholar
  100. Bhattacharya, B.K.: A pharmacological study on the effect of 5-hydroxytryptamine and its antagonists on the bronchial musculature. Arch. int. Pharmacodyn. 103, 357–367 (1955)PubMedGoogle Scholar
  101. Biber, B., Fara, J., Lundgren, O.: A pharmacological study of intestinal vasodilator mechanisms in the cat. Acta physiol. scand. 90, 673–683 (1974)PubMedCrossRefGoogle Scholar
  102. Bickerton, R.K., Rockhold, W.T., Micalizzi, E.R.: Use of isolated strips of cat spleen for the assay of a-adrenergic blocking compounds. J. Pharm. Sci. 51, 837–840 (1962)PubMedCrossRefGoogle Scholar
  103. Bindler, E.H., Gyermek, L.: Influence of 5-HT antagonists on the ganglionic stimulant action of 5-HT and DMPP. Fed. Proc. 20, 319 (1961)Google Scholar
  104. Bircher, R., Schalch, W.R.: Über die Wirkung von Mutterkornalkaloiden bei histaminergischen Reaktionen. Helv. physiol. pharmacol. Acta 6, 813–820 (1948)PubMedGoogle Scholar
  105. Birmingham, A.T., Szolcsányi, J.: Competitive blockade of adrenergic α-receptors and histamine receptors by thymoxamine. J. Pharm. Pharmacol. 17, 449–458 (1965)PubMedCrossRefGoogle Scholar
  106. Birmingham, A.T., Wilson, A.B.: Preganglionic and postganglionic stimulation of the guineapig isolated vas deferens preparation. Brit. J. Pharmacol. 21, 569–580 (1963)PubMedGoogle Scholar
  107. Birnbaumer, L., Pohl, S.L., Kaumann, A.J.: Receptors and acceptors: A necessary distinction in hormone binding studies. Adv. Cyclic Nucleotide Res. 4, 239–281 (1974)PubMedGoogle Scholar
  108. Blakeley, A.G.H., Brown, G.L., Ferry, C.B.: Pharmacological experiments on the release of the sympathetic transmitter. J. Physiol. (Lond.) 167, 505–514 (1963)Google Scholar
  109. Bloom, F.E., Costa, E., Salmoiraghi, G.C.: Analysis of individual rabbit olfactory bulb neuron responses to the microelectrophoresis of acetylcholine, norepinephrine and serotonin synergists and antagonists. J. Pharmacol. exp. Ther. 146, 16–23 (1964)PubMedGoogle Scholar
  110. Bloom, F.E., Hoffer, B.J., Siggins, G.R., Barker, J.L., Nicoll, R.A.: Effects of serotonin on central neurons: Microiontophoretic administration. Fed. Proc. 31, 97–106 (1972)PubMedGoogle Scholar
  111. Bloom, F.E., Hoffer, B.J., Nelson, C., Sheu, Y., Siggins, G.R.: The physiology and pharmacology of serotonin mediated synapses. In: Serotonin and Behavior. Barchas, J., Usdin, E. (eds.), pp. 249–261. New York: Academic Press 1973Google Scholar
  112. Boakes, R.J., Bradley, P.B., Briggs, I., Dray, A.: Antagonism by LSD to effects of 5-HT on single neurones. Brain Res. 15, 529–531 (1969)PubMedCrossRefGoogle Scholar
  113. Boakes, R.J., Bradley, P.B., Briggs, I., Dray, A.: Effects of lysergic acid derivatives on 5-hydroxytryptamine excitation of brain stem neurones. Brit. J. Pharmacol. 38, 453P–454P (1970a)Google Scholar
  114. Boakes, R.J., Bradley, P.B., Briggs, I., Dray, A.: Antagonism of 5-hydroxytryptamine by LSD-25 in the central nervous system: A possible neuronal basis for the actions of LSD-25. Brit. J. Pharmacol. 40, 202–218 (1970b)Google Scholar
  115. Boggan, W.O., Freedman, D.X.: LSD tolerance and brain serotonin metabolism. Fed. Proc. 32, 694 (1973)Google Scholar
  116. Bond, H.W., Guth, P.S.: Interaction of 5-hydroxytryptamine and lysergic acid diethylamide in the central nervous system. Pharmacologist 6, 171 (1964)Google Scholar
  117. Born, G.V.R.: The uptake of adrenaline by human blood platelets. Naunyn-Schmiedebergs Arch. Pharmacol. 259, 155–156 (1967)Google Scholar
  118. Born, G.V.R., Smith, J.B.: Uptake, metabolism and release of [3H]-adrenaline by human platelets. Brit. J. Pharmacol. 39, 765–778 (1970)Google Scholar
  119. Born, G.V.R., Mills, D.C.B., Roberts, G.C.K.: Potentiation of platelet aggregation by adrenaline. J. Physiol. (Lond.) 191, 43P–44P (1967a)Google Scholar
  120. Born, G.V.R., Day, M., Stockbridge, A.: The uptake of amines by human erythrocytes in vitro. J. Physiol. (Lond.) 193, 405–418 (1967b)Google Scholar
  121. Born, G.V.R., Juengjaroen, K., Michal, F.: Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues. Brit. J. Pharmacol. 44, 117–139 (1972)Google Scholar
  122. Borsy, J., Magó-Karacsony, E., Balogh, T., Pik, K.: Preparation new semi-synthetic lysergic acid derivatives: Investigation into the correlation of molecular structure and antiserotonin activity II. Acta pharm. hung. 43, 207–217 (1973)PubMedGoogle Scholar
  123. Boullin, D.J., Green, A.R.: Effect of brain 5-HT agonists and antagonists on platelet aggregation. Sixth Internat. Congr. Pharmacol., Helsinki, 1975. Abstract 695Google Scholar
  124. Boullin, D.J., Green, A.R., Grimes, R.P.J.: Human blood platelet aggregation induced by dopamine, 5-hydroxytryptamine and analogues. J. Physiol. (Lond.) 252, 46P–47P (1975a)Google Scholar
  125. Boullin, D.J., Grimes, R.P.J., Orr, M.W.: The actions of flupethixol upon 5-hydroxytryptamine-induced aggregation and the uptake of 5-hydroxytryptamine and dopamine by human blood platelets. Brit. J. Pharmacol. 55, 555–557 (1975b)Google Scholar
  126. Boyd, H., Chang, V., Rand, M.J.: The anticholinesterase activity of some antiadrenaline agents. Brit. J. Pharmacol. 15, 525–531 (1960)PubMedGoogle Scholar
  127. Bradley, P.B.: The effects of 5-hydroxytryptamine on the electrical activity of the brain and on behaviour in the conscious cat. In: 5-Hydroxytryptamine. Lewis, G.P. (ed.), pp. 214–220. London: Pergamon Press 1958Google Scholar
  128. Bradley, P.B., Hance, A.J.: The effects of intraventricular injections of D-lysergic acid diethylamide (LSD 25) and 5-hydroxytryptamine (serotonin) on the electrical activity of the brain of the conscious cat. J. Physiol. (Lond.) 132, 50P–51P (1956a)Google Scholar
  129. Bradley, P.B., Hance, A.J.: The effects of intraventricular injections of drugs on the electrical activity of the brain of the conscious cat. Electroenceph. clin. Neurophysiol. 8, 699–700 (1956b)CrossRefGoogle Scholar
  130. Bradley, P.B., Wolstencroft, J.H.: The action of drugs on single neurones in the brain stem. In: Neuro-Psychopharmacology. Bradley, P.B., Fluegel, F., Hoch, P.H. (eds.), pp. 237–240. Amsterdam: Elsevier 1964Google Scholar
  131. Bradley, P.B., Wolstencroft, J.H.: Actions of drugs on single neurones in the brain stem. Brit. med. Bull. 21, 15–18 (1965)PubMedGoogle Scholar
  132. Bradshaw, C.M., Roberts, M.H.T., Szabadi, E.: Effect of mescaline on single cortical neurones. Brit. J. Pharmacol. 43, 871–873 (1971)Google Scholar
  133. Bramwell, G.J., Gonye, T.: Responses of midbrain neurones to iontophoretically applied 5-hydroxytryptamine. Brit. J. Pharmacol. 48, 357P–358P (1973)Google Scholar
  134. Briggs, I.: Excitatory responses to raphe stimulation in the rat bulbar reticular formation. J. Physiol. (Lond.) 256, 111P (1976)Google Scholar
  135. Brodie, B.B.: Storage and release of 5-hydroxytryptamine (HT). Possible significance in chemical mediation in brain. In: Ciba Symposium on Hypertension, pp. 64–83. London: Churchill 1954Google Scholar
  136. Brodie, B., Shore, P.A., Pletscher, A.: Serotonin-releasing activity limited to Rauwolfia alkaloids with tranquilizing action. Science 123, 992–993 (1956)PubMedCrossRefGoogle Scholar
  137. Broom, W.A., Clark, A.J.: The standardisation of ergot preparations. J. Pharmacol. exp. Ther. 22, 59–74 (1923)Google Scholar
  138. Brown, B.E.: Proctolin: A peptide transmitter candidate in insects. Life Sci. 17, 1241–1252 (1975)PubMedCrossRefGoogle Scholar
  139. Brown, L.: The release and fate of the transmitter liberated by adrenergic nerves. Proc. roy. Soc. B 162, 1–19 (1965)CrossRefGoogle Scholar
  140. Brown, G.L., Dale, H.: The pharmacology of ergometrine. Proc. roy. Soc. B 118, 446–477 (1935)CrossRefGoogle Scholar
  141. Brown, G.L., Gillespie, J.S.: The output of sympathetic transmitter from the spleen of the cat. J. Physiol. (Lond.) 138, 81–102 (1957)Google Scholar
  142. Brown, G.L., Davies, B.N., Ferry, C.B.: The effect of neuronal rest on the output of sympathetic transmitter from the spleen. J. Physiol. (Lond.) 159, 365–380 (1961)Google Scholar
  143. Brownlee, G., Johnson, E.S.: The site of the 5-hydroxytryptamine receptor on the intramural nervous plexus of the guinea-pig isolated ileum. Brit. J. Pharmacol. 21, 306–322 (1963)PubMedGoogle Scholar
  144. Brügger, I.: Experimenteller Beitrag zur Wirkungsweise vegetativer Pharmaka. Arch. int. Pharmacodyn. 59, 43–60 (1938)Google Scholar
  145. Brügger, J.: Die isolierte Samenblase des Meerschweinchens als biologisches Testobjekt zur quantitativen Differenzierung der sympathikolytischen Wirkung der genuinen Mutterkornalkaloide und ihrer Dihydroderivate. Helv. physiol. pharmacol. Acta 3, 117–134 (1945)Google Scholar
  146. Brundin, J.: The effect of prostaglandin E on the response of the rabbit oviduct to hypogastric nerve stimulation. Acta physiol. scand.73, 54–57 (1968)PubMedCrossRefGoogle Scholar
  147. Buchan, P., Lewis, A.J., Sugrue, M.F.: A comparison of the accumulation of noradrenaline and 5-hydroxytryptamine into arterial smooth muscle. Brit. J. Pharmacol. 52, 132P–133P (1974)Google Scholar
  148. Bucknell, A., Whitney, B.: A preliminary investigation of the pharmacology of the human isolated taenia coli preparation. Brit. J. Pharmacol. 23, 164–175 (1964)PubMedGoogle Scholar
  149. Bullard, B.: The nervous control of the anterior byssus retractor muscle of Mytilus edulis. Comp. Biochem. Physiol. 23, 749–759 (1967)PubMedCrossRefGoogle Scholar
  150. Burgers, A.C.J., Imai, K.: The melanophore-stimulating potency of single pituitary glands of normal and of D-lysergic acid diethylamide (D-LSD)-treated Xenopus laevis. Gen. comp. Endocr. 2, 603–604 (1962)Google Scholar
  151. Burgers, A.C.J., Leemreis, W., Dominiczak, T., Van Oordt, G.J.: Inhibition of the secretion of intermedine by D-lysergic acid diethylamide (LSD-25) in the toad, Xenopus laevis. Acta endocr. (Kbh.) 29, 191–200 (1958)Google Scholar
  152. Burgers, A.C.J., Zandee, D.I., Van Bakel, J.M.M., Hillemans, G.M.L., Van Oordt, G.J.: The effect of LSD-derivatives and serotonin on the melanophores of the toad, Xenopus laevis. Acta physiol. pharmacol. need. 11, 341–342 (1962)Google Scholar
  153. Burn, J.H., Ng, K.K.F.: The action of Hydergine at postganglionic sympathetic terminations. J. Physiol. (Lond.) 175, 66P (1964)Google Scholar
  154. Burnstein, S., Levin, E., Varanelli, C.: Prostaglandins and cannabis — II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem. Pharmacol. 22, 2908–2910 (1973)Google Scholar
  155. Burt, D.R., Creese, I., Snyder, S.H.: Binding interaction of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Molec. Pharmacol. 12, 631–638 (1976a)Google Scholar
  156. Burt, D.R., Creese, I., Snyder, S.H.: Properties of [3H] haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Molec. Pharmacol. 12, 800–812 (1976b)Google Scholar
  157. Cambridge, G.W., Holgate, J.A.: Superfusion as a method for the study of drug antagonism. Brit. J. Pharmacol. 10, 326–334 (1955)PubMedGoogle Scholar
  158. Cannon, W.B., Rosenblueth, A.: Autonomic neuro-effector systems. Experimental Biology Monographs. New York: MacMillan 1937Google Scholar
  159. Carlsson, A., Lindqvist, M: The effect of L-tryptophan and some psychotropic drugs on the formation of 5-hydroxytryptophan in the mouse brain in vivo. J. Neural Transm. 33, 23–43 (1972)PubMedCrossRefGoogle Scholar
  160. Carlsson, A., Shore, P.A., Brodie, B.B.: Release of serotonin from blood platelets by reserpine in vitro. J. Pharmacol. exp. Ther. 120, 334–339 (1957)PubMedGoogle Scholar
  161. Carlsson, A., Bedard, P., Lindqvist, M., Magnusson, T.: The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine. Biochem. J. 128, 70P–71P (1972a)PubMedGoogle Scholar
  162. Carlsson, A., Bedard, P., Lindqvist, M., Magnusson, T.: The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. In: Neurotransmitters and Metabolic Regulation. Smellie, R.M.S. (ed.), pp. 17–32. London: The Biochemical Society 1972bGoogle Scholar
  163. Carpi, A., Virno, M.: The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog. Brit. J. Pharmacol. 12, 232–239 (1957)PubMedGoogle Scholar
  164. Carroll, P.R., Glover, W.E.: Independence of the vasoconstrictor and the potentiating effects of 5-hydroxytryptamine and some ergot derivatives. Proc. Aust. physiol. pharmacol. Soc. 4, 40 (1973)Google Scholar
  165. Carroll, P.R., Ebeling, P.W., Glover, W.E.: Vascular responses to some drugs used in the treatment of migraine. Abstracts, Australasian Society for Clinical and Experimental Pharmacologists, November 1972Google Scholar
  166. Carroll, P.R., Ebeling, P.W., Glover, W.E.: The responses of the human temporal and rabbit ear artery to 5-hydroxytryptamine and some of its antagonists. Ajebak 52, 813–823 (1974)PubMedGoogle Scholar
  167. Casentini, S., Galli, G.: Serotonina, antiserotoninici e motilita gastrica. Boll. Soc. ital. Biol. sper. 32, 1640–1642 (1956)PubMedGoogle Scholar
  168. Cerletti, A.: Lysergic acid diethylamide (LSD) and related compounds. In: Neuropharmacology. Abramson, H.A. (ed.), pp. 9–84. Trans. Second Conf. Princeton: Josiah Macy, Jr., Foundation 1955Google Scholar
  169. Cerletti, A.: Ergostin — Neue Perspektiven der Chemie und Pharmakologie des Mutterkorns. Med. exp. (Basel) 8, 278–286 (1963)CrossRefGoogle Scholar
  170. Cerletti, A., Berde, B.: Die Wirkung von D-Lysergsäure-diäthylamid (LSD 25) und 5-Oxytryptamin auf die Chromatophoren von Poecilia reticulatus. Experientia (Basel) 11, 312–313 (1955)CrossRefGoogle Scholar
  171. Cerletti, A., Berde, B.: New approaches in the development of compounds from ergot with potential therapeutic use in migraine. In: Background to Migraine. Smith, R. (ed.), pp. 53–64. London: William Heinemann Medical Books 1967Google Scholar
  172. Cerletti, A., Doepfner, W.: Über die 5-Oxytryptamin-hemmende Wirkung von LSD-Derivaten und andern Lysergsäureamiden am isolierten Rattenuterus. 20th Intern. Physiol. Congress Bruxelles, 1956, Abstr. Comm., pp. 165–166Google Scholar
  173. Cerletti, A., Doepfner, W.: Spezifische Steigerung der serotonin-antagonistischen Wirkung von Lysergsäurederivaten durch Methylierung des Indolstickstoffes der Lysergsäure. Helv. physiol. pharmacol. Acta 16, C55–C57 (1958a)Google Scholar
  174. Cerletti, A., Doepfner, W.: Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. Pharmacol. exp. Ther. 122, 124–136 (1958b)PubMedGoogle Scholar
  175. Cerletti, A., Konzett, H.: Spezifische Hemmung von 5-Oxytryptamin-Effekten durch Lysergsäurediäthylamid und ähnliche Körper. Naunyn-Schmiedebergs Arch. Pharmacol. 228, 146–148 (1956)CrossRefGoogle Scholar
  176. Cerletti, A., Rothlin, E.: Role of 5-hydroxytryptamine in mental diseases and its antagonism to lysergic acid derivatives. Nature (Lond.) 176, 785–786 (1955)CrossRefGoogle Scholar
  177. Chahl, L.A., Ladd, R.J.: The effects of prostaglandins E1, E2 and F on the cutaneous vasculature of the rat. Brit. J. Pharmacol. 56, 317–322 (1976)Google Scholar
  178. Chahl, L.A., O’Donnell, S.R.: The effects on some receptors of guinea-pig trachea of a series of sympathomimetic amines. Europ. J. Pharmacol. 16, 201–208 (1971)CrossRefGoogle Scholar
  179. Chambers, P.N., Marshall, P.B.: Similar pharmacological properties of ergometrine and methysergide. J. Pharm. Pharmacol. 19, 65 (1967)PubMedCrossRefGoogle Scholar
  180. Chan, P.S., Ellenbogen, L.: New evidence for the β-adrenergic receptor blocking activity of dihydroergotamine. Arch. int. Pharmacodyn. 209, 204–213 (1974)PubMedGoogle Scholar
  181. Chase, T.N., Breese, G.R., Kopin, I.J.: Serotonin release from brain slices by electrical stimulation: Regional differences and effect of LSD. Science 157, 1461–1463 (1967)PubMedCrossRefGoogle Scholar
  182. Chase, T.N., Katz, R.I., Kopin, I.J.: Release of [3H] serotonin from brain slices. J. Neurochem. 16, 607–615 (1969)PubMedCrossRefGoogle Scholar
  183. Chodera, A.: Blockade of 5-hydroxytryptamine antidiuresis in rats by 2-bromlysergic acid diethylamide tartrate and 1-methyl-lysergic acid butanolamide. J. Pharm. Pharmacol. 15, 386–389 (1963)PubMedCrossRefGoogle Scholar
  184. Chong, G.C., Phillis, J.W.: Pharmacological studies on the heart of Tapes watlingi: A mollusc of the family Veneridae. Brit. J. Pharmacol. 25, 481–496 (1965)PubMedGoogle Scholar
  185. Christ, D.D., Nishi, S.: Site of adrenaline blockade in the superior cervical ganglion of the rabbit. J. Physiol. (Lond.) 213, 107–117 (1971)Google Scholar
  186. Christian, S.T., McClain, L.D., Morin, R.D., Benington, F.: Blockage of LSD binding at its high affinity site on synaptosomal membranes by 1-methyl-1,2,5,6-tetrahydropyridine-N,N-diethyl-carboxamide. Experientia (Basel) 31, 910–911 (1975)CrossRefGoogle Scholar
  187. Chu, D., Sturmer, E.: Studies on the mechanism of action of dihydroergotamine (DHE) on the vascular bed of cat skeletal muscle. Brit. J. Pharmacol. 48, 331P–332P (1973)Google Scholar
  188. Chu, D., Owen, D.A.A., Stürmer, E.: Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad. med. J. 52 (Suppl. 1), 32–36 (1976)Google Scholar
  189. Church, M.K.: Response of rat lung to humoral mediators of anaphylaxis and its modification by drugs and sensitization. Brit. J. Pharmacol. 55, 423–430 (1975)Google Scholar
  190. Church, M.K., Miller, P.: Simple models of anaphylaxis and of histamine and 5-hydroxytryptamine induced inflammation using the mouse pinna. Brit. J. Pharmacol. 55, 315P (1975)Google Scholar
  191. Cima, G., Freschi, C.: Attivitá della serotonina e dei suoi antagonisti sull’uretere isolato. Boll. Soc. ital. Biol. sper. 33, 867–869 (1957)PubMedGoogle Scholar
  192. Cleugh, J., Gaddum, J.H., Holton, P., Leach, E.: Assay of substance P on the fowl rectal caecum. Brit. J. Pharmacol. 17, 144–158 (1961)PubMedGoogle Scholar
  193. Clineschmidt, B.V., Anderson, E.G.: Lysergic acid diethylamide: antagonism of supraspinal inhibiton of spinal reflexes. Brain Res. 16, 296–300 (1969)PubMedCrossRefGoogle Scholar
  194. Clineschmidt, B.V., Anderson, E.G.: The blockade of bulbospinal inhibition by 5-hydroxytryptamine antagonists. Exp. Brain Res. 11, 175–186 (1970)PubMedCrossRefGoogle Scholar
  195. Clineschmidt, B.V., Lotti, V.J.: Indoleamine antagonists: relative potencies as inhibitors of tryptamine-and 5-hydroxytryptophan-evoked responses. Brit. J. Pharmacol. 50, 311–313 (1974)Google Scholar
  196. Closse, A., Hauser, D.: Dihydroergotamine binding to rat brain membranes. Life Sci. 19, 1851–1864 (1976)PubMedCrossRefGoogle Scholar
  197. Cohen, M.L., Berkowitz, B.A.: Differences between the effects of dopamine and apomorphine on rat aortic strips. Europ. J. Pharmacol. 34, 49–58 (1975)CrossRefGoogle Scholar
  198. Collier, J.G., Nachev, C., Robinson, B.F.: Effect of catecholamines and other vasoactive substances on superficial hand veins in man. Clin. Sci. 43, 455–467 (1972)PubMedGoogle Scholar
  199. Constantine, J.W., Knott, C.: Benzquinamide and the 5-hydroxytryptamine receptors in guinea pig trachea. J. Pharmacol. exp. Ther. 146, 400–403 (1964)PubMedGoogle Scholar
  200. Cools, A.R.: Two topographically, functionally and pharmacologically distinct dopamine-sensitive sites within the cat brain. Sixth Internat. Congr. Pharmacol., Helsinki, 1975, Abstract 1149Google Scholar
  201. Cools, A.R., Van Rossum, J.M.: Excitation-mediating and inhibition-mediating dopaminereceptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data. Psychopharmacologia 45, 243–254 (1976)PubMedCrossRefGoogle Scholar
  202. Cools, A.R., Struyker Boudier, H.A.J., Van Rossum, J.M.: Depamine receptors: Selective agonists and antagonists of functionally distinct types within the feline brain. Europ. J. Pharmacol. 37, 283–293 (1976)CrossRefGoogle Scholar
  203. Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J. Pharm. Pharmacol. 25, 409–412 (1973)PubMedCrossRefGoogle Scholar
  204. Corrodi, H., Farnebo, L.O., Fuxe, K., Hamberger, B.: Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Europ. J. Pharmacol. 30, 172–181 (1975)CrossRefGoogle Scholar
  205. Costa, E.: Effects of hallucinogenic and tranquilizing drugs on serotonin evoked uterine contractions. Proc. Soc. exp. Biol. (N.Y.) 91, 39–41 (1956)Google Scholar
  206. Costa, E., Zetler, G.: Interactions between epinephrine and some psychotomimetic drugs. J. Pharmacol. exp. Ther. 125, 230–236 (1959)PubMedGoogle Scholar
  207. Costall, B., Naylor, R.J.: Apomorphine as an antagonist of the dopamine response from the nucleus accumbens. J. Pharm. Pharmacol. 28, 592–595 (1976)PubMedCrossRefGoogle Scholar
  208. Cottrell, G.A.: Direct post-synaptic responses to stimulation of serotonin-containing neurons. Nature (Lond.) 225, 1060–1062 (1970a)CrossRefGoogle Scholar
  209. Cottrell, G.A.: Actions of LSD-25 and reserpine on a serotonergic synapse. J. Physiol. (Lond.) 208, 28P–29P (1970b)Google Scholar
  210. Cottrell, G.A., Macon, J.B.: Synaptic connexions of two symmetrically placed giant serotonin-containing neurones. J. Physiol. (Lond.) 236, 435–464 (1974)Google Scholar
  211. Cottrell, G.A., Berry, M.S., Macon, J.B.: Synapses of a giant serotonin neurone and a giant dopamine neurone: studies using antagonists. Neuropharmacology 13, 431–439 (1974)PubMedCrossRefGoogle Scholar
  212. Couch, J.R.: Blockade of excitatory 5-HT synapse by LSD. Pharmacologist 16, 244 (1974)Google Scholar
  213. Creese, I., Burt, D.R., Snyder, S.H.: The dopamine receptor: differential binding of D-LSD and related agents to agonist and antagonist states. Life Sci. 17, 1715–1720 (1976)CrossRefGoogle Scholar
  214. Cripps, H., Dearnaley, D.P.: Evidence suggesting uptake of noradrenaline at adrenergic receptors in the isolated blood-perfused cat spleen. J. Physiol. (Lond.) 216, 55P–56P (1971)Google Scholar
  215. Cripps, H., Dearnaley, D.P.: Vascular responses and noradrenaline overflow in the isolated blood-perfused cat spleen: some effects of cocaine, normetanephrine and α-blocking agents. J. Physiol. (Lond.) 227, 647–664 (1972)Google Scholar
  216. Crossman, A.R., ElKhawad, A.O.A., Walker, R.J., Woodruff, G.N.: Effects of ergometrine on dopamine receptors. J. Physiol. (Lond.) 232, 59P (1973)Google Scholar
  217. Crunkhorn, P., Meacock, S.C.R.: Mediators of the inflammation induced in the rat paw by carrageenin. Brit. J. Pharmacol. 42, 392–402 (1971)Google Scholar
  218. Crunkhorn, P., Willis, A.L.: Cutaneous reactions to intradermal prostaglandins. Brit. J. Pharmacol. 41, 49–56 (1971)Google Scholar
  219. Cuatrecasas, P., Greaves, M.F.: Receptors and recognition. Series A, Vol. I. London: Chapman and Hall; New York: Wiley 1976Google Scholar
  220. Cuatrecasas, P., Hollenberg, M.D., Chang, K.-J., Bennett, V.: Hormone receptor complexes and their modulation of membrane function. Recent Progr. Hormone Res. 31, 37–94 (1975)PubMedGoogle Scholar
  221. Cumings, J.N.: The relationship of serotonin and platelets in migraine. Arch. Neurobiol. 37 (Suppl.), 67–75, 77–84 (1974)Google Scholar
  222. Cumings, J.N., Hilton, B.P.: Effects of methysergide on platelets incubated with reserpine. Brit. J. Pharmacol. 42, 611–619 (1971)Google Scholar
  223. Curtis, D.R., Davis, R.: A central action of 5-hydroxytryptamine and noradrenaline. Nature (Lond.) 192, 1083–1084 (1961)CrossRefGoogle Scholar
  224. Curtis, D.R., Davis, R.: Pharmacological studies upon neurons of the lateral geniculate nucleus of the cat. Brit. J. Pharmacol. 18, 217–246 (1962)PubMedGoogle Scholar
  225. Curzon, G., Marsden, C.A.: Effect of LSD on rat brain 5-hydroxytryptamine metabolism at elevated environmental temperature. Brit. J. Pharmacol. 56, 368P–369P (1976)Google Scholar
  226. Dahlström, A., Fuxe, K.: Evidence for the existence of mono-amine neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta physiol. scand. 62 (Suppl. 232), 5–55 (1964)Google Scholar
  227. Dahlström, A., Fuxe, K.: Evidence for the existence of mono-amine neurons in the central nervous system. II. Experimentally induced changes in the intraneuronal amine levels of bulbospinal neuron systems. Acta physiol. scand. 64 (Suppl. 247), 7–36 (1965)Google Scholar
  228. Daicoff, G.R., Chavez, F.R., Anton, A.H., Swenson, E.W.: Serotonin-induced pulmonary venous hypertension in pulmonary embolism. Thorac. cardiovasc. Surg. 56, 810–815 (1968)Google Scholar
  229. Dale, H.H.: On some physiological actions of ergot. J. Physiol. (Lond.) 34, 163–206 (1906)Google Scholar
  230. Dalessio, D.J., Camp, W.A., Goodell, H., Chapman, L.F., Zileli, T., Ramos, A.O., Ehrlich, R., Fortuin, F., McCattell, K., Wolff, H.C.: Studies on headache: the relevance of the prophylactic action of UML-491 in vascular headache of the migraine type to the pathophysiology of this syndrome. Wld Neurol. 3, 66–72 (1962)Google Scholar
  231. Da Graca-Fernandez, M., Osswald, W.: Einfluss von Ergotamin und Pentobarbital auf die Blutdruck-und Nickhautwirkungen von Noradrenalin und Tyramin. Med. Pharmacol. exp. 17, 65–71 (1967)Google Scholar
  232. D’Amico, D.J., Patel, B.C., Klawans, H.L.: The effect of methysergide on 5-hydroxytryptamine turnover in whole brain. J. Pharm. Pharmacol. 28, 454–456 (1976)PubMedCrossRefGoogle Scholar
  233. Da Prada, M., Saner, A., Burkhard, W.P., Bartholini, G., Pletscher, A.: Evidence for stimulation of cerebral dopamine receptors by LSD. Sixth Internat. Congr. Pharmacol., Helsinki, 1975a, Abstract 187Google Scholar
  234. Da Prada, M., Saner, A., Burkard, W.P., Bartholini, G., Pletscher, A.: Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors. Brain Res. 94, 67–73 (1975b)PubMedCrossRefGoogle Scholar
  235. Davis, M.E., Adair, F.L., Chen, K.K., Swanson, E.E.: The pharmacologic action of ergotocin, a new ergot principle. J. Pharmacol. exp. Ther. 54, 398–407 (1935)Google Scholar
  236. Davis, W.G: A dual action of 5-hydroxytryptamine on the ovarian suspensory ligament of the rat. J. Pharm. Pharmacol. 28, 502–504 (1976)PubMedCrossRefGoogle Scholar
  237. Day, M., Vane, J.R.: An analysis of the direct and indirect actions of drugs on the isolated guinea-pig ileum. Brit. J. Pharmacol. 20, 150–170 (1963)PubMedGoogle Scholar
  238. Deffenu, G., Mantegazzini, P.: Effects of 5-hydroxytryptamine on spinal reflexes of the cat. Psychopharmacologia 10, 96–102 (1966)PubMedCrossRefGoogle Scholar
  239. De La Lande, I.S., Cannel, V.A., Waterson, J.G: The interaction of serotonin and noradrenaline on the perfused artery. Brit. J. Pharmacol. 28, 255–272 (1966)Google Scholar
  240. De La Lande, I.S., Rand, M.J.: A simple isolated nerve-blood vessel preparation. Aust. J. exp. Biol. med. Sci. 43, 639–656 (1965)PubMedCrossRefGoogle Scholar
  241. Delay, J., Thuillier, J.: Dualité d’action du diethylamide de l’acide lysergique sur la contraction uterine provoquée par la 5-hydroxytryptamine (sérotonine). C.R. Soc. Biol. (Paris) 150, 1335–1336 (1956)Google Scholar
  242. Del Bianco, P.L., Fanciullacci, M., Franchi, G., Sicuteri, F.: Human 5-hydroxytryptamine venomotor receptors. Pharmacol. Res. Commun. 7, 395–408 (1975)CrossRefGoogle Scholar
  243. Del Bianco, P.L., Franchi, G., Fanciullacci, M., Sicuteri, F.: Clinical pharmacology of 5-hydroxytryptamine and catecholamines venomotor receptors. Arch. int. Pharmacodyn. 196 (Suppl.), 113–116 (1972)PubMedGoogle Scholar
  244. Del Greco, F., Masson, G.M.C., Corcoran, A.C.: Renal and arterial effects of serotonin in the anesthetized rat. Amer. J. Physiol. 187, 509–514 (1956)Google Scholar
  245. Dengler, H.J., Spiegel, H.E., Titus, E.O.: Effects of drugs on uptake of isotopic norepinephrine by cat tissues. Nature (Lond.) 191, 816–817 (1961)CrossRefGoogle Scholar
  246. Dette, G.A., Wesemann, W.: Studies on serotonin binding proteins of nerve ending membranes. J. Neural Transm. 37, 281–295 (1975)PubMedCrossRefGoogle Scholar
  247. Diab, I.M., Freedman, D.X., Roth, L.J.: [3H] Lysergic acid diethylamide: cellular autoradiographic localization in rat brain. Science 173, 1022–1024 (1971)PubMedCrossRefGoogle Scholar
  248. Diaz, J.-L., Huttunen, M.O.: Persistent increase in brain serotonin turnover after chronic administration of LSD in the rat. Science 174, 62–64 (1971)PubMedCrossRefGoogle Scholar
  249. Diaz, P., Ngai, S.H., Costa, E.: The effect of LSD on the metabolism of rat brain serotonin (5-HT). Pharmacologist 9, 251 (1967)Google Scholar
  250. Diaz, P.M., Ngai, S.H., Costa, E.: Factors modulating brain serotonin turnover. Adv. Pharmacol. Chemother. 6B, 75–92 (1968)CrossRefGoogle Scholar
  251. Dingledine, R., Goldstein, A., Kendig, J.: Effects of narcotic opiates and serotonin on the electrical behaviour of neurons in the guinea-pig myenteric plexus. Life Sci. 14, 2299–2309 (1974)PubMedCrossRefGoogle Scholar
  252. Doepfner, W., Cerletti, A.: Über den Serotonin-Antagonismus einiger Antihistaminika unter Berücksichtigung ihrer chemischen Struktur. Int. Arch. Allergy 10, 348–354 (1957)PubMedCrossRefGoogle Scholar
  253. Doepfner, W., Cerletti, A.: Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat’s paw by serotonin. Int. Arch. Allergy 12, 89–97 (1958)PubMedCrossRefGoogle Scholar
  254. Dougan, D.F.H., McLean, J.R.: Evidence for the presence of dopaminergic nerves and receptors in the intestine of a mollusc, Tapes watlingi. Comp. gen. Pharmacol. 1, 33–46 (1970)PubMedCrossRefGoogle Scholar
  255. Drakontides, A.B., Gershon, M.D.: 5-Hydroxytryptamine receptors in the mouse duodenum. Brit. J. Pharmacol. 33, 480–492 (1968)PubMedGoogle Scholar
  256. Dretchen, K., Ghoneim, M.M., Long, J.P.: Interactions of serotonin with neuromuscular blocking agents. Europ. J. Pharmacol. 18, 121–127 (1972)CrossRefGoogle Scholar
  257. Drew, G.M.: Effects of α-adrenoceptor agonists and antagonists on pre-and postsynaptically located α-adrenoceptors. Europ. J. Pharmacol. 36, 313–320 (1976)CrossRefGoogle Scholar
  258. Drummond, A.H., Gordon, J.L.: Platelet release reaction induced by 5-hydroxytryptamine. J. Physiol. (Lond.) 240, 39P–40P (1974)Google Scholar
  259. Drummond, A.H., Gordon, J.L.: Inhibition of 5-hydroxy-[3H]-tryptamine binding to rat blood platelets by 5-HT antagonists and uptake inhibitors. Brit. J. Pharmacol. 55, 257–258 (1975a)Google Scholar
  260. Drummond, A.H., Gordon, J.L.: Specific binding sites for 5-hydroxytryptamine on rat blood platelets. Biochem. J. 150, 129–132 (1975b)PubMedGoogle Scholar
  261. Drummond, A.H., Whigham, K.A.E., Prentice, C.R.M.: Effects of chlorprothixene isomers on platelet 5-hydroxytryptamine receptors: evidence for different 5-hydroxytryptamine conformations at uptake and stimulatory sites. Europ. J. Pharmacol. 37, 385–388 (1976)CrossRefGoogle Scholar
  262. Dyer, D.C.: The pharmacology of spirally-cut sheep umbilical blood vessels. Pharmacologist 11, 230 (1969)Google Scholar
  263. Dyer, D.C.: The pharmacology of isolated sheep umbilical blood vessels. J. Pharmacol. exp. Ther. 175, 565–570 (1970)PubMedGoogle Scholar
  264. Dyer, D.C.: Evidence for the action of D-lysergic acid diethylamide, mescaline and bufotenine on 5-hydroxytryptamine receptors in umbilical vasculature. J. Pharmacol. exp. Ther. 188, 336–341 (1974)PubMedGoogle Scholar
  265. Dyer, D.C., Gant, D.W.: Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature. J. Pharmacol. exp. Ther. 184, 366–375 (1973)PubMedGoogle Scholar
  266. Dyer, D.C., Ueland, K., Eng, M.: Responses of isolated monkey umbilical veins to biogenic amines and polypeptides. Arch. int. Pharmacodyn. 200, 213–221 (1972)PubMedGoogle Scholar
  267. Dykstra, S.L., Berdahl, J.M., Campbell, K.N., Combs, C.M., Lankin, D.G: Phenylindenes and phenylindans with antireserpine activity. J. med. Chem. 10, 418–428 (1967)PubMedCrossRefGoogle Scholar
  268. Dykstra, S.J., Minielli, J.L., Lawson, J.E., Ferguson, H.C., Dungan, K.W.: Lysergic acid and quinidine analogs. 2-(O-acylamino-phenethyl) piperidines. J. med. Chem. 16, 1015–1020 (1973)PubMedCrossRefGoogle Scholar
  269. Ehrenpreis, S., Fleisch, J.H., Mittag, T.W.: Approaches to the molecular nature of pharmacological receptors. Pharmacol. Rev. 21, 131–181 (1969)PubMedGoogle Scholar
  270. Eliasson, R., Åström, A.: Pharmacological studies on the perfused human placenta. Acta Pharmacol. (Kbh.) 11, 254–264 (1955)CrossRefGoogle Scholar
  271. ElKhawad, A.O., Woodruff, G.N.: Evidence for direct stimulation of dopamine receptors by ergometrine in mice and rats. Sixth Internat. Congr. Pharmacol., Helsinki, 1975, Abstract 1147Google Scholar
  272. ElKhawad, A.O., Munday, K.A., Poat, J.A., Woodruff, G.N.: The effect of dopamine receptor stimulants on locomotor activity and cyclic AMP levels in the rat striatum. Brit. J. Pharmacol. 53, 456P–457P (1975)Google Scholar
  273. Engberg, I., Lundberg, A., Ryall, R.W.: The effect of reserpine on transmission from the flexor reflex afferents. Acta physiol. scand. 68 (Suppl. 277), 45 (1966)Google Scholar
  274. Engberg, I., Lundberg, A., Ryall, R.W.: The effect of reserpine on transmission in the spinal cord. Acta physiol. scand. 72, 115–122 (1968a)PubMedCrossRefGoogle Scholar
  275. Engberg, I., Lundberg, A., Ryall, R.W.: Is the tonic decerebrate inhibition of reflex paths mediated by monoaminergic pathways? Acta physiol. scand. 72, 123–133 (1968b)PubMedCrossRefGoogle Scholar
  276. Engelhardt, G.: Zur Pharmakologie des 9,10-Dihydro-10-(1-methyl-4-piperidyliden)-9-anthrol (WA 335), eines Histamin-und Serotoninantagonisten. Arzneimittel-Forsch. 25, 1723–1737 (1975)Google Scholar
  277. Erspamer, V.: Modificazioni delle azioni dell enteramina ad opera di farmaci simpaticomimetici e di farmaci simpaticolitici. Ricerca Sci. 22, 1568–1577 (1952)Google Scholar
  278. Erspamer, V.: Pharmacological studies on enteramine (5-Hydroxytryptamine). Arch. int. Pharmacodyn. 93, 293–316 (1953)PubMedGoogle Scholar
  279. Euler, U.S.v.: Effect of some metabolic factors and drugs on uptake and release of catecholamines in vitro and in vivo. In: New Aspects of Storage and Release Mechanisms of Catecholamines. Schumann, H.J., Kroneberg, G. (eds.), pp. 144–158. Berlin-Heidelberg-New York: Springer 1970Google Scholar
  280. Euler, U.S.v.: Adrenergic nerve particles in relation to uptake and release of neurotransmitter. J. Endocr. 55, 2–9 (1972)Google Scholar
  281. Euler, U.S.v., Hedqvist, P.: Inhibitory action of prostaglandins E1 and E2 on the neuromuscular transmission in the guinea-pig vas deferens. Acta physiol. scand. 77, 510–512 (1969)CrossRefGoogle Scholar
  282. Euler, U.S.v., Lishajko, F.: Inhibitory action of adrenergic blocking agents on catecholamine release and uptake in isolated nerve granules. Acta physiol. scand. 68, 257–262 (1966)CrossRefGoogle Scholar
  283. Euler, U.S.v., Lishajko, F.: Inhibitory action of adrenergic blocking agents on reuptake and net uptake of noradrenaline in nerve granules. Acta physiol. scand. 74, 501–506 (1968)CrossRefGoogle Scholar
  284. Evans, D.H.L., Schild, H.O., Thesleff, S.: Effects of drugs on depolarized plain muscle. J. Physiol. (Lond.) 143, 474–485 (1958)Google Scholar
  285. Eyre, P.: Pharmacology of bovine pulmonary vein anaphylaxis in vitro. Brit. J. Pharmacol. 43, 302–311 (1971)Google Scholar
  286. Eyre, P.: Atypical tryptamine receptors in sheep pulmonary vein. Brit. J. Pharmacol. 55, 329–333 (1975)Google Scholar
  287. Fanchamps, A., Doepfner, W., Weidmann, H., Cerletti, A.: Pharmakologische Charakterisierung von Deseril, einem Serotonin-Antagonisten. Schweiz. med. Wschr. 90, 1040–1046 (1960)PubMedGoogle Scholar
  288. Fanciullacci, M., Franchi, G., Sicuteri, F.: Facilitazione dell’ azione venocostrittrice della 5-idrossitriptamina da ergotamina, metisergide e LSD-25 nell’uomo. Boll. Soc. ital. Biol. sper. 51, 517–522 (1975)PubMedGoogle Scholar
  289. Fara, J.: Mesenteric vasodilator responses to 5-hydroxytryptamine. Gastroenterology 66, 689 (1974)Google Scholar
  290. Farnebo, L.-O., Hamberger, B.: Drug-induced changes in the release of [3H]-noradrenaline from field stimulated rat iris. Brit. J. Pharmacol. 43, 97–106 (1971a)Google Scholar
  291. Farnebo, L.-O., Hamberger, B.: Drug-induced changes in the release of 3H-monoamines from field stimulated rat brain slices. Acta physiol. scand. (Suppl.) 371, 35–44 (1971b)CrossRefGoogle Scholar
  292. Farnebo, L.-O., Hamberger, B.: Regulation of [3H] 5-hydroxytryptamine release from rat brain slices. J. Pharm. Pharmacol. 26, 642–644 (1974)PubMedCrossRefGoogle Scholar
  293. Farrow, J.T., Van Vunakis, H.: Binding of D-lysergic acid diethylamide to subcellular fractions from rat brain. Nature (Lond.) 237, 164–165 (1972)CrossRefGoogle Scholar
  294. Farrow, J.T., Van Vunakis, H.: Characteristics of D-lysergic acid diethylamide binding to subcellular fractions derived from rat brain. Biochem. Pharmacol. 22, 1103–1113 (1973)PubMedCrossRefGoogle Scholar
  295. Feldman, J.M., Lebovitz, H.E.: Specificity of serotonin inhibition of insulin release from golden hamster pancreas. Diabetes 19, 475–479 (1970a)PubMedGoogle Scholar
  296. Feldman, J.M., Lebovitz, H.E.: Mechanism of epinephrine and serotonin inhibition of insulin release in the golden hamster in vitro. Diabetes 19, 480–486 (1970b)PubMedGoogle Scholar
  297. Ferrini, R., Glässer, A.: Antagonism of central effects of tryptamine and 5-hydroxytryptophan by 1,6-dimethyl-8β-carbo-benzyloxyaminomethyl-10α-ergoline). Psychopharmacologia 8, 271–276 (1965)PubMedCrossRefGoogle Scholar
  298. Fillion, G., Fillion, M.-P., Spirakis, Ch., Bahers, J.-M., Jacob, J.: 5-Hydroxytryptamine binding to synaptic membranes from rat brain. Life Sci. 18, 65–74 (1976)PubMedCrossRefGoogle Scholar
  299. Fingerman, M., Rao, K.R.: Action of biogenic amines on crustacean chromatophores. Comp. gen. Pharmacol. 1, 341–348 (1970)PubMedCrossRefGoogle Scholar
  300. Fingl, E., Gaddum, J.H.: Hydroxytryptamine blockade by dihydroergotamine in vitro. Fed. Proc. 12, 320 (1953)Google Scholar
  301. Fishlock, D.J.: The action of 5-hydroxytryptamine on the circular muscle of the human ileum and colon in vitro. J. Physiol. (Lond.) 170, 11P–12P (1964)Google Scholar
  302. Fishlock, D.J., Parks, A.G., Dewell, J.V.: Action of 5-hydroxytryptamine on the human stomach, duodenum and jejunum in vitro. Gut 6, 338–342 (1965)PubMedCrossRefGoogle Scholar
  303. Fleckenstein, A.: A quantitative study of antagonists of adrenaline on the vessels of the rabbit’s ear. Brit. J. Pharmacol. 7, 553–562 (1952)PubMedGoogle Scholar
  304. Fleisch, J.H., Maling, H.M., Brodie, B.B.: Evidence for existence of alpha-adrenergic receptors in the mammalian trachea. Amer. J. Physiol. 218, 596–599 (1970)PubMedGoogle Scholar
  305. Flückiger, E., Balthasar, H.U.: Dihydroergocristin: Unterschiedliche Wirkungen an venösem und arteriellem Gewebe. Arzneimittel-Forsch. 17, 6–9 (1967)Google Scholar
  306. Flückiger, E., Salzmann, R.: Serotoninantagonismus an der Placenta. Experientia (Basel) 17, 131 (1961)CrossRefGoogle Scholar
  307. Foote, W.E., Sheard, M.H., Aghajanian, G.K.: Comparison of effects of LSD and amphetamine on midbrain raphe units. Nature (Lond.) 222, 567–569 (1969)CrossRefGoogle Scholar
  308. Fozard, J.R.: Clonidine and methysergide: effects on an isolated artery. Naunyn-Schmiedebergs Arch. Pharmacol. 279 (Suppl.), R21 (1973a)Google Scholar
  309. Fozard, J.R.: Drug interactions on an isolated artery. In: Background to Migraine. Cumings, J.N. (ed.), pp. 150–169. London: William Heinemann Medical Books 1973bGoogle Scholar
  310. Fozard, J.R.: The mechanisms by which migraine prophylactic drugs modify vascular reactivity in vitro. “Headache ‘76”, Joint Meeting of the Italian Headache and the Scandinavian Migraine Societies, Florence, 1976a, Abstract, pp. 7–8Google Scholar
  311. Fozard, J.R.: Comparative effects of four migraine prophylactic drugs on an isolated extracranial artery. Europ. J. Pharmacol. 36, 127–139 (1976b)CrossRefGoogle Scholar
  312. Fozard, J.R., Berry, J.L.: Interactions between antimigraine drugs and a high affinity uptake and storage machanism for 5-hydroxytryptamine. Pharmacology 14, 357–361 (1976)PubMedCrossRefGoogle Scholar
  313. Fozard, J.R., Leach, G.D.H.: The hypotensive action of 5-hydroxytryptamine (5-HT) in anaesthetised and pithed rats. Europ. J. Pharmacol. 2, 239–249 (1968)CrossRefGoogle Scholar
  314. Fozard, J.R., Wright, J.L.: Interaction between antimigraine drugs and a high affinity uptake and storage mechanism for 5-hydroxytryptamine. Sixth Migraine Symposium, London, 1974, Abstract, pp. 9–10Google Scholar
  315. Frankhuijzen, A.L.: Analysis of ergotamine-5-HT interaction on the isolated rat stomach preparation. Europ. J. Pharmacol. 30, 205–212 (1975)CrossRefGoogle Scholar
  316. Frankhuijzen, A.L., Bonta, I.L.: Effect of mianserin, a potent anti-serotonin agent, on the isolated rat stomach fundus preparation. Europ. J. Pharmacol. 25, 40–50 (1974a)CrossRefGoogle Scholar
  317. Frankhuijzen, A.L., Bonta, I.L.: Receptors involved in the action of 5-HT and tryptamine on the isolated rat stomach fundus preparation. Europ. J. Pharmacol. 26, 220–230 (1974b)CrossRefGoogle Scholar
  318. Fredholm, B.B., Rosell, S.: Fate of 3H-noradrenaline in canine subcutaneous adipose tissue. Acta physiol. scand. 80, 404–411 (1970)PubMedCrossRefGoogle Scholar
  319. Freedman, D.X.: LSD-25 and brain serotonin in reserpinized rat. Fed. Proc. 19, 266 (1960)Google Scholar
  320. Freedman, D.X.: Effects of LSD-25 on brain serotonin. J. Pharmacol. exp. Ther. 134, 160–166 (1961)PubMedGoogle Scholar
  321. Freedman, D.X.: Psychotomimetic drugs and brain biogenic amines. Amer. J. Psychiat. 119, 843–850 (1963)PubMedGoogle Scholar
  322. Freedman, D.X.: Aspects of the biochemical pharmacology of psychotropic drugs. In: Psychiatric Drugs. Solomon, P. (ed.), pp. 32–57. New York: Grune and Stratton 1966Google Scholar
  323. Freedman, D.X.: LSD, psychotogenic procedures and brain neuro-humors. Psychopharmacol. Bull. 11, 42–43 (1975)PubMedGoogle Scholar
  324. Freedman, D.X., Aghajanian, G.K.: Approaches to the pharmacology of LSD-25. Lloydia 29, 309–314 (1967)Google Scholar
  325. Freedman, D.X., Boggan, W.O.: Brain serotonin metabolism after tolerance dosage of LSD. Adv. Biochem. Psychopharmacol. 10, 151–157 (1974)PubMedGoogle Scholar
  326. Freedman, D.X., Coquet, C.A.: Regional and subcellular distribution of LSD and effects on 5-HT levels. Pharmacologist 7, 183 (1965)Google Scholar
  327. Freedman, D.X., Giarman, N.J.: LSD-25 and the status and level of brain serotonin. Ann. N.Y. Acad. Sci. 96, 98–106 (1962)PubMedCrossRefGoogle Scholar
  328. Freedman, D.X., Gottlieb, R., Lovell, R.A.: Psychotomimetic drugs and brain 5-hydroxytryptamine metabolism. Biochem. Pharmacol. 19, 1181–1188 (1970)CrossRefGoogle Scholar
  329. Fregnan, G.B., Glässer, A.H.: Activity of eledoisin, other polypeptides and ergometrine on the uterus in situ of rabbit and other animal species. J. Pharm. Pharmacol. 16, 744–750 (1964)PubMedCrossRefGoogle Scholar
  330. Fregnan, G.B., Glasser, A.H.: Structure-activity relationship of various acyl derivatives of 6-methyl-8β-aminomethyl-10α-ergoline (dihydrolysergamine). Experientia (Basel) 24, 150–151 (1968)CrossRefGoogle Scholar
  331. Froment, J.L., Eskazan, E., Jouvet, M.: Effets du LSD et du méthysergide sur les pointes ponto géniculo occipitales. C.R. Soc. Biol. (Paris) 165, 2153–2157 (1971)Google Scholar
  332. Furchgott, R.F.: Dibenamine blockade in strips of rabbit aorta and its use in differentiating receptors. J. Pharmacol. exp. Ther. 111, 265–284 (1954)PubMedGoogle Scholar
  333. Furchgott, R.F.: The pharmacology of vascular smooth muscle. Pharmacol. Rev. 7, 183–265 (1955)PubMedGoogle Scholar
  334. Furchgott, R.F.: Receptors for sympathomimetic amines. In: Ciba Foundation Symposium on Adrenergic Mechanisms. Wolstenholme, G.E.W., O’Connor, M. (eds.), pp. 246–252. London: J. and A. Churchill 1960Google Scholar
  335. Furchgott, R.F.: The pharmacological differentiation of adrenergic receptors. Ann. N.Y. Acad. Sci. 139, 553–570 (1967)PubMedCrossRefGoogle Scholar
  336. Furchgott, R.F.: The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Handbook of Experimental Pharmacology. Catecholamines. Blaschko, H., Muscholl, E. (eds.), Vol. XXXIII, pp. 283–335. Berlin-Heidelberg-New York: Springer 1972Google Scholar
  337. Furukawa, K., Nomoto, T.: 5-Hydroxytryptamine receptors in isolated rat ileum. Jap. J. Pharmacol. 24 (Suppl.), 95 (1974)PubMedCrossRefGoogle Scholar
  338. Furukawa, K., Nomoto, T.: Changes in the response to ACh, nicotine and 5-hydroxytryptamine in chemical sympathectomized rat ileum. Jap. J. Pharmacol. 25 (Suppl.), 29P (1975)CrossRefGoogle Scholar
  339. Fuxe, K.: Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monoamine terminals in the central nervous system. Acta physiol. scand. 64 (Suppl. 247), 37–85 (1965)Google Scholar
  340. Fuxe, K., Corrodi, H., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Ergocornine and 2-Br-α-ergocryptine. Evidence for prolonged dopamine receptor stimulation. Med. Biol. 52, 121–132 (1974)PubMedGoogle Scholar
  341. Fuxe, K., Agnati, L., Everitt, B.: Effects of methergoline on central monoamine neurones. Evidence for a selective blockade of central 5-HT receptors. Neurosci. Lett. 1, 283–290 (1975a)PubMedCrossRefGoogle Scholar
  342. Fuxe, K., Agnati, L.F., Hökfelt, T., Jonsson, G., Lidbrink, P., Ljungdahl, A., Lofstrom, A., Ungerstedt, U.: The effect of dopamine receptor stimulating and blocking agents on the activity of supersensitive dopamine receptors and on the amine turnover in various dopamine nerve terminal systems in the rat brain. J. Pharmacol. (Paris) 6, 117–129 (1975b)Google Scholar
  343. Gaddum, J.H.: The action of adrenalin and ergotamine on the uterus of the rabbit. J. Physiol. (Lond.) 61, 141–150 (1926)Google Scholar
  344. Gaddum, J.H.: Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J. Physiol. (Lond.) 121, 15P (1953)Google Scholar
  345. Gaddum, J.H.: Drugs antagonistic to 5-hydroxytryptamine. In: Ciba Symposium on Hypertension. Wolstenholme, G.E.W., Cameron, M.P. (eds.), pp. 75–77. London: J. and A. Churchill 1954Google Scholar
  346. Gaddum, J.H.: Drugs which antagonize the actions of 5-hydroxytryptamine on peripheral tissues. In: 5-Hydroxytryptamine. Lewis, G.P. (ed.), pp. 195–205. New York: Pergamon Press 1957Google Scholar
  347. Gaddum, J.H., Hameed, K.A.: Drugs which antagonize 5-hydroxytryptamine. Brit. J. Pharmacol. 9, 240–248 (1954)PubMedGoogle Scholar
  348. Gaddum, J.H., Paasonen, M.K.: The use of some molluscan hearts for the estimation of 5-hydroxytryptamine. Brit. J. Pharmacol. 10, 474–483 (1955)PubMedGoogle Scholar
  349. Gaddum, J.H., Picarelli, Z.P.: Two kinds of tryptamine receptor. Brit. J. Pharmacol. 12, 323–328 (1957)PubMedGoogle Scholar
  350. Gaddum, J.H., Szerb, J.C.: Assay of substance P on goldfish intestine in a microbath. Brit. J. Pharmacol. 17, 451–463 (1961)PubMedGoogle Scholar
  351. Gaddum, J.H., Vogt, M.: Some central actions of 5-hydroxytryptamine and various antagonists. Brit. J. Pharmacol. 11, 175–179 (1956)PubMedGoogle Scholar
  352. Gaddum, J.H., Hebb, C.O., Silver, A., Swan, A.A.B.: 5-Hydroxytryptamine. Pharmacological action and destruction in perfused lungs. Quart. J. exp. Physiol. 38, 255–262 (1953)PubMedGoogle Scholar
  353. Gaddum, J.H., Hameed, K.A., Hathway, D.E., Stephens, F.F.: Quantitative studies of antagonists for 5-hydroxytryptamine. Quart. J. exp. Physiol. 40, 49–74 (1955)PubMedGoogle Scholar
  354. Gagnon, D.J.: Contraction of the rat colon by sympathomimetic amines: effect of methysergide and 5-HT desensitization. Europ. J. Pharmacol. 17, 319–324 (1972)CrossRefGoogle Scholar
  355. Gallager, D.W., Aghajanian, G.K.: Chlorimipramine and LSD: differential effects on the in vivo release of 3H-5HT. Pharmacologist 16, 244 (1974)Google Scholar
  356. Gallager, D.W., Aghajanian, G.K.: Effects of chlorimipramine and lysergic acid diethylamide on efflux of precursor-formed 3H-serotonin: correlations with serotonergic impulse flow. J. Pharmacol. exp. Ther. 193, 785–795 (1975)PubMedGoogle Scholar
  357. Gallager, D.W., Aghajanian, G.K.: Inhibition of firing of raphe neurones by tryptophan and 5-hydroxytryptophan: blockade by inhibiting serotonin synthesis with Ro-4-4602. Neuropharmacology 15, 149–156 (1976)PubMedCrossRefGoogle Scholar
  358. Gant, D.W., Dyer, D.C.: D-Lysergic acid diethylamide (LSD-25): a constrictor of human umbilical vein. Life Sci. 10, 235–240 (1971)CrossRefGoogle Scholar
  359. Garrett, R.L., Brown, J.H.: Bradykinin-potentiated contractions induced by serotonin (5-HT), norepinephrine (NE) and potassium (K+) in rabbit aortic strips. Pharmacologist 12, 263 (1970)Google Scholar
  360. Garrett, R.L., Brown, J.H.: Bradykinin interaction with 5-hydroxytryptamine, norepinephrine and potassium chloride in rabbit aorta. Proc. Soc. exp. Biol. (N.Y.) 139, 1344–1348 (1972)Google Scholar
  361. Garrett, W.J.: The effects of adrenaline, noradrenaline and dihydroergotamine on excised human myometrium. Brit. J. Pharmacol. 10, 39–44 (1955)PubMedGoogle Scholar
  362. Gautrelet, J., Scheiner, H.: Détermination du pouvoir anticholinesterasique de différentes substances par la méthode de la décontraction du muscle droit de l’abdomen de la grenouille contracté par l’acétylcholine. C.R. Soc. Biol. (Paris) 131, 738–740 (1939)Google Scholar
  363. Gelfand, M.D., West, G.B.: Experimental studies with the butanolamide and propanolamide of 1-methyl-lysergic acid. Int. Arch. Allergy 18, 286–291 (1961)PubMedCrossRefGoogle Scholar
  364. Gerschenfeld, H.M.: Serotonin: Two different inhibitory actions on snail neurons. Science 171, 1252–1254 (1971)PubMedCrossRefGoogle Scholar
  365. Gerschenfeld, H.M., Paupardin, D.: Actions of 5-hydroxytryptamine on mulluscan neuronal membranes. In: Drug Receptors. Rang, H.P. (ed.), pp. 45–61. London: Macmillan 1972Google Scholar
  366. Gerschenfeld, H.M., Paupardin-Tritsch, D.: Ionic mechanisms and receptor properties underlying the responses of molluscan neurones to 5-hydroxytryptamine. J. Physiol. (Lond.) 243, 427–456 (1974a)Google Scholar
  367. Gerschenfeld, H.M., Paupardin-Tritsch, D.: On the transmitter function of 5-hydroxytryptamine at excitatory and inhibitory monosynaptic junctions. J. Physiol. (Lond.) 243, 457–481 (1974b)Google Scholar
  368. Gerschenfeld, H.M., Paupardin-Tritsch, D.: Excitatory and inhibitory monosynaptic actions mediated by a serotonin ccntaining neuron in Aplysia californica. J. Physiol. (Lond.) 243, 28P–29P (1974c)Google Scholar
  369. Gerschenfeld, H.M., Stefani, E.: 5-Hydroxytryptamine receptors and synaptic transmission in molluscan neurones. Nature (Lond.) 205, 1216–1218 (1965)CrossRefGoogle Scholar
  370. Gerschenfeld, H.M., Stefani, E.: An electrophysiological study of 5-hydroxytryptamine receptors of neurones in the molluscan nervous system. J. Physiol. (Lond.) 185, 684–700 (1966)Google Scholar
  371. Gerschenfeld, H.M., Stefani, E.: Acetylcholine and 5-hydroxytryptamine receptors in neurones of the land-snail Cryptomphallus aspersa. J. Physiol. (Lond.) 191, 14P–15P (1967)Google Scholar
  372. Gerschenfeld, H.M., Stefani, E.: Evidence for an excitatory transmitter role of serotonin in molluscan central synapses. In: Advances in Pharmacology. Garattini, S., Shore, P.A. (eds.), pp. 369–392. New York-London: Academic Press 1968Google Scholar
  373. Gerschenfeld, H.M., Tauc, L.: Différents aspects de la pharmacologic des synapses dans le système nerveux central des mollusques. J. Physiol. (Paris) 56, 360–361 (1964)Google Scholar
  374. Gilbert, J.-C., Goldberg, L.I.: Characterization by cyproheptadine of the dopamine-induced contraction in canine isolated arteries. J. Pharmacol. exp. Ther. 193, 435–442 (1975)PubMedGoogle Scholar
  375. Gillespie, J.S., Kirpekar, S.M.: Uptake and release of H3-noradrenaline by the splenic nerves. J. Physiol. (Lond.) 178, 44P–45P (1965a)Google Scholar
  376. Gillespie, J.S., Kirpekar, S.M.: The inactivation of infused noradrenaline by the cat spleen. J. Physiol. (Lond.) 176, 205–227 (1965b)Google Scholar
  377. Gillespie, J.S., McGrath, J.C.: The effect of lysergic acid diethylamide (LSD) on the vas deferens and anococcygeus muscle. Brit. J. Pharmacol. 52, 128P (1974)Google Scholar
  378. Gillespie, J.S., McGrath, J.C: The effects of lysergic acid diethylamide on the response to field stimulation of the rat vas deferens and the rat and cat anococcygeus muscles. Brit. J. Pharmacol. 54, 481–488 (1975)Google Scholar
  379. Gillespie, J.S., Muir, T.C.: A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Brit. J. Pharmacol. 30, 78–87 (1967)PubMedGoogle Scholar
  380. Gillespie, J.S., Hamilton, D.N.H., Hosie, R.J.A.: The extraneuronal uptake and localization of noradrenaline in the cat spleen and the effect on this of some drugs, of cold and of denervation. J. Physiol. (Lond.) 206, 563–590 (1970)Google Scholar
  381. Ginzel, K.H.: The action of lysergic acid diethylamide (LSD 25), its 2-brom derivative (BOL 148) and of 5-hydroxytryptamine (5-HT) on the peristaltic reflex of the guinea-pig ileum. J. Physiol. (Lond.) 137, 62P–63P (1957)Google Scholar
  382. Ginzel, K.H., Kottegoda, S.R.: A study of the vascular actions of 5-hydroxytryptamine, tryptamine, adrenaline and nor-adrenaline. Quart. J. exp. Physiol. 38, 225–231 (1953)PubMedGoogle Scholar
  383. Glegg, A.M., Turner, P.: Cholinergic interactions of methysergide and cinanserin on isolated human smooth muscle. Arch. int. Pharmacodyn. 191, 301–309 (1971)PubMedGoogle Scholar
  384. Glover, W.E., Marshall, R.J., Whelan, R.F.: The antagonism of the vascular effects of 5-hydroxytryptamine by BOL 148 and sodium salicylate in the human subject. Brit. J. Pharmacol. 12, 498–503 (1957)PubMedGoogle Scholar
  385. Glowinski, J., Hamon, M., Hery, F.: Regulation of 5-HT synthesis in central serotoninergic neurons. In: New Concepts in Neurotransmitter Regulation. Mandell, A.J. (ed.), pp. 239–257. New York: Plenum Press 1973CrossRefGoogle Scholar
  386. Görlitz, B.D., Frey, H.H.: Comparison of the blocking effects of antagonists of adrenaline and 5-hydroxytryptamine on their mutual receptors. J. Pharm. Pharmacol. 25, 651–653 (1973)PubMedCrossRefGoogle Scholar
  387. Goetz, C.G., Klawans, H.L.: Myoclonus, methysergide, and serotonin. Lancet 1974/I, 1284–1285CrossRefGoogle Scholar
  388. Gogerty, J.H., Dille, J.M.: Pharmacology of D-lysergic acid morpholide (LSM). J. Pharmacol. exp. Ther. 120, 340–348 (1957)PubMedGoogle Scholar
  389. Gokhale, S.D., Gulati, O.D., Kelkar, L.V., Kelkar, V.V.: Effect of some drugs on human umbilical artery in vitro. Brit. J. Pharmacol. 27, 332–346 (1966)PubMedGoogle Scholar
  390. Goldberg, L.I.: Comparison of putative dopamine receptors in blood vessels and the central nervous system. Adv. Neurol. 9, 53–56 (1975)PubMedGoogle Scholar
  391. Goldberg, L.I., Toda, N.: Dopamine induced relaxation of isolated canine renal, mesenteric and femoral arteries contracted with prostaglandin F. Circulat. Res. 36 (Suppl. I), 97–102 (1975)PubMedGoogle Scholar
  392. Goldberg, L.I., Tjandramaga, T.B., Anton, A.H., Toda, N.: New investigations of the cardiovascular actions of dopamine. In: Frontiers in Catecholamine Research. Usdin, E., Snyder, S. (eds.), pp. 513–521. New York: Pergamon Press 1973Google Scholar
  393. Goldman, J.M., Hadley, M.E.: In vitro demonstration of adrenergic receptors controlling melanophore responses of the lizard, Anolis carolinensis. J. Pharmacol. exp. Ther. 166, 1–7 (1969)PubMedGoogle Scholar
  394. Goldman, J.M., Hadley, M.E.: Direct agonistic and antagonistic effects of ergotamine on vertebrate melanophores. Arch. int. Pharmacodyn. 183, 239–246 (1970a)PubMedGoogle Scholar
  395. Goldman, J.M., Hadley, M.E.: Cyclic AMP and adrenergic receptors in melanophore responses to methylxanthines. Europ. J. Pharmacol. 12, 365–370 (1970b)CrossRefGoogle Scholar
  396. Goldman, J.M., Hadley, M.E.: Sulfhydryl requirement for alpha adrenergic receptor activity and melanophore stimulating hormone (MSH) action on melanophores. J. Pharmacol. exp. Ther. 182, 93–100 (1972)PubMedGoogle Scholar
  397. Gonzáles, R., Garcia, M., Rojas, R.: The mode of action of serotonin on the isolated atrium of hamsters. Sixth Internat. Congr. Pharmacol., Helsinki, 1975, Abstract 1433Google Scholar
  398. Gordon, J.L., Drummond, A.H.: Irreversible aggregation of pig platelets and release of intracellular constituents induced by 5-hydroxytryptamine. Biochem. Pharmacol. 24, 33–36 (1975)PubMedCrossRefGoogle Scholar
  399. Greeff, K., Holtz, P.: Über die Uteruswirkung des Adrenalins und Arterenols. Ein Beitrag zum Problem der Uterusinnervation Arch. int. Pharmacodyn. 88, 228–252 (1951)PubMedGoogle Scholar
  400. Greeff, K., Benfey, B.G., Bokelmann, A.: Anaphylaktische Reaktionen am isolierten Herzvorhofpräparat des Meerschweinchens und ihre Beeinflussung durch Antihistaminica, BOL, Dihydroergotamin und Reserpin. Naunyn-Schmiedebergs Arch. Pharmacol. 236, 421–434 (1959)Google Scholar
  401. Greenberg, D.A., U’Prichard, D.C., Snyder, S.H.: Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states. Life Sci. 19, 69–76 (1976)PubMedCrossRefGoogle Scholar
  402. Greenberg, M.J.: The responses of the venus heart to catecholamines and high concentrations of 5-hydroxytryptamine. Brit. J. Pharmacol. 15, 365–374 (1960a)PubMedGoogle Scholar
  403. Greenberg, M.J.: Structure-activity relationship of tryptamine analogues on the heart of Venus mercenaria. Brit. J. Pharmacol. 15, 375–388 (1960b)Google Scholar
  404. Grove, D.J., O’Neill, J.G., Spillett, P.B.: The action of 5-hydroxytryptamine on longitudinal gastric smooth muscle of the plaice, Pleuronectes platessa. Comp. gen. Pharmacol. 5, 229–238 (1974)CrossRefGoogle Scholar
  405. Guimarães, S.: Reversal by pronethalol of dibenamine blockade: A study on the seminal vesicle of the guinea-pig. Brit. J. Pharmacol. 36, 594–601 (1969a)Google Scholar
  406. Guimarães, S.: Alpha excitatory, alpha inhibitory and beta inhibitory adrenergic receptors in the guinea-pig stomach. Arch. int. Pharmacodyn. 179, 188–201 (1969b)PubMedGoogle Scholar
  407. Guimarães, S., Osswald, W.: Adrenergic receptors in the veins of the dog. Europ. J. Pharmacol. 5, 133–140 (1969)CrossRefGoogle Scholar
  408. Gulati, O.D., Kelkar, V.V.: Effect of tyramine on human umbilical artery in vitro. Brit. J. Pharmacol. 42, 155–158 (1971)Google Scholar
  409. Guth, P.S., Spirtes, M.A.: Interaction in the central nervous system between serotonin and lysergic acid derivatives. In: Neuropsychopharmacology. Proc. 1st. Intern. Congr. Neuropharmacol., Rome, Bradley, P.B., Deniker, P., Radouco-Thomas, C. (eds.), pp. 319–323. London: Elsevier 1958Google Scholar
  410. Gyermek, L.: The action of 5-hydroxytryptamine on the urinary bladder of the dog. Pharmacologist 2, 89 (1960)Google Scholar
  411. Gyermek, L.: Action of 5-hydroxytryptamine on the urinary bladder of the dog. Arch. int. Pharmacodyn. 137, 137–144 (1962)PubMedGoogle Scholar
  412. Gyermek, L.: Drugs which antagonize 5-hydroxytryptamine and related indolealkylamines. In: 5-Hydroxytryptamine and Related Indolealkylamines. Handbook of Experimental Pharmacology. Eichler, O., Farah, A. (eds.), Vol. XIX, pp. 471–528. Berlin-Heidelberg-New York: Springer 1966Google Scholar
  413. Gyermek, L., Bindler, E.: Blockade of the ganglionic stimulant action of 5-hydroxytryptamine. J. Pharmacol. exp. Ther. 135, 344–348 (1962)PubMedGoogle Scholar
  414. Gyermek, L., Sumi, T.: Potentiating actions of indolealkylamines and lysergic acid diethylamide on reflexes elicited by 5-hydroxytryptamine. Proc. Soc. exp. Biol. (N.Y.) 114, 436–439 (1963)Google Scholar
  415. Gyires, K., Knoll, J.: Inflammation and writhing syndrome inducing effect of PGE1, PGE2 and the inhibition of these actions. Pol. J. Pharmacol. Pharm. 27, 257–264 (1975)PubMedGoogle Scholar
  416. György, L., Borbely, L., Kelemen, B., Somkúti, T.: Über die adrenerg-erregenden Eigenschaften des Ergotoxins. Acta physiol. Acad. Sci. hung. 14, 391–398 (1958a)Google Scholar
  417. György, L., Somkuti, T., Kelemen, B., Borbély, L.: The problem of ergotoxin-adrenaline synergism and antagonism: the effect of general anaesthesia. Acta physiol. Acad. Sci. hung. 14, 287–300 (1958b)Google Scholar
  418. Haefely, W.: Effects of serotonin (5-HT) and some related indole compounds in a mammalian sympathetic ganglion. Experientia (Basel) 27, 1112 (1971)Google Scholar
  419. Haefely, W.: The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ. Naunyn-Schmiedebergs Arch. Pharmacol. 281, 145–165 (1974)PubMedCrossRefGoogle Scholar
  420. Haefely, W., Ruch-Monachon, M.A., Jalfre, M.: Interaction of psychotropic agents with central neurotransmitters as revealed by their effects on PGO waves in the cat. Arzneimittel-Forsch. 26, 1036–1039 (1976)Google Scholar
  421. Haeusler, G., Finch, L.: Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn-Schmiedebergs Arch. Pharmacol. 272, 101–116 (1972)PubMedCrossRefGoogle Scholar
  422. Haigler, H.J., Aghajanian, G.K.: Mescaline and LSD: Direct and indirect effects on serotonin-containing neurons in brain. Europ. J. Pharmacol. 21, 53–60 (1973a)CrossRefGoogle Scholar
  423. Haigler, H.J., Aghajanian, G.K.: A comparison of effects of D-lysergic acid diethylamide (LSD) and serotonin on pre-and postsynaptic cells in the serotonin system. Fed. Proc. 32, 303 (1973b)Google Scholar
  424. Haigler, H.J., Aghajanian, G.K.: Peripheral serotonin antagonists: failure to antagonize serotonin in brain areas receiving a prominent serotonergic input. J. Neural Transm. 35, 257–273 (1974a)CrossRefGoogle Scholar
  425. Haigler, H.J., Aghajanian, G.K.: Lysergic acid diethylamide and serotonin: a comparison of effects on serotonergic neurons and neurons receiving serotonergic input. J. Pharmacol. exp. Ther. 188, 688–699 (1974b)PubMedGoogle Scholar
  426. Halaris, A.E., Lovell, R.A.: On the nature of the serotonin binding after LSD. Fed. Proc. 32, 694 (1973)Google Scholar
  427. Halaris, A.E., Freedman, D.X., Fang, V.S.: Plasma corticoids and brain tryptophan after acute and tolerance dosage of LSD. Life Sci. 17, 1467–1472 (1975)PubMedCrossRefGoogle Scholar
  428. Hall, W.J., O’Connor, P.C.: The action of vasoactive drugs on longitudinal and circular muscle of dog mesenteric vein. J. Pharm. Pharmacol. 25, 109–118 (1973)PubMedCrossRefGoogle Scholar
  429. Halmagyi, D.F.J., Colebatch, H.J.H.: Serotonin-like cardiorespiratory effects of a serotonin antagonist. J. Pharmacol. exp. Ther. 134, 47–52 (1961)PubMedGoogle Scholar
  430. Hamon, M., Glowinski, J.: Regulation of serotonin synthesis. Life Sci. 15, 1533–1548 (1974)PubMedCrossRefGoogle Scholar
  431. Hamon, M., Bourgoin, S., Jagger, J., Glowinski, J.: Effects of LSD on synthesis and release of 5-HT in rat brain slices. Brain Res. 69, 265–280 (1974)PubMedCrossRefGoogle Scholar
  432. Hamon, M., Bourgoin, S., Enjalbert, A., Bockaert, J., Hery, F., Ternaux, J.P., Glowinski, J.: The effect of quipazine on 5-HT metabolism in the rat brain. Naunyn-Schmiedebergs Arch. Pharmacol. 294, 99–108 (1976a)PubMedCrossRefGoogle Scholar
  433. Hamon, M., Bourgoin, S., Hery, F., Ternaux, J.P.: In vivo and in vitro activation of soluble tryptophan hydroxylase from rat brainstem. Nature (Lond.) 260, 61–63 (1976b)CrossRefGoogle Scholar
  434. Handforth, A., Sourkes, T.L.: Inhibition by dopamine agonists of dopamine accumulation following γ-hydroxybutyrate treatment. Europ. J. Pharmacol. 34, 311–319 (1975)CrossRefGoogle Scholar
  435. Handschumacher, R.E., Vane, J.R.: Studies relating constrictions to entrance of 5-hydroxytryptamine (5-HT) and tryptamine (T) in smooth muscle. Fed. Proc. 22, 167 (1963)Google Scholar
  436. Handschumacher, R.E., Vane, J.R.: The relationship between the penetration of tryptamine and 5-hydroxytryptamine into smooth muscle and the associated contractions. Brit. J. Pharmacol. 29, 105–118 (1967)PubMedGoogle Scholar
  437. Hardebo, J.E., Edvinsson, L.: Mechanical actions of serotonin and the effect of related inhibitors in intracranial and extracranial vessels. “Headache ‘76”, Joint Meeting of the Italian Headache and the Scandinavian Migraine Societies, Florence, 1976, Abstract, pp. 11–13Google Scholar
  438. Hariri, M.: Uptake of 5-hydroxytryptamine by Mesocestoides corti (Cestoda). J. Parasit. 61, 440–448 (1975)CrossRefGoogle Scholar
  439. Harper, M.J.K., Skarnes, R.C.: Inhibition of abortion and fetal death produced by endotoxin or prostaglandin F. Prostaglandins 2, 295–309 (1972)PubMedCrossRefGoogle Scholar
  440. Hauge, A., Lunde, P.K.M., Waaler, B.A.: The effect of bradykinin, kallidin and eledoisin upon the pulmonary vascular bed of an isolated blood-perfused rabbit lung preparation. Acta physiol. scand. 66, 269–277 (1966)PubMedCrossRefGoogle Scholar
  441. Hayashi, A.: Receptors for phenylephrine and 5-hydroxytryptamine in the rat jejunum. Fukushima J. med. Sci. 21, 59–68 (1975)PubMedGoogle Scholar
  442. Hedqvist, P.: Modulating effect of prostaglandin E2 on noradrenaline release from the isolated cat spleen. Acta physiol. scand. 75, 511–512 (1969)PubMedCrossRefGoogle Scholar
  443. Hedqvist, P.: Studies on the effect of prostaglandins E1 and E2 on the sympathetic neuromuscular transmission in some animal tissues. Acta physiol. scand. (Suppl.) 345, 1–40 (1970a)Google Scholar
  444. Hedqvist, P.: Control by prostaglandin E2 of sympathetic neurotransmission in the spleen. Life Sci. 9, 269–278 (1970b)PubMedCrossRefGoogle Scholar
  445. Hedqvist, P.: Dissociation of prostaglandin and a-receptor mediated control of adrenergic transmitter release. Acta physiol. scand. 87, 42A–43A (1973)Google Scholar
  446. Hedqvist, P.: Role of the a-receptor in the control of noradrenaline release from sympathetic nerves. Acta physiol. scand. 90, 158–165 (1974)PubMedCrossRefGoogle Scholar
  447. Hedqvist, P., Brundin, J.: Inhibition by prostaglandin Ex of noradrenaline release and of effector response to nerve stimulation in the cat spleen. Life Sci. 8, 389–395 (1969)PubMedCrossRefGoogle Scholar
  448. Hedqvist, P., von Euler, U.S.: Prostaglandin-induced neurotransmission failure in the fieldstimulated, isolated vas deferens. Neuropharmacology 11, 177–187 (1972)PubMedCrossRefGoogle Scholar
  449. Hedqvist, P., Stjärne, L., Wennmalm, Å.: Inhibition by prostaglandin E2 of sympathetic neurotransmission in the rabbit heart. Acta physiol. scand. 79, 139–141 (1970)PubMedCrossRefGoogle Scholar
  450. Henderson, G., North, R.A.: Presynaptic action of 5-hydroxytryptamine in the myenteric plexus of the guinea-pig ileum. Brit. J. Pharmacol. 54, 265 (1975)Google Scholar
  451. Hertzler, E.C.: 5-Hydroxytryptamine and transmission in sympathetic ganglia. Brit. J. Pharmacol. 17, 406–413 (1961)PubMedGoogle Scholar
  452. Herxheimer, H.: Further observations on the influence of 5-hydroxytryptamine on bronchial function. J. Physiol. (Lond.) 122, 49P–50P (1953)Google Scholar
  453. Herxheimer, H.: The 5-hydroxytryptamine shock in the guinea-pig. J. Physiol. (Lond.) 128, 435–445 (1955)Google Scholar
  454. Herxheimer, H.: Bronchoconstrictor agents and their antagonists in the intact guinea-pig. Arch. int. Pharmacodyn. 106, 371–380 (1956)PubMedGoogle Scholar
  455. Higgins, W.J.: Intracellular actions of 5-hydroxytryptamine on the bivalve myocardium. J. exp. Zool. 190, 99–109 (1974)PubMedCrossRefGoogle Scholar
  456. Hillman, G.R., Olsen, N.J., Senft, A.W.: Effect of methysergide and dihydroergotamine on Schistosoma mansoni. J. Pharmacol. exp. Ther. 188, 529–535 (1974)PubMedGoogle Scholar
  457. Hill-Samli, M., MacLeod, R.M.: Thyrotropin-releasing hormone blockade of the ergocryptine and apomorphine inhibition of prolactin release in vitro. Proc. Soc. exp. Biol. (N.Y.) 149, 511–514 (1975)Google Scholar
  458. Hilton, B.P., Cumings, J.N.: An assessment of platelet aggregation induced by 5-hydroxytryptamine. J. clin. Path. 24, 250–258 (1971)PubMedCrossRefGoogle Scholar
  459. Hirst, G.D.S., McKirdy, H.C.: Synaptic potentials recorded from neurones of the submucous plexus of guinea-pig intestine. J. Physiol. (Lond.) 249, 369–385 (1975)Google Scholar
  460. Hirst, G.D.S., Silinsky, E.M.: Some effects of 5-hydroxytryptamine, dopamine and noradrenaline on neurones in the submucous plexus of guinea-pig small intestine. J. Physiol. (Lond.) 251, 817–832 (1975)Google Scholar
  461. Hitner, H., Di Gregorio, G.J.: Preliminary investigation of the peripheral sympathomimetic effects of phencyclidine. Arch. int. Pharmacodyn. 212, 36–42 (1974)PubMedGoogle Scholar
  462. Hökfelt, T., Fuxe, K.: On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Brain-Endocrine Interaction. Median Eminence: Structure and Function, Knigge, K.M., Scott, D.F., Weindt, A. (eds.), pp. 181–223. Basle: Karger 1972Google Scholar
  463. Holgate, J.A., Warner, B.T.: Evaluation of antagonists of histamine, 5-hydroxytryptamine and acetylcholine in the guinea-pig. Brit. J. Pharmacol. 15, 561–566 (1960)PubMedGoogle Scholar
  464. Hollenberg, M.D., Cuatrecasas, P.: Studies on the interaction of hormones with plasma membrane receptors. Biochem. Actions Horm. 3, 41–85 (1975)Google Scholar
  465. Holroyde, M.C., Eyre, P.: Reactivity of isolated bovine mesenteric and hepatic veins to vasoactive agents and specific antigen. Europ. J. Pharmacol. 30, 36–42 (1975)CrossRefGoogle Scholar
  466. Holzbauer, M., Vogt, M.: Modification by drugs of the response of the rat’s uterus to adrenaline. Brit. J. Pharmacol. 10, 186–190 (1955)PubMedGoogle Scholar
  467. Hughes, J.: Inhibition of noradrenaline release by lysergic acid diethylamide. Brit. J. Pharmacol. 49, 706–708 (1973)Google Scholar
  468. Hughes, J., Vane, J.R.: An analysis of the responses of the isolated portal vein of the rabbit to electrical stimulation and to drugs. Brit. J. Pharmacol. 30, 46–66 (1967)PubMedGoogle Scholar
  469. Hughes, J., Vane, J.R.: Relaxations of the isolated portal vein of the rabbit induced by nicotine and electrical stimulation. Brit. J. Pharmacol. 39, 476–489 (1970)Google Scholar
  470. Hughes, J., Kosterlitz, H.W., Leslie, F.M.: Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Brit. J. Pharmacol. 53, 371–381 (1975)Google Scholar
  471. Ichimasa, S., Kushiku, K., Furukawa, T.: Pharmacological studies on ganglionic transmission: Influence of antagonists on the catecholamine-induced ganglionic inhibition in the cardiac sympathetic ganglia. Jap. J. Pharmacol. 25 (Suppl.), 20 (1975)Google Scholar
  472. Innes, I.R.: Identification of the smooth muscle excitatory receptors for ergot alkaloids. Brit. J. Pharmacol. 19, 120–128 (1962a)PubMedGoogle Scholar
  473. Innes, I.R.: An action of 5-hydroxytryptamine on adrenaline receptors. Brit. J. Pharmacol. 19, 427–441 (1962b)PubMedGoogle Scholar
  474. Innes, I.R., Kohli, J.D.: Excitatory action of sympathomimetic amines on 5-hydroxytryptamine receptors of gut. Brit. J. Pharmacol. 35, 383–393 (1969)Google Scholar
  475. Iturriza, F.C.: The effect of D-lysergic acid diethylamide on the melanophores of the toad Bufo arenarum under different experimental conditions. Acta endocr. (Kbh.) 48, 322–328 (1965)Google Scholar
  476. Iturriza, F.C., Koch, O.R.: Effect of administration of lysergic acid diethylamide (LSD) on the colloid vesicles of the pars intermedia of the toad pituitary. Endocrinology 75, 615–616 (1964)PubMedCrossRefGoogle Scholar
  477. Iversen, L.L.: The inhibition of noradrenaline uptake by drugs. In: Advances in Drug Research. Harper, N.J., Simmonds, A.B. (eds.), pp. 1–46. London-New York: Academic Press 1965Google Scholar
  478. Iversen, L.L.: The uptake and storage of noradrenaline in sympathetic nerves. Cambridge: University Press 1967Google Scholar
  479. Iversen, L.L.: Catecholamine uptake processes. Brit. med. Bull. 29, 130–135 (1973)PubMedGoogle Scholar
  480. Jacoby, J.H., Shabshelowitz, H., Fernstrom, J.D., Wurtman, R.J.: The mechanism by which methiothepin, a putative serotonin receptor antagonist, increases brain 5-hydroxyindole levels. J. Pharmacol. exp. Ther. 195, 257–264 (1975)PubMedGoogle Scholar
  481. Jafferji, S.S., Michell, R.H.: Stimulation of phosphatidylinositol turnover by histamine, 5-hydroxytryptamine and adrenaline in the longitudinal smooth muscle of guinea-pig ileum. Biochem. Pharmacol. 25, 1429–1430 (1976)PubMedCrossRefGoogle Scholar
  482. Jalfre, M., Monachon, M.-A., Haefely, W.: Pharmacological modifications of benzoquinolizine-induced geniculate spikes. Experientia (Basel) 26, 691 (1970)Google Scholar
  483. Jalfre, M., Monachon, M.A., Haefely, W.: Drugs and PGO waves in the cat. In: First Can. Int. Symposium of Sleep. McClure, D.J. (ed.), pp. 155–185. Montreal: Roche Scientific Service 1972Google Scholar
  484. Jalfre, M., Ruch-Monachon, M.-A., Haefely, W.: Methods for assessing the interaction of agents with 5-hydroxytryptamine neurons and receptors in the brain. Adv. Biochem. Psychopharmacol. 10, 121–134 (1974)PubMedGoogle Scholar
  485. Jang, C.S.: The potentiation and paralysis of adrenergic effects by ergotoxine and other substances. J. Pharmacol. exp. Ther. 71, 87–94 (1941)Google Scholar
  486. Jaques, R., Bein, H.J., Meier, R.: 5-Hydroxytryptamine antagonists, with special reference to the importance of sympathomimetic amines and isopropyl-noradrenaline. Helv. physiol. Pharmacol. Acta 14, 269–278 (1956)PubMedGoogle Scholar
  487. Jasmin, G., Bois, P.: Effect of various agents on the development of kidney infarcts in rats treated with serotonin. Lab. Invest. 9, 503–513 (1960)PubMedGoogle Scholar
  488. Jenkinson, D.H., Morton, I.K.M.: Adrenergic blocking drugs as tools in the study of the actions of catecholamines on the smooth muscle membrane. Ann. N.Y. Acad. Sci. 139, 762–771 (1967a)PubMedCrossRefGoogle Scholar
  489. Jenkinson, D.H., Morton, I.K.M.: The effect of noradrenaline on the permeability of depolarized intestinal smooth muscle to inorganic ions. J. Physiol. (Lond.) 188, 373–386 (1967b)Google Scholar
  490. Jenkinson, D.H., Morton, I.K.M.: The role of α-and β-adrenergic receptors in some actions of catecholamines on intestinal smooth muscle. J. Physiol. (Lond.) 188, 387–402 (1967c)Google Scholar
  491. Joiner, P.D., Kadowitz, P.J., Davis, L.B., Hyman, A.L.: Contractile responses of canine isolated intrapulmonary arteries (IPA) and veins (IPV) to norepinephrine (NE), serotonin (5-HT) and tyramine (TYR). Pharmacologist 16, 299 (1974)Google Scholar
  492. Joiner, P.D., Kadowitz, P.J., Davis, L.B., Hyman, A.L.: Contractile responses of canine isolated pulmonary lobar arteries and veins to norepinephrine, serotonin and tyramine. Canad. J. Physiol. Pharmacol. 53, 830–838 (1975)CrossRefGoogle Scholar
  493. Kahn, C.R.: Membrane receptors for hormones and neurotransmitters. J. Cell Biol. 70, 261–286 (1976)PubMedCrossRefGoogle Scholar
  494. Kahr, H., Fischer, W.: Die Wirkung des 5-Oxtryptamins auf das Pigmentsystem der Haut. Klin. Wschr. 35, 41–44 (1957)PubMedCrossRefGoogle Scholar
  495. Kalbermatten, J.P. de: Effet de la sérotonine sur l’hypersensibilité de dénervation du ganglion sympathique cervical isolé du rat. Helv. physiol. pharmacol. Acta 20, 294–315 (1962)Google Scholar
  496. Karlsberg, P., Adams, J.E., Elliott, H.W.: Inhibition and reversal of serotonin-induced cerebral vasospasm. Surg. Forum 13, 425–427 (1962)Google Scholar
  497. Karlsberg, P., Elliott, H.W., Adams, J.E.: Effects of various pharmacologic agents on cerebral arteries. Neurology (Minneap.) 13, 772–778 (1963)Google Scholar
  498. Katsuragi, T., Suzuki, T.: Methysergide-induced potentiation of the cholinergic response of the guinea-pig vas deferens. Jap. J. Pharmacol. 24 (Suppl.), 145 (1974)PubMedGoogle Scholar
  499. Katz, R.I., Kopin, I.J.: Effect of D-LSD and related compounds on release of norepinephrine-H3 and serotonin-H3 evoked from brain slices by electrical stimulation. Pharmacol. Res. Commun. 1, 54–62 (1969)CrossRefGoogle Scholar
  500. Kawai, N.: Release of 5-hydroxytryptamine from slices of superior colliculus by optic tract stimulation. Neuropharmacology 9, 395–397 (1970)PubMedCrossRefGoogle Scholar
  501. Kawai, N., Yamamoto, C.: Antagonism between serotonin and LSD studied in vitro in thin sections from the superior colliculus of guinea-pig. Brain Res. 7, 325–328 (1968)PubMedCrossRefGoogle Scholar
  502. Kawai, N., Yamamoto, C.: Effects of 5-hydroxytryptamine, LSD and related compounds on electrical activities evoked in vitro in thin sections from the superior colliculus. Int. J. Neuropharmacol. 8, 437–449 (1969)PubMedCrossRefGoogle Scholar
  503. Kelly, M.J.: Receptors for dopamine in some isolated vascular tissues of the dog. Brit. J. Pharmacol. 46, 575P–577P (1972)Google Scholar
  504. Kerkut, G.A., Laverack, M.S.: A cardio-accelerator present in tissue extracts of the snail Helix aspersa. Comp. Biochem. Physiol. 1, 62–71 (1960)CrossRefGoogle Scholar
  505. Khairallah, P.A., Page, I.H., Türker, R.K.: Some properties of prostaglandin E1 action on muscle. Arch. int. Pharmacodyn. 169, 328–341 (1967)PubMedGoogle Scholar
  506. Kimura, M., Waki, I., Tamura, H.: Actions of dibenamine on adrenergic β-receptors in cat’s papillary muscle (Molecular pharmacological studies on drug-receptor interaction systems in drug action IX). Jap. J. Pharmacol. 20, 16–22 (1970)PubMedCrossRefGoogle Scholar
  507. King, T.O.: Hydroxytryptamine. The antagonism of its broncho-constrictor action. Int. Physiologenkongress, Brüssel, August 1956, p. 499Google Scholar
  508. King, T.O.: The antagonism of 5-hydroxytryptamine pneumoconstriction. Arch. int. Pharmacodyn. 110, 71–76 (1957)PubMedGoogle Scholar
  509. King, A.R., Martin, I.L., Melville, K.A.: Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels. Brit. J. Pharmacol. 52, 419–425 (1974)Google Scholar
  510. Kirpekar, S.M., Cervoni, P.: Effect of cocaine, phenoxybenzamine and phentolamine on the catecholamine output from spleen and adrenal medulla. J. Pharmacol. exp. Ther. 142, 59–70 (1963)PubMedGoogle Scholar
  511. Kirpekar, S.M., Puig, M.: Effect of flow-stop on noradrenaline release from normal spleens and spleens treated with cocain, phentolamine or phenoxybenzamine. Brit. J. Pharmacol. 43, 359–369 (1971)Google Scholar
  512. Klawans, Jr., H.L., Goetz, C., Weiner, W.J.: 5-Hydroxytryptophan-induced myoclonus in guinea-pigs and the possible role of serotonin in infantile myoclonus. Neurology (Minneap.) 23, 1234–1240 (1973)Google Scholar
  513. Klawans, H.L., D’Amico, D.J., Patel, B.C.: Behavioral supersensitivity to 5-hydroxytryptophan induced by chronic methysergide pretreatment. Psychopharmacologia 44, 297–300 (1975)PubMedCrossRefGoogle Scholar
  514. Klinge, E., Sjöstrand, N.O.: Contraction and relaxation of the retractor penis muscle and the penile artery of the bull. Acta physiol. scand. (Suppl.) 420, 1–88 (1974)Google Scholar
  515. Kohli, J.D.: Receptors for sympathomimetic amines in the rabbit aorta: Differentiation by specific antagonists. Brit. J. Pharmacol. 32, 273–279 (1968)PubMedGoogle Scholar
  516. Kohli, J.D.: A comparative study of dopamine and noradrenaline on the rabbit aorta. Canad. J. Physiol. Pharmacol. 47, 171–174 (1969)CrossRefGoogle Scholar
  517. Kohli, J.D., Innes, I.R.: Differentiation between norepinephrine (NE) and 5-hydroxytryptamine (5-HT) receptors in vascular smooth muscle with 2-bromo-lysergic acid diethylamide (BOL). Pharmacologist 6, 207 (1964)Google Scholar
  518. Komiskey, H.L., Rudy, T.A.: The involvement of methysergide-sensitive receptors and prostaglandins in the hyperthermia evoked by 5-HT in the cat. Res. Commun. Chem. Path. Pharmacol. 11, 195–208 (1975)Google Scholar
  519. Konzett, H.: The effects of 5-hydroxytryptamine and its antagonists on tidal air. Brit. J. Pharmacol. 11, 289–294 (1956)PubMedGoogle Scholar
  520. Konzett, H.: Specific antagonism of dibenamine to ergometrine. In: Ciba Foundation Symposium on Adrenergic Mechanisms. Wolstenholme, G.E.W., O’Connor, M. (eds.), pp. 463–465. London: J. and A. Churchill 1960Google Scholar
  521. Kopin, I.J.: V. Interaction between the drugs and brain amines. Neurosci. Res. Prog. Bull. 8, 27–32 (1970)Google Scholar
  522. Kostowski, W., Giacalone, E.: Effect of psychotropic drugs on the release of serotonin induced by electrical stimulation of midbrain raphe in rats. In: The Present Status of Psychotropic Drugs. Cerletti, A., Bove, F.J. (eds.), pp. 289–291. Amsterdam: Excerpta Medica Foundation 1969Google Scholar
  523. Kostowski, W., Gumulka, W., Jerlicz, M.: The effects of serotonin injections into the locus coeruleus on ponto geniculo occipital (PGO) waves and cortical EEG pattern in cats. Pol. J. Pharmacol. Pharm. 27, 127–137 (1975)PubMedGoogle Scholar
  524. Krishnamurty, V.S.R.: Receptors for sympathomimetic amines and 5-hydroxytryptamine in the rat aorta. Arch. int. Pharmacodyn. 189, 90–99 (1971)PubMedGoogle Scholar
  525. Krivoy, W. A.: The preservation of substance P by lysergic acid diethylamide. Brit. J. Pharmacol. 12, 361–364 (1957)PubMedGoogle Scholar
  526. Krnjević, K., Phillis, J.W.: Actions of certain amines on cerebral cortical neurones. Brit. J. Pharmacol. 20, 471–490 (1963a)PubMedGoogle Scholar
  527. Krnjević, K., Phillis, J.W.: Iontophoretic studies of neurones in the mammalian cerebral cortex. J. Physiol. (Lond.) 165, 274–304 (1963b)Google Scholar
  528. Kuhar, M.J., Roth, R.H., Aghajanian, G.K.: Selective reduction of tryptophan hydroxylase activity in rat forebrain after midbrain raphe lesions. Brain Res. 35, 167–176 (1971)PubMedCrossRefGoogle Scholar
  529. Kuhar, M.J., Aghajanian, G.K., Roth, R.H.: Tryptophan hydroxylase activity and synaptosomal uptake of serotonin in discrete brain regions after midbrain lesions: correlations with serotonin levels and histochemical fluorescence. Brain Res. 44, 165–176 (1972a)PubMedCrossRefGoogle Scholar
  530. Kuhar, M.J., Roth, R.H., Aghajanian, G.K.: Synaptosomes from forebrains of rats with midbrain raphe lesions: selective reductions of serotonin uptake. J. Pharmacol. exp. Ther. 181, 36–45 (1972b)PubMedGoogle Scholar
  531. Langer, S.Z., Enero, M.A., Adler-Graschinsky, E., Dubocovich, M.L., Celuchi, S.M.: Presynaptic regulatory mechanisms for noradrenaline release by nerve stimulation. In: Central Action of Drugs in Blood Pressure Regulation. Davies, D.S., Reid, J.L. (eds.), pp. 133–150. Kent: Pitman Medical Publishing 1975Google Scholar
  532. Lecomte, J.: Sensibilisation à l’adrénaline par la 5-hydroxytryptamine. Arch. int. Physiol. Biochim. 61, 84–85 (1953)CrossRefGoogle Scholar
  533. Legge, K.F., Randic, M., Straughan, D.W.: The pharmacology of neurones in the pyriform cortex. Brit. J. Pharmacol. 26, 87–107 (1966)PubMedGoogle Scholar
  534. Leitch, J.L., Liebig, C.S., Haley, T.J.: The use of the rat’s isolated seminal vesicle for the assay of sympatholytic drugs. Brit. J. Pharmacol. 9, 236–239 (1954)PubMedGoogle Scholar
  535. Leonard, B.E., Liska, K.J.: Effects of morpholino-, pyrrolidino-, piperizino-, and cyclooctylderivatives of beta-alanine on brain amines and amino acids. Life Sci. 10, 93–104 (1971)CrossRefGoogle Scholar
  536. Levy, B., Ahlquist, R.P.: An analysis of adrenergic blocking activity. J. Pharmacol. exp. Ther. 133, 202–210 (1961)PubMedGoogle Scholar
  537. Levy, B., Tozzi, S.: The adrenergic receptive mechanism of the rat uterus. J. Pharmacol. exp. Ther. 142, 178–184 (1963)PubMedGoogle Scholar
  538. Levy, B., Wilkenfeld, E.: The actions of selective β-receptor antagonists on the guinea-pig trachea. Europ. J. Pharmacol. 11, 67–74 (1970)CrossRefGoogle Scholar
  539. Levy, J., Michel-Ber, E.: Contribution à l’action pharmacologique exercée par la sérotonine sur quelques organes isolés (intestine et oreillette). J. Physiol. (Paris) 48, 1051–1084 (1956)Google Scholar
  540. Liao, S.: Cellular receptors and mechanisms of action of steroid hormones. Int. Rev. Cytol. 41, 87–172 (1975)PubMedCrossRefGoogle Scholar
  541. Liebeswar, G., Goldman, J.E., Koester, J., Mayeri, E.: Neural control of circulation in Aplysia. III. Neurotransmitters. J. Neurophysiol. 38, 767–779 (1975)PubMedGoogle Scholar
  542. Lin, R.C., Ngai, S.H., Costa, E.: Lysergic acid diethylamide: role in conversion of plasma tryptophan to brain serotonin (5-hydroxytryptamine). Science 166, 237–239 (1969)PubMedCrossRefGoogle Scholar
  543. Lingjaerde, O. Jr.: Effects of ergotamine and dihydroergotamine on uptake of 5-hydroxytryptamine in blood platelets. Europ. J. Pharmacol. 13, 76–82 (1970)CrossRefGoogle Scholar
  544. Little, K.D., DiStefano, V., Leary, D.E.: LSD and serotonin effects on spinal reflexes in the cat. J. Pharm. exp. Ther. 119, 161 (1957)Google Scholar
  545. Loew, D.M., Depoortere, H., Buerki, H.R.: Effects of dihydrogenated ergot alkaloids on the sleep-wakefulness cycle and on brain biogenic amines in the rat. Arzneimittel-Forsch. 26, 1080–1083 (1976)Google Scholar
  546. Loew, E.R., Kaiser, M.E., Moore, V.: Effect of various drugs on experimental asthma produced in guinea-pig by exposure to atomized histamine. J. Pharm. exp. Ther. 86, 1–6 (1946)Google Scholar
  547. Loewi, O., Navratil, E.: Über humorale Übertragbarkeit der Herznervenwirkung. XI. Über den Mechanismus der Vaguswirkung von Physostigmin und Ergotamin. Pflügers Arch. 214, 689–696 (1926)CrossRefGoogle Scholar
  548. Lovell, R.A., Freedman, D.X.: Stereospecific receptor sites for D-lysergic acid diethylamide in rat brain: Effects of neurotransmitters, amine antagonists, and other psychotropic drugs. Molec. Pharmacol. 12, 620–630 (1976)Google Scholar
  549. Lovell, R.A., Rosecrans, J.A., Freedman, D.X.: Effects of LSD on rat brain serotonin metabolism. Fed. Proc. 26, 708 (1967)Google Scholar
  550. Ludány, G., Gáti, T., Szabó, St., Hideg, J.: 5-Hydroxytryptamin (Enteramin, Serotonin) und die Darmzottenbewegung. Arch. int. Pharmacodyn. 118, 62–69 (1959)PubMedGoogle Scholar
  551. Lum, B.K.B., Kermani, M.H., Heilman, R.D.: Intestinal relaxation produced by sympathomimetic amines in the isolated rabbit jejunum: selective inhibition by adrenergic blocking agents and by cold storage. J. Pharmacol. exp. Ther. 154, 463–471 (1966)PubMedGoogle Scholar
  552. McCulloch, M.W., Rand, M.J., Story, D.F.: Inhibition of 3H-noradrenaline release from sympathetic nerves of guinea-pig atria by a presynaptic α-adrenoceptor mechanism. Brit. J. Pharmacol. 46, 523P–524P (1972)Google Scholar
  553. MacLeod, R.M., Lehmeyer, J.E.: Regulation of the synthesis and release of prolactin. In: Lactogenic Hormones. Wolstenholme, G.E.W., Knight, J. (eds.). A Ciba Foundation Symposium, pp. 53–76. Edinburgh-London: Churchill Livingstone 1972Google Scholar
  554. MacLeod, R.M., Lehmeyer, J.E.: Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94, 1077–1085 (1974)PubMedCrossRefGoogle Scholar
  555. Magistretti, M., Valzelli, L.: Ricerche sulla attività inotropa della serotonina sull’orecchietta e sul cuore isolati. Boll. Soc. ital. Biol. sper. 31, 1035–1037 (1955)PubMedGoogle Scholar
  556. Malanga, C.J.: Dopaminergic responses by gill cilia of bivalve molluscs. Fed. Proc. 32, 691 (1973)Google Scholar
  557. Malanga, C.J.: Dopaminergic stimulation of ciliary activity in the gill of the bivalve mollusc, Mytilus edulis. Fed. Proc. 33, 551 (1974)Google Scholar
  558. Maling, H.M., Webster, M.E., Williams, M.A., Saul, W., Anderson, W., Jr.: Inflammation induced by histamine, serotonin, bradykinin and compound 48/80 in the rat: antagonists and mechanisms of action. J. Pharmacol. exp. Ther. 191, 300–310 (1974)PubMedGoogle Scholar
  559. Malorny, G., Orzechowski, G.: Untersuchungen liber die Wirkungsweise der Sympathicomimetica. III. Über die ephedrinahnliche Wirkung der Secalealkaloide Ergotamin und Ergometrin. Naunyn-Schmiedebergs Arch. Pharmacol. 196, 253–259 (1940)CrossRefGoogle Scholar
  560. Mansour, T.E.: Effect of lysergic acid diethylamide, serotonin and related compounds on a parasitic trematode, Fasciola hepatica. Fed. Proc. 15, 454–455 (1956)Google Scholar
  561. Mansour, T.E.: The effect of lysergic acid diethylamide, 5-hydroxytryptamine, and related compounds on the liver fluke, Fasciola hepatica. Brit. J. Pharmacol. 12, 406–409 (1957)PubMedGoogle Scholar
  562. Mansour, T.E., Lago, A.D., Hawkins, J.L.: Occurrence and possible role of serotonin in Fasciola hepatica. Fed. Proc. 16, 319 (1957)Google Scholar
  563. Mansour, T.E., Sutherland, E.W., Rail, T.W., Bueding, E.: The effect of serotonin (5-hydroxytryptamine) on the formation of adenosine 3′,5′-phosphate by tissue particles from the liver fluke, Fasciola hepatica. J. biol. Chem. 235, 466–470 (1960)PubMedGoogle Scholar
  564. Marchbanks, R.M.: Serotonin binding to nerve ending particles and other preparations from rat brain. J. Neurochem. 13, 1481–1493 (1966)PubMedCrossRefGoogle Scholar
  565. Marchbanks, R.M.: Inhibitory effects of lysergic acid derivatives and reserpine on 5-HT binding to nerve ending particles. Biochem. Pharmacol. 16, 1971–1979 (1967)PubMedCrossRefGoogle Scholar
  566. Marchbanks, R.M., Rosenblatt, F., O’Brien, R.D.: Serotonin binding to nerve-ending particles of the rat brain and its inhibition by lysergic acid diethylamide. Science 144, 1135–1137 (1964)PubMedCrossRefGoogle Scholar
  567. Markstein, R., Wagner, H.: The effect of dihydroergotoxin, phentolamine and pindolol on catecholamine-stimulated adenylcyclase in rat cerebral cortex. F.E.B.S. Lett. 55, 275–277 (1975)CrossRefGoogle Scholar
  568. Markstein, R., Wagner, H.: Effect of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology 24 (Suppl. I), 94–105 (1978)PubMedCrossRefGoogle Scholar
  569. Markstein, R. et al.: unpublished results 1976Google Scholar
  570. Marley, E., Vane, J.R.: Tryptamines and spinal cord reflexes in cats. Brit. J. Pharmacol. 31, 447–465 (1967)PubMedGoogle Scholar
  571. Marley, E., Whelan, J.E.: Some unexpected pharmacological effects of p-chlorophenylalanine methyl ester (PCPA methyl ester). Brit. J. Pharmacol. 52, 133P–134P (1974)Google Scholar
  572. Marley, E., Whelan, J.E.: Some pharmacological effects of p-chlorphenylalanine unrelated to tryptophan hydroxylase inhibition. Brit. J. Pharmacol. 56, 133–144 (1976)Google Scholar
  573. Marrazzi, A.S.: The effects of certain drugs on cerebral synapses. Ann. N.Y. Acad. Sci. 66, 496–507 (1957)PubMedCrossRefGoogle Scholar
  574. Marrazzi, A.S., Hart, E.R.: Evoked cortical responses under the influence of hallucinogens and related drugs. Electroencephalogr. Clin. Neurophysiol. 7, 146 (1955a)Google Scholar
  575. Marrazzi, A.S., Hart, E.R.: Relationship of hallucinogens to adrenergic cerebral neurohumors. Science 121, 365–367 (1955b)PubMedCrossRefGoogle Scholar
  576. Martin, W.R., Eades, C.G.: The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens. Psychopharmacologia 17, 242–257 (1970)PubMedCrossRefGoogle Scholar
  577. Matin, M.A., Vijayvargiya, R.: Chlorpromazine-lysergic acid diethylamide antagonism. J. Pharm. Pharmacol. 19, 192–193 (1967)PubMedCrossRefGoogle Scholar
  578. Matthes, K.: The action of blood on acetylcholine. J. Physiol. (Lond.) 70, 338–348 (1930)Google Scholar
  579. Maurer, R., Grieder, A.: Effects of dihydroergotamine on cAMP content in cultured glial cells. Experientia (Basel) 31, 730–731 (1975)Google Scholar
  580. Mawson, C., Whittington, H.: Evaluation of the peripheral and central antagonistic activities against 5-hydroxytryptamine of some new agents. Brit. J. Pharmacol. 39, 223P (1970)Google Scholar
  581. Mchedlishvili, G.I., Ormotsadze, L.G.: Experimental models of spasm of the internal carotid artery. Pat. Fiziol. eksp. Ter. 5, 79–81 (1974)PubMedGoogle Scholar
  582. Mena, M.A., Vidrio, H.: On the mechanism of the coronary dilator effect of serotonin in the dog. Europ. J. Pharmacol. 36, 1–5 (1976)CrossRefGoogle Scholar
  583. Mendez, R.: Antagonism of adrenaline by ergotamine. J. Pharmacol. 32, 451–464 (1928)Google Scholar
  584. Metcalfe, H.L., Turner, P.: Pharmacological studies of cinanserin in human isolated smooth muscle. Brit. J. Pharmacol. 37, 519P (1969)Google Scholar
  585. Metcalfe, H.L., Turner, P.: A comparison of the effects of cinanserin and methysergide on responses of isolated smooth muscle to acetylcholine. Arch. int. Pharmacodyn. 183, 148–158 (1970)PubMedGoogle Scholar
  586. Meyer, D.K., Abele, M., Hertting, G.: Influence of serotonin on water intake and the reninangiotensin system in the rat. Arch. int. Pharmacodyn. 212, 130–140 (1974)PubMedGoogle Scholar
  587. Michal, F.: D-receptor for serotonin on blood platelets. Nature (Lond.) 221, 1253–1254 (1969)CrossRefGoogle Scholar
  588. Michal, F., Motamed, M.: Time-dependent potentiation and inhibition by 5-hydroxytryptamine of platelet aggregation induced by ADP. Brit. J. Pharmacol. 54, 221–222 (1975)Google Scholar
  589. Michal, F., Motamed, M.: Shape change and aggregation of blood platelets: interaction between the effects of adenosine diphosphate, 5-hydroxytryptamine and adrenaline. Brit. J. Pharmacol. 56, 209–218 (1976)Google Scholar
  590. Mielke, H., Seiler, K.-U., Stumpf, U., Wassermann, O.: Über eine Beziehung zwischen dem Serotoninstoffwechsel und der pulmonalen Hypertonic bei Ratten nach Gabe verschiedener Anorektika. Z. Kardiol. 62, 1090–1098 (1973)PubMedGoogle Scholar
  591. Mills, D.C.B., Roberts, G.C.K.: Effects of adrenaline on human blood platelets. J. Physiol. (Lond.) 193, 443–453 (1967)Google Scholar
  592. Mitchell, J.R.A., Sharp, A.A.: Platelet clumping in vitro. Brit. J. Haematol. 10, 78–93 (1964)CrossRefGoogle Scholar
  593. Mörsdorf, K., Bode, H.H.: Zur Beeinflussung der Permeabilitatssteigernden Wirkung des Serotonins durch verschiedenartige Pharmaka. Arch. int. Pharmacodyn. 118, 292–297 (1959)PubMedGoogle Scholar
  594. Monachon, M.-A., Burkhard, W.P., Jalfre, M., Haefely, W.: Blockade of central 5-hydroxytryptamine receptors by methiothepin. Naunyn-Schmiedebergs Arch. Pharmacol. 274, 192–197 (1972)PubMedCrossRefGoogle Scholar
  595. Mosko, S., Jacobs, B.L.: Effect of peripherally administered serotonin on the neuronal activity of midbrain raphe neurons. Brain Res. 79, 315–320 (1974)PubMedCrossRefGoogle Scholar
  596. Mouton, Y., Demaille, A.: La barriere capillaire du mesentere de rat ayant recu une injection intravasculaire d’hepatome ascitique de Zajdela. III. Influence de la sérotonine et de l’histamine sur l’extravasation tumorale. C. R. Soc. Biol. (Paris) 169, 974–978 (1975)Google Scholar
  597. Müller-Schweinitzer, E.: Investigations on the mode of action of dihydroergotamine in human saphenous and dog saphenous and femoral veins. Naunyn-Schmiedebergs Arch. Pharmacol. 279 (Suppl.), R44 (1973)Google Scholar
  598. Müller-Schweinitzer, E.: Further studies on the mode of action of ergotamine on canine vein strips. Naunyn-Schmiedebergs Arch. Pharmacol. 282 (Suppl.), R68 (1974a)PubMedGoogle Scholar
  599. Müller-Schweinitzer, E.: Enhanced synthesis of prostaglandin-like substance(s) contributes to the mode of action of dihydroergotamine. Naunyn-Schmiedebergs Arch. Pharmacol. 285 (Suppl.), R57 (1974b)Google Scholar
  600. Müller-Schweinitzer, E.: Studies on the peripheral mode of action of dihydroergotamine in human and canine veins. Europ. J. Pharmacol. 27, 231–237 (1974c)CrossRefGoogle Scholar
  601. Müller-Schweinitzer, E.: Differentiation between serotonin-and alpha-adrenoceptor blocking agents in isolated canine saphenous arteries. Naunyn-Schmiedebergs Arch. Pharmacol. 287 (Suppl.), R21 (1975a)PubMedGoogle Scholar
  602. Müller-Schweinitzer, E.: unpublished results 1975 bGoogle Scholar
  603. Müller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn-Schmiedebergs Arch. Pharmacol. 292, 113–118 (1976a)PubMedCrossRefGoogle Scholar
  604. Müller-Schweinitzer, E.: Evidence for stimulation of 5-HT receptors in canine saphenous arteries by ergotamine. Naunyn-Schmiedebergs Arch. Pharmacol. 295, 41–44 (1976b)PubMedCrossRefGoogle Scholar
  605. Müller-Schweinitzer, E.: Comparative studies on the mode of action of ergotamine in canine and human arteries. “Headache ‘76”, Joint Meeting of the Italian Headache and the Scandinavian Migraine Societies, Florence, 1976c, Abstract, pp. 22–23Google Scholar
  606. Müller-Schweinitzer, E.: Comparative studies on the mode of action of ergotamine in canine and human arteries. In: Proceedings of “Headache ‘76”. Torino: C.G. Edizioni Medico-Scientifico 1976d (in press)Google Scholar
  607. Müller-Schweinitzer, E., Brundell, J.: Enhanced prostaglandin synthesis contributes to the venoconstrictor activity of ergotamine. Blood Vessels 12, 193–205 (1975a)PubMedGoogle Scholar
  608. Müller-Schweinitzer, E., Brundell, J.: Modification of canine vascular smooth muscle responses to dihydroergotamine by endogenous prostaglandin synthesis. Europ. J. Pharmacol. 34, 197–206 (1975b)CrossRefGoogle Scholar
  609. Müller-Schweinitzer, E., Stürmer, E.: Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Experientia (Basel) 28, 743 (1972)Google Scholar
  610. Müller-Schweinitzer, E., Stürmer, E.: Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Brit. J. Pharmacol. 51, 441–446 (1974a)Google Scholar
  611. Müller-Schweinitzer, E., Stürmer, E.: Studies on the mechanism of the venoconstrictor activity of ergotamine on isolated canine saphenous veins. Blood Vessels 11, 183–190 (1974b)PubMedGoogle Scholar
  612. Müller-Schweinitzer, E., Stürmer, E.: Effects of ergotamine on the responses of isolated saphenous and external carotid arteries of the dog to noradrenaline and serotonin: Sixth Internat. Congress Pharmacol., Helsinki, 1975, Abstract 1555Google Scholar
  613. Mulder, A.H., Stoof, J.C., Tilders, F.J.H.: Depolarization-induced release of central neurotransmitters from rat brain synaptosomes embedded in sephadex G-15 in a superfusion system. Sixth Internat. Congress Pharmacol., Helsinki, 1975, Abstract 1118Google Scholar
  614. Munday, K.A., Poat, J.A., Woodruff, G.N.: Structure activity studies on dopamine receptors, a comparison between rat striatal adenylate cyclase and Helix aspersa neurones. Brit. J. Pharmacol. 57, 452P–453P (1976)Google Scholar
  615. Nair, X.: Contractile responses of guinea-pig umbilical arteries to various hallucinogenic agents. Res. Commun. Chem. Path. Pharmacol. 9, 535–542 (1974)Google Scholar
  616. Nair, X., Dyer, D.C.: Responses of guinea-pig umbilical vasculature to vasoactive drugs. Europ. J. Pharmacol. 27, 294–304 (1974)CrossRefGoogle Scholar
  617. Nakanishi, H., Takeda, H.: The possible role of adenosine triphosphate in chemical transmission between the hypogastric nerve ending and seminal vesicle in the guinea-pig. Jap. J. Pharmacol. 23 (Suppl.), 19 (1973a)CrossRefGoogle Scholar
  618. Nakanishi, H., Takeda, H.: The possible role of adenosine triphosphate in chemical transmission between the hypogastric nerve terminal and seminal vesicle in the guinea-pig. Jap. J. Pharmacol. 23, 479–490 (1973b)PubMedCrossRefGoogle Scholar
  619. Nakano, J.: Effects of prostaglandins E1, A1 and F on the coronary and peripheral circulations. Proc. Soc. exp. Biol. (N.Y.) 127, 1160–1163 (1968)Google Scholar
  620. Nanda, T.C.: The action of ergotamine on the response of the rabbit’s gut to adrenaline. J. Pharmacol. exp. Ther. 42, 9–16 (1931)Google Scholar
  621. Narebski, J., Romanowski, W., Kadziella, W.: Effect of 1-methyl-d-lysergic butanolamide (Deseril) on EEG changes due to 5-hydroxytryptamine and 5-hydroxytryptophane. Acta physiol. pol. 14, 157–170 (1963)PubMedGoogle Scholar
  622. Nathanson, J.A., Greengard, P.: Serotonin-sensitive adenylate cyclase in neural tissue and its similarity to the serotonin receptor: a possible site of action of lysergic acid diethylamide. Proc. natl. Acad. Sci. (Wash.) 71, (3) 797–801 (1974)CrossRefGoogle Scholar
  623. Navratil, E.: Über die Beeinflussung der Cholinesterase durch Ergobasin. Klin. Wschr. 2, 64–65 (1937)CrossRefGoogle Scholar
  624. Ng, K.Y., Chase, T.N., Kopin, I.J.: Drug-induced release of 3H-norepinephrine and 3H-serotonin from brain slices. Nature (Lond.) 228, 468–469 (1970)CrossRefGoogle Scholar
  625. Nielsen, K.C., Owman, C.: Contractile response and amine receptor mechanisms in isolated middle cerebral artery of the cat. Brain Res. 27, 33–42 (1971)PubMedCrossRefGoogle Scholar
  626. Nilsson, S.: Adrenergic innervation and drug responses of the oval sphincter in the swimbladder of the cod Gadus morhua. Acta physiol. scand. 83, 446–453 (1971)PubMedCrossRefGoogle Scholar
  627. Nishi, K.: The action of 5-hydroxytryptamine on chemoreceptor discharges of the cat’s carotid body. Brit. J. Pharmacol. 55, 27–40 (1975)Google Scholar
  628. North, R.A., Henderson, G.: Action of morphine on guinea-pig myenteric plexus and mouse vas deferens studied by intracellular recording. Life Sci. 17, 63–66 (1975)PubMedCrossRefGoogle Scholar
  629. O’Brien, J.R.: A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J. clin. Path. 17, 275–281 (1964)PubMedCrossRefGoogle Scholar
  630. Offermeier, J., Ariens, E.J.: Serotonin. I. Receptors involved in its action. Arch. int. Pharmacodyn. 164, 192–215 (1966)PubMedGoogle Scholar
  631. Ogle, C.W., Wong, C.Y.: The inhibitory and excitatory properties of alpha adrenoceptors in the rat stomach. Life Sci. 10, 153–159 (1971)CrossRefGoogle Scholar
  632. O’Malley, B.W., Hardman, J.G.: Hormon action, part A: steroid hormones. Methods Enzymol. 36, 135–411 (1975)CrossRefGoogle Scholar
  633. Osborne, N.N., Hiripi, L., Neuhoff, V.: The in vitro uptake of biogenic amines by snail Helix pomatia nervous tissue. Biochem. Pharmacol. 24, 2141–2148 (1975)PubMedCrossRefGoogle Scholar
  634. Osswald, W., Guimarães, S.: Über den Mechanismus der Isoprenalinumkehr. Naunyn-Schmiedebergs Arch. Pharmacol. 243, 1–15 (1962)Google Scholar
  635. Osswald, W., Guimarães, S., Garret, J.: Influence of propranolol and ICI 50.172 on the cardiovascular actions of catecholamines as modified by ergotamine. J. Pharmacol. exp. Ther. 174, 315–322 (1970)PubMedGoogle Scholar
  636. Owen, D.A.A., Herd, J.K., Kalberer, F., Pacha, W., Salzmann, R.: The influence of ergotamine and methysergide on the storage of biogenic amines. Headache 11, 91–92 (1971a)Google Scholar
  637. Owen, D.A.A., Herd, J.K., Kalberer, F., Pacha, W., Salzmann, R.: The influence of ergotamine and methysergide on the storage of biogenic amines. In: Proc. Intern. Headache Symposium, Elsinore, Denmark. Dalessio, D.J., Dalsgaard-Nielson, T., Diamond, S. (eds.), pp. 153–161. Basle: Sandoz 1971bGoogle Scholar
  638. Paasonen, M.K., Giarman, N.J.: Brain levels of 5-hydroxytryptamine after various agents. Arch. int. Pharmacodyn. 114, 189–200 (1958)PubMedGoogle Scholar
  639. Pacha, W., Salzmann, R.: Inhibition of the re-uptake of neuronally liberated noradrenaline and α-receptor blocking action of some ergot alkaloids. Brit. J. Pharmacol. 38, 439P–440P (1970)Google Scholar
  640. Palmer, G.C., Burks, T.F.: Central and peripheral adrenergic blocking actions of LSD and BOL. Europ. J. Pharmacol. 16, 113–116 (1971)CrossRefGoogle Scholar
  641. Panigel, M.: Contribution à la physiologie de la circulation foeto-placentaire. I. Etude de la vaso-motricité des artères du cordon ombilical humain. J. Physiol. (Paris) 51, 941–969 (1959)Google Scholar
  642. Panigel, M.: Placental perfusion experiments. Amer. J. Obstet. Gynec. 84, 1664–1683 (1962)Google Scholar
  643. Parker, G.H.: The responses of catfish melanophores to ergotamine. Biol. Bull. 81, 163–167 (1941)CrossRefGoogle Scholar
  644. Parmley, W. W., Rabinowitz, B., Chuck, L.: The role of alpha adrenergic receptors in mediating positive inotropic effects in ventricular myocardium. Amer. J. Cardiol. 33, 161 (1974)CrossRefGoogle Scholar
  645. Parratt, J.R., West, G.B.: Inhibition of oedema production in the rat. J. Physiol. (Lond.) 135, 24P–25P (1957a)Google Scholar
  646. Parratt, J.R., West, G.B.: 5-Hydroxytryptamine and the anaphylactoid reaction in the rat. J. Physiol. (Lond.) 139, 27–41 (1957b)Google Scholar
  647. Parratt, J.R., West, G.B.: Inhibition by various substances of oedema formation in the hind-paw of the rat induced by 5-hydroxytryptamine, histamine, dextran, eggwhite and compound 48/80. Brit. J. Pharmacol. 13, 65–70 (1958)PubMedGoogle Scholar
  648. Passow, H., Schniewind, H., Weiss, C.: Die Wirkung von 5-Hydroxytryptamin auf das Gefäßsystem der isolierten Rattenniere. Naunyn-Schmiedebergs Arch. Pharmacol. 240, 179–186 (1960)Google Scholar
  649. Paterson, G.: The response to transmural stimulation of isolated arterial strips and its modification by drugs. J. Pharm. Pharmacol. 17, 341–349 (1965)PubMedCrossRefGoogle Scholar
  650. Patten, B.M., Oliver, K.L., Engel, W.K.: Serotonin-induced muscle weakness. Arch. Neurol. (Chic.) 31, 347–349 (1974)CrossRefGoogle Scholar
  651. Paul, S.M., Halaris, A.E.: Rat brain de-acetylating activity: Stereospecific inhibition by LSD and serotonin-related compounds. Biochem. biophys. Res. Commun. 70, 207–211 (1976)PubMedCrossRefGoogle Scholar
  652. Paul, S.M., Halaris, A.E., Freedman, D.X., Hsu, L.L.: Rat brain aryl acylamidase: Stereospecific inhibition by LSD and serotonin-related compounds. J. Neurochem. 27, 625–627 (1976)PubMedCrossRefGoogle Scholar
  653. Pert, C.B., Snyder, S.H.: Properties of opiate-receptor binding in rat brain. Proc. natl. Acad. Sci. (Wash.) 70, 2243–2247 (1973)CrossRefGoogle Scholar
  654. Peters, D.A.V.: Comparison of the chronic and acute effects of D-lysergic acid diethylamide (LSD) treatment on rat brain serotonin and norepinephrine. Biochem. Pharmacol. 23, 231–237 (1974a)PubMedCrossRefGoogle Scholar
  655. Peters, D.A.V.: Chronic lysergic acid diethylamide administration and serotonin turnover in various regions of rat brain. J. Neurochem. 23, 625–628 (1974b)PubMedCrossRefGoogle Scholar
  656. Pfeifer, Y., Sadowsky, E., Sulman, F.G.: Prevention of serotonin abortion in pregnant rats by five serotonin antagonists. Obstet. Gynecol. 33, 709–714 (1969)PubMedGoogle Scholar
  657. Phillis, J.W., Tebecis, A.K., York, D.H.: The inhibitory action of monoamines on lateral geniculate neurones. J. Physiol. (Lond.) 190, 563–581 (1967)Google Scholar
  658. Pichler, E., Lazarini, W., Filippi, R.: Über schraubenförmige Struktur von Arterien. II. Mitteilung: Pharmakologische Strukturanalyse von Hirnarterien. Naunyn-Schmiedebergs Arch. Pharmacol. 219, 420–439 (1953)Google Scholar
  659. Pichler, E., Ostfeld, A.M., Goodell, H., Wolff, H.G.: Studies on headache: Central versus peripheral action of ergotamine tartrate and its relevance to the therapy of migraine headache. Arch. Neurol. Psychiat. (Chic.) 76, 571–577 (1956)Google Scholar
  660. Pijnenburg, A.J.J., van Rossum, J.M.: Stimulation of locomotor activity following injection of dopamine into the nucleus accumbens. J. Pharm. Pharmacol. 25, 1003–1004 (1973)PubMedCrossRefGoogle Scholar
  661. Pijnenburg, A.J.J., Woodruff, G.N., van Rossum, J.M.: Ergometrine induced locomotor activity following intracerebral injection into the nucleus accumbens. Brain Res. 59, 289–302 (1973)PubMedCrossRefGoogle Scholar
  662. Pik, K., Borsy, J.: The mechanism of action of GYKI-32084, a new antiserotonin agent. Naunyn-Schmiedebergs Arch. Pharmacol. 284 (Suppl.), R62 (1974)Google Scholar
  663. Pitzele, S., Dobell, A.R.C.: Inhibition of serotonin-induced blood cell aggregation in the dog. Surgery 73, 416–422 (1973)PubMedGoogle Scholar
  664. Politoff, A., Macri, F.: Pharmacologic differences between isolated, perfused arteries of the choroid plexus and of the brain parenchyma. Int. J. Neuropharmacol. 5, 155–162 (1966)PubMedCrossRefGoogle Scholar
  665. Poulson, E., Robson, J.M.: Prevention by antagonists of the toxic action of 5-hydroxytryptamine on pregnancy. Brit. J. Pharmacol. 21, 150–154 (1963)PubMedGoogle Scholar
  666. Pourrias, B.: Analyse des effets tensionels et cardiaques de la tryptine. J. Pharmacol. (Paris) 6, 153–164 (1975)Google Scholar
  667. Prince, W.T., Berridge, J., Rasmussen, H.: Role of calcium and adenosine-3′,5′-cyclic monophosphate in controlling fly salivary gland secretion. Proc. natl. Acad. Sci. (Wash.) 69, 553–557 (1972)CrossRefGoogle Scholar
  668. Proudfit, K., Anderson, E.G.: Alteration by serotonin antagonists of the effects of bulbospinal stimulation on spinal reflex pathways. Fed. Proc. 31, 270 (1972)Google Scholar
  669. Proudfit, H.K., Anderson, E.G.: Influence of serotonin antagonists on bulbospinal systems. Brain Res. 61, 331–341 (1973)PubMedCrossRefGoogle Scholar
  670. Przewlocki, R.: The effect of serotonin microinjections into the nuclei amygdale on EEG and behaviour in the rabbit. Pol. J. Pharmacol. Pharm. 27 (Suppl.), 209–216 (1975)PubMedGoogle Scholar
  671. Rand, M.J., McCulloch, M.W., Story, D.F.: Pre-junctional modulation of noradrenergic transmission by noradrenaline, dopamine and acetylcholine. In: Central Action of Drugs in Blood Pressure Regulation. Davies, D.S., Reid, J.L. (eds.), pp. 94–132. Kent: Pitman Medical Publishing 1975Google Scholar
  672. Randic, M., Padjen, A.: Effect of N,N-dimethyltryptamine and D-lysergic acid diethylamide on the release of 5-hydroxy-indoles in rat forebrain. Nature (Lond.) 230, 532–533 (1971)CrossRefGoogle Scholar
  673. Rao, K.R., Fingerman, M.: Action of biogenic amines on crustacean chromatophores. II. Analysis of the responses of erythrophores in the fiddler crab, Uca pugilator, to indolealkylamines and an eyestalk hormone. Comp. gen. Pharmacol. 1, 117–126 (1970)PubMedCrossRefGoogle Scholar
  674. Regoli, D., Vane, J.R.: A sensitive method for the assay of angiotensin. Brit. J. Pharmacol. 23, 351–359 (1964)PubMedGoogle Scholar
  675. Reichenberg, K., Wiszniowska, G., Marchaj, J.: The influence of 5-hydroxytryptophan (5-HTP) administered into the lateral brain ventricle on the behavior and body temperature in rats. Pol. J. Pharmacol. Pharm. 27 (Suppl.), 217–222 (1975)PubMedGoogle Scholar
  676. Rico, J.M.G.T., Rico, J.T., Ferreira, J.M.C., Cravo, A.C.: L’effet des prostaglandines PGE1, PGE2 et PGF sur la perméabilité vasculaire chez le rat. C.R. Soc. Biol. (Paris) 167, 1315–1318 (1973)Google Scholar
  677. Roberts, M.H., Straughan, D.W.: Excitation and depression of cortical neurones by 5-hydroxytryptamine. J. Physiol. (Lond.) 193, 269–294 (1967)Google Scholar
  678. Rocha e Silva, M., Valle, J.R., Picarelli, Z.P.: A pharmacological analysis of the mode of action of serotonin (5-hydroxytryptamine) upon the guinea-pig ileum. Brit. J. Pharmacol. 8, 378–388 (1953)PubMedGoogle Scholar
  679. Rossler, R., Unna, K.: Zur Pharmakologie des neuen Mutterkornalkaloides Sensibamin. Naunyn-Schmiedebergs Arch. Pharmacol. 179, 115–126 (1935)CrossRefGoogle Scholar
  680. Rose, J.C., Lazaro, E.J.: Pulmonary vascular responses to serotonin and effects of certain serotonin antagonists. Circulat. Res. 6, 283–288 (1958)PubMedGoogle Scholar
  681. Rosecrans, J.A., Lovell, R.A., Freedman, D.X.: Effects of lysergic acid diethylamide on the metabolism of brain 5-hydroxytryptamine. Biochem. Pharmacol. 16, 2011–2021 (1967)PubMedCrossRefGoogle Scholar
  682. Rosenblueth, A.: The action of certain drugs on the nictitating membrane. Amer. J. Physiol. 100, 443–446 (1932)Google Scholar
  683. Ross, S.B., Renyi, A.L.: Accumulation of tritiated 5-hydroxytryptamine in brain slices. Life Sci. 6, 1407–1415 (1967)PubMedCrossRefGoogle Scholar
  684. Roth, J.: Peptide hormone binding to receptors: a review of direct studies in vitro. Metabolism 22, 1059–1073 (1973)PubMedCrossRefGoogle Scholar
  685. Rothlin, E.: Über die pharmakologische und therapeutische Wirkung des Ergotamins auf den Sympathicus. Klin. Wschr. 4, 1437–1443 (1925)CrossRefGoogle Scholar
  686. Rothlin, E.: Zur Pharmakologie des Sympathicolyticums Dihydroergotamin DHE 45. Schweiz. med. Wschr. 76, 1254–1259 (1946)PubMedGoogle Scholar
  687. Rothlin, E.: The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. schweiz. Akad. med. Wiss. 2, 249–273 (1946/47)Google Scholar
  688. Rothlin, E.: Pharmacology of lysergic acid diethylamide (LSD) and some of its related compounds. In: Psychotropic drugs. Garattini, S., Ghetti, V. (eds.), pp. 36–47. Amsterdam: Elsevier Press 1957aGoogle Scholar
  689. Rothlin, E.: Lysergic acid diethylamide and related substances. Ann. N.Y. Acad. Sci. 66, 668–676 (1957b)PubMedCrossRefGoogle Scholar
  690. Rothlin, E.: Pharmacology of lysergic acid diethylamide and some of its related compounds. J. Pharm. Pharmacol. 9, 569–587 (1957c)PubMedCrossRefGoogle Scholar
  691. Rothlin, E., Berde, B.: Über die Wirkung hydrierter Mutterkornalkaloide auf isolierte Muskelstreifen des menschlichen Uterus nahe am Termin, am Termin und während der Geburt. Helv. physiol. pharmacol. Acta 12, 191–205 (1954)PubMedGoogle Scholar
  692. Rothlin, E., Brügger, J.: Quantitative Differenzierung von 4 genuinen und hydrierten Mutterkornalkaloiden am isolierten Kaninchen-Uterus und an der isolierten Samenblase des Meerschweinchens. Helv. physiol. pharmacol. Acta 3, C43–C44 (1945a)Google Scholar
  693. Rothlin, E., Brügger, J.: Quantitative Untersuchungen der sympathikolytischen Wirkung genuiner Mutterkornalkaloide und derer Dihydroderivate am isolierten Uterus des Kaninchens. Helv. physiol. pharmacol. Acta 3, 519–535 (1945b)Google Scholar
  694. Rothlin, E., Cerletti, A.: Pharmakologie des Hochdrucks. Verh. dtsch. Ges. Kreisl.-Forsch. 15, 158–185 (1949)Google Scholar
  695. Rothlin, E., Konzett, H., Cerletti, A.: The antagonism of ergot alkaloids towards the inhibitory response of the isolated rabbit intestine to epinephrine and norepinephrine. J. Pharmacol. exp. Ther. 112, 185–190 (1954)PubMedGoogle Scholar
  696. Rózsa, K.S., Graul, C.: Is serotonin responsible for the stimulative effect of the extracardiac nerve in Helix pomatia? Ann. Biol. Tihany 31, 85–96 (1964)Google Scholar
  697. Ruch-Monachon, M.-A., Jalfre, M., Haefely, W.: Drugs and PGO waves in the lateral geniculate body of the curarized cat. II. PGO wave activity and brain 5-hydroxytryptamine. Arch. int. Pharmacodyn. 219, 269–286 (1976a)PubMedGoogle Scholar
  698. Ruch-Monachon, M.-A., Jalfre, M., Haefely, W.: Drugs and PGO waves in the lateral geniculate body of the curarized cat. V. Miscellaneous compounds. Synopsis of the role of central neurotransmitters on PGO wave activity. Arch. int. Pharmacodyn. 219, 326–346 (1976b)PubMedGoogle Scholar
  699. Ruckebusch, Y., Roche, M., Schurch, D.: Parallelisms des effets des psychodysleptiques majeure sur la toxicité de groupe et de taux cérébral en sérotonine. C.R. Soc. Biol. (Paris) 159, 1745–1748 (1965)Google Scholar
  700. Rudzik, A.D., Miller, J.W.: The mechanism of uterine inhibitory action of relaxin-containing ovarian extracts. J. Pharmacol. exp. Ther. 138, 82–87 (1962)PubMedGoogle Scholar
  701. Saad, K.: The effect of drugs on the isolated splenic capsule of man and other animals. Quart. J. Pharm. Pharmacol. 8, 31–38 (1935)Google Scholar
  702. Sachs, E., Yonkman, F.F.: The pharmacological behavior of the intraocular muscles. V. The action of yohimbine and ergotamine on the dilator iridis. J. Pharmacol. exp. Ther. 75, 105–110 (1942)Google Scholar
  703. Salmoiraghi, G.C., McCubbin, J.W., Page, I.H.: Effects of D-lysergic acid diethylamide and its brom derivative on cardiovascular responses to serotonin and on arterial pressure. J. Pharmacol. exp. Ther. 119, 240–247 (1957)PubMedGoogle Scholar
  704. Salmoiraghi, G.C., Bloom, F.E., Costa, E.: Adrenergic mechanisms in rabbit olfactory bulb. Amer. J. Physiol. 207, 1417–1424 (1964)PubMedGoogle Scholar
  705. Salzmann, R., Kalberer, F.: Antimigraine drugs and storage of serotonin. In: Background to Migraine. Cumings, J.N. (ed.), pp. 63–72. London: William Heinemann Medical Books 1973Google Scholar
  706. Salzmann, R., Pacha, W.: Vergleichende Untersuchungen über die Beeinflussung adrenerger Reaktionen durch Ergotamin und Dihydroergotamin an verschiedenen Versuchsmodellen. Helv. physiol. pharmacol. Acta 26, CR246–CR248 (1968)Google Scholar
  707. Salzmann, R., Pacha, W.: The effects of ergot compounds on the release of noradrenaline and prostaglandins from the isolated perfused cat spleen during nerve stimulation. Postgrad. med. J. 52 (Suppl. 1), 24–31 (1976)Google Scholar
  708. Salzmann, R., Weidmann, H.: Die Wirkung von Ergotamin auf humorale und neuronale Effekte an der Nickhaut der Katze. Helv. physiol. pharmacol. Acta 24, C117 (1966)Google Scholar
  709. Salzmann, R., Pacha, W., Weidmann, H.: Der Einfluß von Ergotamin auf humorale und neuronale Wirkungen an der Nickhaut und an der Milz der Katze. Helv. physiol. pharmacol. Acta 25, CR433–CR435 (1967)PubMedGoogle Scholar
  710. Salzmann, R., Pacha, W., Taeschler, M., Weidmann, H.: The effect of ergotamine on humoral and neuronal actions in the nictitating membrane and the spleen of the cat. Naunyn-Schmiedebergs Arch. Pharmacol. 261, 360–378 (1968)Google Scholar
  711. Sankar, D.V.S., Sankar, D.B., Phipps, E., Gold, E.: Effect of administration of lysergic acid diethylamide on serotonin levels in the body. Nature (Lond.) 191, 499–500 (1961)CrossRefGoogle Scholar
  712. Sankar, D.V.S., Phipps, E., Gold, E., Sankar, D.B.: Effect of LSD, BOL, and chlorpromazine on “Neurohormone” metabolism. Ann. N.Y. Acad. Sci. 96, 93–97 (1962)PubMedCrossRefGoogle Scholar
  713. Sankar, D.V.S., Broer, H.H., Cates, N., Sankar, D.B.: Studies on biogenic amines and psychoactive drug actions, with special reference to lysergic acid diethyl amide. Trans. N.Y. Acad. Sci. 26, 369–379 (1964)PubMedGoogle Scholar
  714. Sankar, D.V.S., Cates, N.R., Domjan, M.: Comparative biochemical pharmacology of psychoactive drugs. Clin. Res. 17, 395 (1969)Google Scholar
  715. Sato, M., Sawada, M.: Selective blocking action of LSD on inhibitory dopamine receptors. Neuropharmacology 14, 883–886 (1975)PubMedCrossRefGoogle Scholar
  716. Savini, E.C.: The antagonism between 5-hydroxytryptamine and certain derivatives of lysergic acid. Brit. J. Pharmacol. 11, 313–317 (1956)PubMedGoogle Scholar
  717. Saxena, P.R.: The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12, 44–45 (1972a)PubMedCrossRefGoogle Scholar
  718. Saxena, P.R.: The effects of some antimigraine drugs on the vascular resistance in the external carotid bed of the dog. In: Vascular Smooth Muscle. Betz, E. (ed.), pp. 93–95. Berlin-Heidelberg-New York: Springer 1972bCrossRefGoogle Scholar
  719. Saxena, P.R.: Selective carotid vasoconstriction by ergotamine as a relevant mechanism in its antimigraine action. Arch. Neurobiol. 37 (Suppl.), 301–315 (1974a)Google Scholar
  720. Saxena, P.R.: Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effect. Europ. J. Pharmacol. 27, 99–105 (1974b)CrossRefGoogle Scholar
  721. Saxena, P.R.: On the mechanism of action of methysergide in vascular headaches of migraine type. In: Headache, II. Biochemical Bases and Drug Therapy. Munch. Med. Wochenschr. (ed.), pp. 91–100, 137–138. München: O. Spatz 1975Google Scholar
  722. Saxena, P.R., De Vlaam-Schluter, G.M.: Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine-studies in an experimental model for migraine. Headache 13, 142–163 (1974)PubMedCrossRefGoogle Scholar
  723. Saxena, P.R., van Houwelingen, P., Bonta, I.L.: The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Europ. J. Pharmacol. 13, 295–305 (1971)CrossRefGoogle Scholar
  724. Schanberg, S.M., Giarman, N.J.: Uptake of serotonin (5-HT) and 5-hydroxytryptophan (5-HTP) by brain slices. Pharmacologist 2, 67 (1960)Google Scholar
  725. Schanberg, S.M., Giarman, N.J.: Drug-induced alterations in the sub-cellular distribution of 5-hydroxytryptamine in rat’s brain. Biochem. Pharmacol. 11, 187–194 (1962)PubMedCrossRefGoogle Scholar
  726. Scherbel, A.: Pharmacodynamic effects of UML-491 in animal and man. Wiss. Ausstellung, 6. Int. Kongress Inn. Med., Basel, August 1960, AbstractGoogle Scholar
  727. Schild, H.O.: pA, a new scale for the measurement of drug antagonism. Brit. J. Pharmacol. 2, 189–206 (1947)PubMedGoogle Scholar
  728. Schild, H.O.: Non-competitive antagonism. J. Physiol. (Lond.) 124, 33P–34P (1954)Google Scholar
  729. Schild, H.O.: Effect of adrenaline on depolarized smooth muscle. In: Ciba Foundation Symposium on Adrenergic Mechanisms. Wolstenholme, G.E.W., O’Connor, M. (eds.), pp. 288–294. London: J. and A. Churchill 1960Google Scholar
  730. Schild, H.O.: Parallelism of log dose-response curves in competitive antagonism. Pharmacol. Res. Commun. 1, 1–2 (1969)CrossRefGoogle Scholar
  731. Schild, H.O.: Some aspects of receptor pharmacology of ergotamine. Postgrad. med. J. 52 (Suppl. 1), 9–11 (1976)PubMedGoogle Scholar
  732. Schildkraut, J.J., Schanberg, S.M., Breese, G.R., Kopin, I.J.: Effects of psychoactive drugs on the metabolism of intracisternally administered serotonin in rat brain. Biochem. Pharmacol. 18, 1971–1978 (1969)PubMedCrossRefGoogle Scholar
  733. Schlientz, W., Brunner, R., Rüegger, A., Berde, B., Stürmer, E., Hofmann, A.: β-Ergokryptin, ein neues Alkaloid der Ergotoxin-Gruppe. Pharm. Acta Helv. 43, 497–509 (1968)PubMedGoogle Scholar
  734. Schönbaum, E., Lamar, J.-C.: Anti-serotonin drugs in nasal vessels. Sixth Internat. Congress Pharmacology, Helsinki, 1975, Abstract 698Google Scholar
  735. Schönbaum, E., Vargaftig, B.B., Lefort, J.: Nasal vessels and serotonin. Pharmacologist 16, 243 (1974)Google Scholar
  736. Schönbaum, E., Vargaftig, B.B., Lefort, J., Lamar, J.C., Hasenack, T.: An unexpected effect of serotonin antagonists on the canine nasal circulation. Headache 15, 180–187 (1975)PubMedCrossRefGoogle Scholar
  737. Scholtysik, G.: Inhibition of accelerator nerve stimulation in cats by dihydroergotoxine. Sixth Internat. Congress Pharmacology, Helsinki, 1975, Abstract 742Google Scholar
  738. Schorderet, M.: Direct evidence for the stimulation of rabbit retina dopamine receptors by ergot alkaloids. Neurosci. Lett. 2, 87–91 (1976)PubMedCrossRefGoogle Scholar
  739. Schorderet, M., Frangaki, A.: Effects of antiparkinsonian drugs on cAMP accumulation in rabbit retina. Experientia (Basel) 32, 782 (1976)Google Scholar
  740. Schubert, J., Nybäck, H., Sedvall, G.: Accumulation and disappearance of 3H-5-hydroxytryptamine formed from 3H-tryptophan in mouse brain: effect of LSD 25. Europ. J. Pharmacol. 10, 215–224 (1970)CrossRefGoogle Scholar
  741. Schwarz, B.E., Wakim, K.G., Bickford, R.G., Lichtenheld, F.R.: Behavioural and electroencephalographic effects of hallucinogenic drugs. Arch. Neurol. Psychiat. (Chic.) 75, 83–90 (1956)Google Scholar
  742. Scriabine, A., Bellet, S., Kershbaum, A., Feinberg, L.J.: Effect of dihydroergotamine on plasma free fatty acids (FFA) in dogs. Life Sci. 7, 453–463 (1968)PubMedCrossRefGoogle Scholar
  743. Segal, M.: Physiological and pharmacological evidence for a serotonergic projection to the hippocampus. Brain Res. 94, 115–131 (1975)PubMedCrossRefGoogle Scholar
  744. Segal, M., Bloom, F.E.: The projection of midline raphe nuclei to the hippocampus of the rat. Fed. Proc. 33, 299 (1974)Google Scholar
  745. Seiler, K.-U., Wassermann, O.: MAO-inhibitory properties of anorectic drugs. J. Pharm. Pharmacol. 25, 576–578 (1973)PubMedCrossRefGoogle Scholar
  746. Shaskan, E.G., Snyder, S.H.: Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J. Pharm. exp. Ther. 175, 404–418 (1970)Google Scholar
  747. Shaw, E., Woolley, D.W.: Yohimbine and ergot alkaloids as naturally occurring antimetabolites of serotonin. J. biol. Chem. 203, 978–989 (1953)Google Scholar
  748. Shaw, E., Woolley, D.W.: Some serotoninlike activities of lysergic acid diethylamide. Science 124, 121–122 (1956)PubMedCrossRefGoogle Scholar
  749. Shibuya, T., Anderson, E.G.: The influence of chronic cord transection on the effects of 5-hydroxytryptophan, L-tryptophan and pargyline on spinal neuronal activity. J. Pharmacol. exp. Ther. 164, 185–190 (1968)PubMedGoogle Scholar
  750. Shields, P.J., Eccleston, D.: Evidence for the synthesis and storage of 5-hydroxytryptamine in two separate pools in the brain. J. Neurochem. 20, 881–888 (1973)PubMedCrossRefGoogle Scholar
  751. Shimahara, T., Tauc, L.: Heterosynaptic facilitation in the giant cell of Aplysia. J. Physiol. (Lond.) 247, 321–342 (1975)Google Scholar
  752. Sicuteri, F., Michelacci, S., Franchi, G.: Antagonism between an antiserotonin-the butanolamide of 1-methyl-lysergic acid-and the effects of a histamine-liberating substance 48/80 B.W. in man. Int. Arch. Allergy 15, 291–299 (1959)PubMedCrossRefGoogle Scholar
  753. Sicuteri, F., Franchi, G., Michelacci, S.: Inhibition by lysergic acid derivatives of bronchospasm induced in guinea-pigs by serotonin aerosol. Med. Exp. 3, 89–94 (1960)Google Scholar
  754. Sicuteri, F., Del Bianco, P.L., Fanciullacci, M., Franchi, G.: II test della venocostrizione per la misura della sensibilita alia 5-idossitriptamina e alle catecolamine nell’uomo. Boll. Soc. ital. Biol. sper. 40, 1148–1150 (1964a)PubMedGoogle Scholar
  755. Sicuteri, F., Fanciullacci, M., Del Bianco, P.L., Franchi, G.: Inibizione della venocostrizione da 5-idrossitriptamina nell’uomo da parte del metisergide (UML-491) e di altri antiserotoninici. Boll. Soc. ital. Biol. sper. 40, 1151–1152 (1964b)PubMedGoogle Scholar
  756. Sicuteri, F., Franchi, G., Fanciullacci, M.: Serotonin potentiation of methysergide, LSD 25 and ergotamine in man: An informal approach to migraine pharmacology. In: Headache, II. Biochemical Bases and Drug Therapy. Munch. Med. Wochenschr. (ed.), pp. 101–104, 137–138. München: O. Spatz 1975Google Scholar
  757. Simon, G., Winter, M.: The effect of sympatholytic and sympathomimetic agents on acetylcholinesterase and cholinesterase activity in vitro. Biochem. Pharmacol. 25, 881–882 (1976)PubMedCrossRefGoogle Scholar
  758. Slater, I.H., Davis, K.H., Leary, D.E., Boyd, E.S.: The action of serotonin and lysergic acid diethylamide on spinal reflexes. J. Pharmacol. exp. Ther. 113, 48–49 (1955)Google Scholar
  759. Smith, C.B.: Relaxation of the nictitating membrane of the spinal cat by sympathomimetic amines. J. Pharmacol. exp. Ther. 142, 163–170 (1963)PubMedGoogle Scholar
  760. Snider, S.R., Hutt, C., Stein, B., Fahn, S.: Increase in brain serotonin produced by bromocryptine. Neurosci. Lett. 1, 237–241 (1975)CrossRefGoogle Scholar
  761. Snider, S.R., Hutt, C., Stein, B., Prasad, A.L.N., Fahn, S.: Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J. Pharm. Pharmacol. 28, 563–566 (1976)PubMedCrossRefGoogle Scholar
  762. Snyder, S.H., Bennett, J.P.: Neurotransmitter receptors in the brain: biochemical identification. Annu. Rev. Physiol. 38, 153–175 (1976)PubMedCrossRefGoogle Scholar
  763. Sofia, R.D., Vassar, H.B.: The effects of ergotamine and methysergide on serotonin metabolism in the rat brain. Arch. int. Pharmacodyn. 216, 40–50 (1975)PubMedGoogle Scholar
  764. Sollero, L., Page, I.H., Salmoiraghi, G.C.: Brom-lysergic acid diethylamide: A highly potent serotonin antagonist. J. Pharmacol. exp. Ther. 117, 10–15 (1956)PubMedGoogle Scholar
  765. Sollmann, T.: A Manual of Pharmacology and its Applications to Therapeutics and Toxicology, 7th ed. Philadelphia-London: W.B. Saunders 1948Google Scholar
  766. Sollmann, T., Brown, E.D.: Intravenous injection of ergot. J. Amer. med. Ass. 45, 229–240 (1905)CrossRefGoogle Scholar
  767. Sonneville, P.F.: An indirect action of dopamine on the rat fundus strip mediated by 5-hydroxytryptamine. Europ. J. Pharmacol. 2, 367–370 (1968)CrossRefGoogle Scholar
  768. Spano, P.F., Cattabeni, F., Govoni, S., Trabucchi, M.: Selective stimulation by d-LSD of dopamine-sensitive adenylate cyclase in various rat brain areas. Sixth Internat. Congress Pharmacol., Helsinki, 1975a, Abstract 186Google Scholar
  769. Spano, P.F., Kumakura, K., Tonon, G.C., Govoni, S., Trabucchi, M.: LSD and dopaminesensitive adenylate cyclase in various rat brain areas. Brain Res. 93, 164–167 (1975b)PubMedCrossRefGoogle Scholar
  770. Sparber, S.B.: Neurochemical changes associated with schedule controlled behavior. Fed. Proc. 34, 1802–1812 (1975)PubMedGoogle Scholar
  771. Stacey, R.S.: Uptake of 5-hydroxytryptamine by platelets. Brit. J. Pharmacol. 16, 284–295 (1961)PubMedGoogle Scholar
  772. Stadler, P.A., Stürmer, E.: Comparative studies on the pharmacological properties of stereoisomers of ergotamine and dihydroergotamine. Naunyn-Schmiedebergs Arch. Pharmacol. 266, 457–458 (1970)Google Scholar
  773. Starke, K.: α-Sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart. Naunyn-Schmiedebergs Arch. Pharmacol. 274, 18–45 (1972)PubMedCrossRefGoogle Scholar
  774. Starke, K., Montel, H.: Sympathomimetic inhibition of noradrenaline release: mediated by prostaglandins? Naunyn-Schmiedebergs Arch. Pharmacol. 278, 111–116 (1973)PubMedCrossRefGoogle Scholar
  775. Starr, M.S., West, G.B.: The effect of bradykinin and anti-inflammatory agents on isolated arteries. J. Pharm. Pharmacol. 18, 838–840 (1966)PubMedCrossRefGoogle Scholar
  776. Stephenson, R.P.: A modification of receptor theory. Brit. J. Pharmacol. 11, 379–393 (1956)PubMedGoogle Scholar
  777. Stevens, B., Baguet, F.: Action de l’acide bromolysergique diethylamide (BOL 148) sur les propriétés mécaniques d’un muscle lisse de Lamellibranche. Arch. int. Physiol. Biochim. 76, 552–554 (1968)PubMedGoogle Scholar
  778. Stjärne, L., Lishajko, F.: Drug-induced inhibition of noradrenaline synthesis in vitro in bovine splenic nerve tissue. Brit. J. Pharmacol. 27, 398–404 (1966)PubMedGoogle Scholar
  779. Stjärne, L., Wennmalm, A.: Quantitative estimation of secretion and reuptake of adrenergic transmitter in the rabbit heart. Acta physiol. scand. 81, 286–288 (1971)PubMedCrossRefGoogle Scholar
  780. Stolk, J.M., Barchas, J.D., Goldstein, M., Boggan, W., Freedman, D.X.: A comparison of psychotomimetic drug effects on rat brain norepinephrine metabolism. J. Pharmacol. exp. Ther. 189, 42–50 (1974)PubMedGoogle Scholar
  781. Stoll, A., Hofmann, A.: The ergot alkaloids. In: The Alkaloids. Manske, R.H.F. (ed.), Chap. 21, Vol. VIII. New York: Academic Press 1965Google Scholar
  782. Stone, C.A., Wenger, H.C., Ludden, C.T., Stavorski, J.M., Ross, C.A.: Antiserotonin-antihistaminic properties of cyproheptadine. J. Pharmacol. exp. Ther. 131, 73–84 (1961)Google Scholar
  783. Stone, T.W.: Further evidence for a dopamine receptor stimulating action of an ergot alkaloid. Brain Res. 72, 177–180 (1974)PubMedCrossRefGoogle Scholar
  784. Straczowski, W., Kalicinski, A., Nowak, W., Malofiejew, M.: The effects of prostaglandin A2 (PGA2) on the guinea-pig isolated ileum. Pol. J. Pharmacol. Pharm. 26, 253–255 (1974)Google Scholar
  785. Strandhoy, J.W., Cronnelly, R., Long, J.P., Williamson, H.E.: Effects of vasoactive agents and diuretics on isolated superfused interlobar renal arteries. Proc. Soc. exp. Biol. (N.Y.) 141, 336–339 (1972)Google Scholar
  786. Streuli, H.: Die Wechselwirkung von inneren Sekreten und die Beziehung dieser Wirkung zum Problem der Erregung und Hemmung. Z. Biol. 66, 167–228 (1916)Google Scholar
  787. Strong, C.G., Bohr, D.F.: Effects of Prostaglandins E1, E2, A1 and F on isolated vascular smooth muscle. Circulation 36 (Suppl. 2), II 244–11 245 (1967a)Google Scholar
  788. Strong, C.G., Bohr, D.F.: Effects of prostaglandins E1, E2, A1 and F on isolated vascular smooth muscle. Amer. J. Physiol. 213, 725–733 (1967b)PubMedGoogle Scholar
  789. Struyker Boudier, H., Van Rossum, J.M.: Dopamine-induced inhibition and excitation of neurones of the snail Helix aspersa. Arch. int. Pharmacodyn. 209, 314–324 (1974)PubMedGoogle Scholar
  790. Struyker Boudier, H.A.J., Gielen, W., Cools, A.R., Van Rossum, J.M.: Pharmacological analysis of dopamine-induced inhibition and excitation of neurones of the snail Helix aspersa. Arch. int. Pharmacodyn. 209, 324–331 (1974)PubMedGoogle Scholar
  791. Struyker Boudier, H., Teppema, L., Cools, A., Van Rossum, J.M.: (3,4-dihydroxy-phenylamino)-2-imidazoline (DPI), a new potent agonist at dopamine receptors mediating neuronal inhibition. J. Pharm. Pharmacol. 27, 882–883 (1975)CrossRefGoogle Scholar
  792. Sugrue, M.F.: A study of the role of noradrenaline in behavioural changes produced in the rat by psychotomimetic drugs. Brit. J. Pharmacol. 35, 243–252 (1969)Google Scholar
  793. Svensson, T.H., Bunney, B.S., Aghajanian, G.K.: Noradrenergic regulation of brain serotonergic neurons: Evidence from single unit studies with clonidine. Pharmacologist 16, 244 (1974)Google Scholar
  794. Swank, R.L., Fellman, J.H.: Blood cell aggregation and biological agents. Bibl. anat. (Basel) 8–9, 98–103 (1966)Google Scholar
  795. Swank, R.L., Fellman, J.H., Hissen, W.W.: Aggregation of blood cells by 5-hydroxytryptamine (serotonin). Circulat. Res. 13, 392–400 (1963)PubMedGoogle Scholar
  796. Szabadi, E., Bradshaw, C.M.: The role of physical and biological factors in determining the time course of neuronal responses. Neuropharmacology 13, 537–545 (1974)PubMedCrossRefGoogle Scholar
  797. Szara, S., Morton, D.M., Aikens, A.: Comparison of hallucinogenic and nonhallucinogenic congeners on regional serotonin metabolism in brain. Pharmacologist 9, 250 (1967)Google Scholar
  798. Takeuchi, H., Mori, A., Kohsaka, M.: Effets des indolamines et de leurs analogues sur l’activité électrique d’un neurone géant identifié d’Achatina fulica Ferussac. C.R. Soc. Biol. (Paris) 186, 658–663 (1974)Google Scholar
  799. Tardos, L., Adam, V.: The chronotropic activity of serotonin. Naunyn-Schmiedebergs Arch. Pharmacol. 248 (Suppl.), R81 (1974)Google Scholar
  800. Tebécis, A.K., DiMaria, A.: A re-evaluation of the mode of action of 5-hydroxytryptamine on lateral geniculate neurones: Comparison with catecholamines and LSD. Exp. Brain Res. 14, 480–493 (1972)PubMedCrossRefGoogle Scholar
  801. Teraki, Y.: A study on the action mechanism of foetal death with 5-HT and the influence of its antagonists. Acta obstet. gynaec. Jap. 17, 142 (1970)Google Scholar
  802. Thierry, A.M., Blanc, G., Sobel, A., Stinus, L., Glowinski, J.: Dopaminergic terminals in rat cortex. Science 182, 499–501 (1973a)PubMedCrossRefGoogle Scholar
  803. Thierry, A.M., Stinus, L., Blanc, G., Glowinski, J.: Some evidence for the existence of dopaminergic neurones in the rat cortex. Brain Res. 50, 230–234 (1973b)PubMedCrossRefGoogle Scholar
  804. Thoenen, H., Hürlimann, A., Haefely, W.: Dual site of action of phenoxybenzamine in the cat’s spleen: Blockade of α-adrenergic receptors and inhibition of re-uptake of neurally released norepinephrine. Experientia (Basel) 20, 272–273 (1964a)CrossRefGoogle Scholar
  805. Thoenen, H., Hürlimann, A., Haefely, W.: Wirkungen von Phenoxybenzamin, Phentolamin und Azapetin auf adrenergische Synapsen der Katzenmilz. Helv. physiol. pharmacol. Acta 22, 148–161 (1964b)PubMedGoogle Scholar
  806. Thompson, J.H., Campbell, L.B.: The influence of 1-methyl-d-lysergic acid butanolamide on gastrointestinal serotonin in the Sprague-Dawley rat. Biochem. Pharmacol. 16, 1377–1380 (1967)PubMedCrossRefGoogle Scholar
  807. Thompson, J.W.: Studies on the responses of the isolated nictitating membrane of the cat. J. Physiol. (Lond.) 141, 46–72 (1958)Google Scholar
  808. Thompson, M.R.: Some properties of ergostetrine. J. Amer. Pharm. Ass. 24, 748–753 (1935)CrossRefGoogle Scholar
  809. Thompson, R.H.S., Tickner, A., Webster, G.R.: Cholinesterase inhibition by lysergic acid diethylamide. Biochem. J. 58, XIX–XX (1954)PubMedGoogle Scholar
  810. Thompson, R.H.S., Tickner, A., Webster, G.R.: The action of lysergic acid diethylamide on mammalian cholinesterases. Brit. J. Pharmacol. 10, 61–65 (1955)PubMedGoogle Scholar
  811. Thulin, A.: Motor and secretory effects of autonomic nerves and drugs in the rat submaxillary gland. Acta physiol. scand. 92, 217–223 (1974)PubMedCrossRefGoogle Scholar
  812. Thulin, A.: Influence of autonomic nerves and drugs on myoepithelial cells in parotid gland of cat. Acta physiol. scand. 93, 477–482 (1975)PubMedCrossRefGoogle Scholar
  813. Tilson, H.A., Sparber, S.B.: Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push-pull cannula. J. Pharmacol. exp. Ther. 181, 387–398 (1972)PubMedGoogle Scholar
  814. Toda, N.: Influence of 5-hydroxykynurenamine, a new serotonin metabolite, on isolated cerebral arteries. Jap. J. Pharmacol. 24 (Suppl.), 68 (1974)PubMedGoogle Scholar
  815. Toda, N.: Analysis of the effect of 5-hydroxykynurenamine, a serotonin metabolite, on isolated cerebral arteries, aortas and atria. J. Pharmacol. exp. Ther. 193, 385–392 (1975)PubMedGoogle Scholar
  816. Toda, N., Goldberg, L.I.: Dopamine-induced relaxation of isolated arterial strips. J. Pharm. Pharmacol. 25, 587–589 (1973)PubMedCrossRefGoogle Scholar
  817. Toda, N., Goldberg, L.I.: Effects of dopamine on isolated canine coronary arteries. Cardiovasc. Res. 9, 384–389 (1975)PubMedCrossRefGoogle Scholar
  818. Toda, N., Goldberg, L.I., Fujiwara, M.: Dopamine-induced relaxation of isolated blood vessels. Jap. J. Pharmacol. 23 (Suppl.), 45 (1973)CrossRefGoogle Scholar
  819. Toda, N., Tokuyama, T., Senoh, S., Hirata, F., Hayaishi, O.: Effects of 5-hydroxykynurenamine, a new serotonin metabolite, on isolated dog basilar arteries. Proc. natl. Acad. Sci. (Wash.) 71, 122–124 (1974)CrossRefGoogle Scholar
  820. Toda, N., Hayashi, S., Fu, W.L.H., Nagasaka, Y.: Serotonin antagonism in isolated canine cerebral arteries. Jap. J. Pharmacol. 26, 57–63 (1976)CrossRefGoogle Scholar
  821. Tomosky, T.K., Bennett, J.L., Bueding, E.: Tryptaminergic and dopaminergic responses of Schistosoma mansoni. J. Pharmacol. exp. Ther. 190, 260–271 (1974)PubMedGoogle Scholar
  822. Tonge, S.R., Leonard, B.E.: The effects of some hallucinogenic drugs upon the metabolism of 5-hydroxy-tryptamine in the brain. Life Sci. 8 (I), 805–814 (1969)PubMedCrossRefGoogle Scholar
  823. Tonge, S.R., Leonard, B.E.: The effect of some hallucinogenic drugs on the amino acid precursors of brain monoamines. Life Sci. 9 (I), 1327–1335 (1970)CrossRefGoogle Scholar
  824. Torre, M., Bogetto, F., Torre, E.: Effect of LSD-25 and 1-methyl-d-lysergic acid butanolamide on rat brain and platelet serotonin levels. Psychopharmacologia 36, 117–122 (1974a)PubMedCrossRefGoogle Scholar
  825. Torre, M., Torre, E., Bogetto, F.: Somministrazione di etanolo a varie dosi: livelli di serotonina cerebrale nel ratto. Somministrazione contemporanea di LSD-25 e UML: Livelli di serotonina cerebrale e comportamento condizionato nel ratto. Boll. Soc. ital. Biol. sper. 50, 1639–1645 (1974b)PubMedGoogle Scholar
  826. Tothill, A.: Investigation of adrenaline reversal in the rat uterus by the induction of resistance to isoprenaline. Brit. J. Pharmacol. 29, 291–301 (1967)PubMedGoogle Scholar
  827. Trabucchi, M., Spano, P.F., Tonon, G.C., Frattola, L.: Effects of bromocriptine on central dopaminergic receptors. Life Sci. 19, 225–232 (1976)PubMedCrossRefGoogle Scholar
  828. Trenchard, A., Turner, P., Pare, C.M.B., Hills, M.: The effects of protryptiline and clomipramine in vitro on the uptake of 5-hydroxytryptamine and dopamine in human platelet-rich plasma. Psychopharmacologia 43, 89–93 (1975)PubMedCrossRefGoogle Scholar
  829. Trendelenburg, U.: The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. J. Pharmacol. exp. Ther. 130, 450–460 (1960)PubMedGoogle Scholar
  830. Türker, K., Kiran, B.K., Kaymakcalan, S.: Distribution of adrenergic receptors in the cat ileum. Arch. int. Pharmacodyn. 156, 130–142 (1965)PubMedGoogle Scholar
  831. Türker, R.K., Khairallah, P.A.: Prostaglandin E1 action on canine isolated tracheal muscle. J. Pharm. Pharmacol. 21, 498–501 (1969)PubMedCrossRefGoogle Scholar
  832. Tuomisto, J.: Inhibition of noradrenaline (NA), dopamine (DA) and 5-HT uptake in synaptosomes by reserpine, 6-hydroxy-1,2,3,4-tetrahydroharmane (6HTH), LSD and ergotamine. J. Pharmacol. (Paris) 5 (Suppl. 2), 100 (1974)Google Scholar
  833. Turner, P.: Some pharmacological studies on drugs used in the prophylactic treatment of migraine. In: Background to Migraine. Cumings, J.N. (ed.), pp. 170–173. London: William Heinemann Medical Books 1973Google Scholar
  834. Twarog, B.M.: Responses of a molluscan smooth muscle to acetylcholine and 5-hydroxytryptamine. J. cell. comp. Physiol. 44, 141–164 (1954)CrossRefGoogle Scholar
  835. Ungar, F., Hitri, A., Alivisatos, S.G.A.: Drug antagonism and reversibility of the binding of indole amines in brain. Europ. J. Pharmacol. 36, 115–125 (1976)CrossRefGoogle Scholar
  836. Urquilla, P.R., Marco, E., Lluch, S.: Pharmacological receptors of the cerebral blood vessels of the goat. Fed. Proc. 33, 568 (1974)Google Scholar
  837. Urquilla, P.R., Marco, E.J., Lluch, S.: Pharmacological receptors of the cerebral arteries of the goat. Blood Vessels 12, 53–67 (1975)PubMedGoogle Scholar
  838. Uzunov, P., Weiss, B.: Psychopharmacological agents and the cyclic AMP system of rat brain. Adv. Cyclic Nucleotide Res. 1, 435–451 (1972)PubMedGoogle Scholar
  839. Valdecasas, F.G., Calvet, F., Cuenca, E., Salva, J.A.: Die potenzierende Wirkung verschiedener psychoaktiver Substanzen auf Adrenalin und Serotonin. Arzneimittel-Forsch. 6, 594–596 (1956)Google Scholar
  840. Vane, J.R.: A sensitive method for the assay of 5-hydroxytryptamine. Brit. J. Pharmacol. 12, 344–349 (1957)PubMedGoogle Scholar
  841. Vane, J.R.: The actions of sympathomimetic amines on tryptamine receptors. In: Ciba Foundation Symposium on Adrenergic Mechanisms, pp. 356–372. London: J. and A. Churchill 1960Google Scholar
  842. Van Rossum, J.M.: Cumulative dose-response curves. II. Technique for the making of doseresponse curves in isolated organs and the evaluation of drug parameters. Arch. int. Pharmacodyn. 143, 299–330 (1963)Google Scholar
  843. Van Rossum, J.M., Pijnenburg, A.J.J., Cools, A.R., Broekkamp, C.L.E., Struyker Boudier, H.A.J.: Behavioural pharmacology of the neostriatum and the limbic striatum. In: Neuropharmacology. Excerpta Medica Int. Congress Series No. 359, pp. 505–516. Amsterdam 1975Google Scholar
  844. Vargaftig, B.B., Lefort, J.: Pharmacological evidence for a vasodilator receptor to serotonin in the nasal vessels of the dog. Europ. J. Pharmacol. 25, 216–225 (1974)CrossRefGoogle Scholar
  845. Vidrio, H., Hong, E.: Vascular tone and reactivity to serotonin in the internal and external carotid vascular beds of the dog. J. Pharmacol. exp. Ther. 197, 49–56 (1976)PubMedGoogle Scholar
  846. Vogel, G., Marek, M.L.: Über die Hemmung verschiedener Rattenpfoten-Oedeme durch Serotonin-Antagonisten. Arzneimittel-Forsch. 11, 1051–1054 (1961)Google Scholar
  847. Vogt, M.: Drugs interfering with central actions of 5-hydroxytryptamine. In: Ciba Foundation Symposium on Hypertension, pp. 209–213. London: J. and A. Churchill 1954Google Scholar
  848. Vogt, M., Gunn, C.G., Sawyer, Ch.: Electroencephalographic effects of intraventricular 5-HT and LSD in the cat. Neurology (Minneap.) 7, 559–566 (1957)Google Scholar
  849. Von Hungen, K., Roberts, S., Hill, D.F.: Serotonin and catecholamine activation of brain adenylate cyclase: Effects of psychoactive drugs. Trans. Amer. Soc. Neurochem. 5, 150 (1974a)Google Scholar
  850. Von Hungen, K., Roberts, S., Hill, D.F.: LSD as an antagonist at central dopamine receptors. Nature (Lond.) 252, 588–589 (1974b)CrossRefGoogle Scholar
  851. Von Hungen, K., Roberts, S., Hill, D.F.: Serotonin-sensitive adenylate cyclase activity in immature rat brain. Brain Res. 84, 257–267 (1975)CrossRefGoogle Scholar
  852. Votava, Z., Lamplová, I.: Antiserotonin effect of derivatives of d-lysergic acid (cycloalkylamides, LSD, ergometrine) and chlorpromazine in rats. Activ. nerv. sup. (Praha) 1, 269–275 (1959)Google Scholar
  853. Votava, Z., Podvalová, I., Semonský, M.: Oxytocic effect of some d-lysergic acid cycloalkylamides. Nature (Lond.) 179, 474–475 (1957)CrossRefGoogle Scholar
  854. Votava, Z., Podvalová, I., Semonský, M.: Studies on the pharmacology of d-lysergic acid cycloalkylamides. Arch. int. Pharmacodyn. 115, 114–130 (1958)PubMedGoogle Scholar
  855. Walker, R.J., Woodruff, G.N., Glaizner, B., Sedden, C.B., Kerkut, G.A.: The pharmacology of Helix dopamine receptor of specific neurones in the snail, Helix aspersa. Comp. Biochem. Physiol. 24, 455–469 (1968)PubMedCrossRefGoogle Scholar
  856. Walsh, J.A.: Antagonism by methysergide of vascular effects of 5-hydroxytryptamine in man. Brit. J. Pharmacol. 30, 518–530 (1967)PubMedGoogle Scholar
  857. Walters, J.R., Roth, R.H., Aghajanian, G.K.: Dopaminergic neurons, similar biochemical and histochemical effects of γ-hydroxybutyrate and acute lesions of the nigro-striatal pathway. J. Pharmacol. exp. Ther. 186, 630–639 (1973)PubMedGoogle Scholar
  858. Watson, P.J.: Drug receptor sites in the isolated superior cervical ganglion of the rat. Europ. J. Pharmacol. 12, 183–193 (1970)CrossRefGoogle Scholar
  859. Weber, H.P., Petcher, T.J.: unpublished observations 1976Google Scholar
  860. Weidmann, H.: Die Wirkung von D-Lysergsäure-diäthylamid und 5-Hydroxytryptamin auf spinale Reflexe. Helv. physiol. pharmacol. Acta 15, C43–C44 (1957)Google Scholar
  861. Weidmann, H., Cerletti, A.: Die Wirkung von D-Lysergsäurediäthylamid und 5-Hydroxytryptamin (Serotonin) auf spinale Reflexe der Katze. Helv. physiol. pharmacol. Acta 15, 376–383 (1957)PubMedGoogle Scholar
  862. Weidmann, H., Taeschler, M.: Influence des substances antimigraineuses sur les effets des catécholamines, de la sérotonine et de la stimulation des nerfs sympathiques. Extrait du Symposium International sur les Céphalées vasculaires, pp. 33–40. St-Germain-en-Laye 1966Google Scholar
  863. Weiss, B.L., Aghajanian, G.K.: Activation of brain serotonin metabolism by heat: Role of midbrain raphe neurons. Brain Res. 26, 37–48 (1971)CrossRefGoogle Scholar
  864. Wellens, D., Szigetvari, E., Wauters, E.: Reflex vasodilation, ergotamine and uptake of circulating norepinephrine. Arch. int. Pharmacodyn. 183, 412–415 (1970)PubMedGoogle Scholar
  865. Welsh, J.H.: Excitation of the heart of Venus mercenaria. Naunyn-Schmiedebergs Arch. Pharmacol. 219, 23–29 (1953)Google Scholar
  866. Welsh, J.H.: Hydroxytryptamine: A neurohormone in the invertebrates. Fed. Proc. 13, 162–163 (1954a)Google Scholar
  867. Welsh, J.H.: Marine invertebrate preparations useful in the bioassay of acetylcholine and 5-hydroxytryptamine. Nature (Lond.) 173, 955–956 (1954b)CrossRefGoogle Scholar
  868. Welsh, J.H.: Neurohormones. In: The Hormones. Pincus, G., Thimann, K.V. (eds.), Chap. 3. New York: Academic Press 1955Google Scholar
  869. Welsh, J.H.: Neurohormones of invertebrates. 1. Cardioregulators of Cyprina and Buccinum. J. Marine Biol. Assoc. United Kingdom 35, 193–201 (1956)CrossRefGoogle Scholar
  870. Welsh, J.H.: Serotonin as a possible neurohumoral agent: Evidence obtained in lower animals. Ann. N.Y. Acad. Sci. 66, 618–630 (1957)PubMedCrossRefGoogle Scholar
  871. Welsh, J.H., McCoy, A.C.: Actions of d-lysergic acid diethylamide and its 2-bromo derivative on heart of Venus mercenaria. Science 125, 348 (1957I)PubMedCrossRefGoogle Scholar
  872. Wennmalm, Å.: Quantitative evaluation of release and reuptake of adrenergic transmitter in the rabbit heart. Acta physiol. scand. 82, 532–538 (1971a)PubMedCrossRefGoogle Scholar
  873. Wennmalm, Å.: Studies on mechanisms controlling the secretion of neurotransmitters in the rabbit heart. Acta physiol. scand. (Suppl.) 365, 1–36 (1971b)Google Scholar
  874. Wenzel, D.G., Su, J.L.: Interactions of nicotine and tyramine with adrenergic blocking agents on ventricle strips. Arch. int. Pharmacodyn. 162, 180–185 (1966a)PubMedGoogle Scholar
  875. Wenzel, D.G., Su, J.L.: Interactions between sympathomimetic amines and blocking agents on the rat ventricle strip. Arch. int. Pharmacodyn. 160, 379–389 (1966b)PubMedGoogle Scholar
  876. West, G.B.: 5-Hydroxytryptamine, tissue mast cells and skin oedema. Int. Arch. Allergy 10, 257–275 (1957)PubMedCrossRefGoogle Scholar
  877. White, R.P., Denton, I.C., Robertson, J.T.: Differential effects of prostaglandins A1, E1 and F on cerebrovascular tone in dogs and rhesus monkeys. Fed. Proc. 30, 625 (1971a)Google Scholar
  878. White, R.P., Heaton, J.A., Denton, I.C.: Pharmacological comparison of prostaglandin F, serotonin and norepinephrine on cerebrovascular tone of monkey. Europ. J. Pharmacol. 15, 300–309 (1971b)CrossRefGoogle Scholar
  879. Whitney, B.: A preliminary investigation of the pharmacology of longitudinal muscle strips from human isolated jejunum. J. Pharm. Pharmacol. 17, 465–473 (1965)PubMedCrossRefGoogle Scholar
  880. Wilhelmi, G.: Ueber die ulcerogene Wirkung von 5-Hydroxytryptamin am Rattenmagen und deren Beeinflussung durch verschiedene Pharmaka. Helv. physiol. pharmacol. Acta 15, C83–C84 (1957)Google Scholar
  881. Wilhelmi, G., Schindler, W.: Über die gastrotrope Wirkung von 5-Hydroxytryptamin (HTA), seiner Vorstufen und der entsprechenden Isomeren bei der Ratte. Naunyn-Schmiedebergs Arch. Pharmacol. 236, 49–51 (1959)Google Scholar
  882. Williams, L.T., Lefkowitz, R.J.: Alpha-adrenergic receptor identification by [3H]dihydroergocryptine binding. Science 192, 791–793 (1976)PubMedCrossRefGoogle Scholar
  883. Wiqvist, N.: Immediate and prolonged effects of relaxin on the spontaneous activity of the mouse and rat uterus. Acta endocr. (Kbh.) 32 (Suppl. 46), 3–32 (1959)Google Scholar
  884. Wise, C.D., Ruelius, H.W.: The binding of serotonin in brain: A study in vitro of the influence of physicochemical factors and drugs. Biochem. Pharmacol. 17, 617–631 (1968)PubMedCrossRefGoogle Scholar
  885. Woodruff, G.N., Agar, J., Albani, M.J., Allen, K.A., Folkard, J.: Observations on some actions of ergometrine, noradrenaline and dopamine on the guinea-pig vas deferens and on the rabbit jejunum. J. Pharm. Pharmacol. 21, 860–861 (1969)PubMedCrossRefGoogle Scholar
  886. Woodruff, G.N., Walker, R.J.: The effect of dopamine and other compounds on the activity of neurones of Helix aspersa. Structure-activity relationships. Int. J. Neuropharmacol. 8, 279–289 (1969)PubMedCrossRefGoogle Scholar
  887. Woodruff, G.N., Walker, J.R., Kerkut, G.A.: Actions of ergometrine on catecholamine receptors in the guinea-pig vas deferens and in the snail brain. Comp. gen. Pharmacol. 1, 54–60 (1970)PubMedCrossRefGoogle Scholar
  888. Woodruff, G.N., Walker, R.J., Kerkut, G.A.: Antagonism by derivatives of lysergic acid of the effect of dopamine on Helix neurones. Europ. J. Pharmacol. 14, 77–80 (1971)CrossRefGoogle Scholar
  889. Woolley, D.W., Shaw, E.: Yohimbine and ergotoxin as naturally occurring antimetabolites of serotonin. Fed. Proc. 12, 293 (1953)Google Scholar
  890. Woolley, D.W., Shaw, E.: A biochemical and pharmacological suggestion about certain mental disorders. Science 119, 587 (1954a)Google Scholar
  891. Woolley, D.W., Shaw, E.: Some neurophysiological aspects of serotonin. Brit. med. J. 2, 122–126 (1954b)PubMedCrossRefGoogle Scholar
  892. Wright, A.M., Moorehead, M., Welsh, J.H.: Actions of derivatives of lysergic acid on the heart of Venus mercenaria. Brit. J. Pharmacol. 18, 440–450 (1962)PubMedGoogle Scholar
  893. Wurzel, M.: Serotonin receptor in rabbit artery. Amer. J. Physiol. 211, 1424–1428 (1966)PubMedGoogle Scholar
  894. Yamaguchi, T.: Effects of 5-hydroxytryptamine on isolated strips of the guinea-pig stomach. Brit. J. Pharmacol. 44, 100–108 (1972)Google Scholar
  895. York, D.H.: Dopamine receptor blockade — a central action of chlorpromazine on striatal neurones. Brain Res. 37, 91–100 (1972)PubMedCrossRefGoogle Scholar
  896. Zakusov, V.V.: Principles of pharmacological influence on coronary chemoreflexes. Arch. int. Pharmacodyn. 140, 646–654 (1962)PubMedGoogle Scholar
  897. Zarolinski, J.F., Browne, R.K.: Effects of dopamine on canine renal artery. Pharmacologist 13, 22 (1971)Google Scholar
  898. Zatz, M., Roth, R.H.: Electroconvulsive shock raises prostaglandins F in rat cerebral cortex. Biochem. Pharmacol. 24, 2101–2103 (1975)PubMedCrossRefGoogle Scholar
  899. Zhabin, Y.M., Urazaeva, Z.V.: Influence of intravenous administration to pregnant rabbits of the diethylamide of lysergic acid on the content of serotonin, histamine and acetyl choline in mothers and young. Farmakol.i Toksikol. 38, 93–95 (1975)Google Scholar
  900. Ziegler, M.G., Lovell, R.A., Freedman, D.X.: Effects of lysergic acid diethylamide on the uptake and retention of brain 5-hydroxytryptamine in vivo and in vitro. Biochem. Pharmacol. 22, 2183–2193 (1973)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • E. Müller-Schweinitzer
  • H. Weidmann

There are no affiliations available

Personalised recommendations